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End of life care is a basic human right. This is the first and largest study 
worldwide to explore aspects of the quality and equity of end of life care 
and patient experience for gynaecological cancer patients in England 
using routine data sources.  
 
 
Most patients wish to die at home or in familiar surroundings which 
could also be care homes. Death at home continues to be regarded as a 
‘proxy’ quality marker for end of life care. However less than half of 
patients achieve this aim of preferred place of death. Long-term 
projections suggest that although the trends towards deaths occurring at 
home or in care homes has increased, the number of hospital deaths will 
continue to rise by 20% by 2030, because of an aging population. This of 
relevance for the care of gynaecological cancer patients, the vast majority 
of whom are over 70 years of age at diagnosis.  
 
In this thesis, I have tested two hypotheses: 
 
‘Can routine data be used to gain a better understanding of aspects of end 




‘that there is no difference in the end of life care of gynaecological cancer 
patients in England from a socio-demographic or geographical 





The aims of the thesis were to establish the strengths and weaknesses of 
routine, person linked, data to assess aspects of the quality and equity of 
end of life care and quality of life of gynaecological cancer patients in 
England. Further, to explore the impact of socio-demographic factors, 
geography, and emergency admissions on place of death and to gain a 
greater understanding of trends in emergency admissions and hospital-
based interventions at the end of life, especially ascites drainage.  
 
 
A quantitative approach has been adopted for this study using over a 
decade of ONS and HES linked data recorded for 71, 269 gynaecological 
cancer patients.  
 
 
This study found that routine data can produce a useful insight into the 
quality of end of life care for gynaecological cancer patients and into 
aspects of their care, which can impinge on their quality of life. The study 
also found that the socio-economic status of gynaecological cancer 
patients impacts on where they die and how they present to hospital in the 
last month of life. The number of emergency admissions has increased 
over the past decade for gynaecological cancer patients. An emergency 
presentation significantly impacted on place of death. Significant 
variables predicting death in hospital were, year of death, age group, 
deprivation status, frequency and length of elective and emergency 
admissions. Each subsequent emergency admission in the last month of 
life increased the odds of death in hospital by 2.4 times. A validated 




identified 73% of hospital deaths with a sensitivity of 75% and a 
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1. Chapter 1: Introduction 
 
 
1.1 The Context 
 
 
‘End of life care and Palliative care is recognised under the international 
human rights law as a basic human right’. Under article 12 of the 
International Covenant on Economic, Social and Cultural rights and 
article 7 of the International Covenant on Civil and Political Rights, ‘all 
member countries of the United Nations are obliged to safeguard patients 
at the end of life against pain and suffering, allowing them to die with 
dignity’ (1, 2).  
 
 
This thesis uses national routine data sources for England; to explore 
what can be known about where patients with gynaecological cancer die 
and what influences whether they die in hospital. In 2011, in the UK 
approximately 20,000 women were diagnosed with gynaecological 
cancer and 7,700 (38%) in 2012, died of their disease 
(http://www.cancerresearchuk.org/cancer-info/cancerstats/keyfacts/). A 
majority of these patients will have required support at the end of life. 
Most gynaecological cancer patients will have extensive input from 
multidisciplinary teams at the start of their cancer diagnosis. This is not 
always the case at the end of life (https://www.england.nhs.uk/wp-
content/uploads/2016/04/speclst-palliatv-care-comms-guid.pdf). It is a 
well-recognised fact that clinicians generally are poor prognosticators of 




a timely enough manner to benefit the patients’ quality of life at the end 
of life (3). However, the cancer trajectory for cancer is thought to run a 
more predictable course compared to other diseases such as congestive 
cardiac failure or chronic respiratory failure (4).  Patients with advanced 
gynaecological cancer may present with incapacitating symptoms 
suggestive of disease recurrence, which hugely impacts on their quality of 
life such as, shortness of breath due to recurrent ascites or pleural 
effusion, or abdominal discomfort secondary to acute bowel obstruction 
(5). Often these patients will be unsuitable for aggressive interventions 
such as surgery or chemotherapy or have become resistant to treatment 
(6). Also, from a social perspective, women are usually the main carers in 
a family and therefore their needs may relate more to social and 
psychological interventions rather than medical. A retrospective case 
series of 113 patients with ovarian cancer, whose case notes were 
reviewed from the year 2000 through to 2006, suggested that at the end of 
life the frequency of symptoms of advanced disease increased (7). 
Moreover, patients tended to present as an emergency into hospital (8). 
However, subsets of patients continue to be exposed to aggressive 
interventions in the absence of a palliative intent (9). This paper also 
reported that emergency admissions at the end of life often resulted in a 
prolonged length of stay in hospital, possible death in hospital with 
possible exposure to unnecessary interventions. This raises a number of 
questions with respect to individual patient populations. This thesis 
concentrates specifically on patients with gynaecological cancer. 
 
 
The author was a completing her fellowship in gynaecological oncology 
during the period of this study and therefore this group is of special 




not go unnoticed by the author that often it was easy for the oncologist to 
agree to further cycles of chemotherapy. Patients often presented via 
emergency for management of their symptoms and the responsibility of 
discussions regarding stopping treatment and best supportive care 
sometimes fell on the palliative care team. The author was therefore 
motivated to explore the end of life phase of gynaecological cancer 
patients. To date there have been no publications describing the trends in 
the place of death of gynaecological cancer patients or the quality of care 
gynaecological cancer patients’ receive, in England, specifically, the 
impact of emergency admissions, interventions and place of residence, on 
place of death. This lead to a list of questions as described below: 
 
 
 Where do gynaecological cancer patients die? 
• What percentages of gynaecological cancer patients are admitted as 
an emergency in the last month of life? 
• Which factors impact on these admissions eventually impacting on 
the place of death of these patients in England?  
• Which interventions are these patients exposed to, whilst in 
hospital?  
• Might it be possible to avoid some of these emergency admissions, 
shorten lengths of stay and prevent some deaths in hospital through 
better communication, physician led interventions in the 
community and specialist palliative care involvement at an early 
stage where needed?  






Focus on evolution of end of life care in England: There has been at least 
a decade of focused attention and national policy aimed at improving end 
of life care starting with the 2008 National End of Life Care Strategy and 




Historically in 2003, the introduction of greater patient choice was set by 
the paper, Best: choice, responsiveness and equity in the NHS 
(https://www.gov.uk/government/publications/building-on-the-best-
choice-responsiveness-and-equity-in-the-nhs). This paper highlighted the 
commitment from the government to ensure all patients had equitable 
access to all aspects of healthcare care including access to specialist 
palliative care and end of life care services. The objective was to provide 
patients with a choice, with respect to place of death, thus encouraging 
the development of community services to support patients who chose to 
die at home if they wished (10).  
 
 
Further to enhancing patient choice, the aim of the 2008, End of Life 
Care Strategy  
(https://assets.publishing.service.gov.uk/government/uploads/system/uplo
ads/attachment_data/file/136431/End_of_life_strategy.pdf) was to 
integrate end of life care services. The following steps were highlighted: 
 Identification of people approaching the end of life and initiating 
discussions about preferences for end of life care; Care planning: 
assessing needs and preferences, agreeing a care plan to reflect these and 
reviewing these regularly; Coordination of care; Delivery of high quality 




death; and Support for carers, both during a person’s illness and after 
their death.  
 
 
The recent government guidance, which includes the End of life Care 
Strategy, and the NICE guidance on End of Life Care for Adults have 
impacted on end of life care practices in the UK. Problems with the 
implementation of the Liverpool care pathway (LCP) resulted in 
significant criticism by patient groups. An independent review led by 
Baroness Neuberger, published July 2013. She advocated that the 
government substitute the LCP by individual care plans over a period of 





Following a review of the LCP (11), The Leadership Alliance for the 
Care of Dying published ‘One Chance to get it Right’ in June 2014. The 
alliance published this report having identified national deficiencies in 
various aspects in end of life care in response to the Baroness Neuberger 
report. The approach focuses on achieving five priorities for care prior to 
death  (http://wales.pallcare.info/files/One_chance_to_get_it_right.pdf ): 
‘The possibility is recognised and communicated clearly, decisions made 
and actions taken in accordance with the person’s needs and wishes, and 
these are regularly reviewed and decisions revised accordingly. 
Sensitive communication takes place between staff and the dying person, 




The dying person, and those identified as important to them, are involved 
in decisions about treatment and care to the extent that the dying person 
wants. 
The needs of families and others identified as important to the dying 
person are actively explored, respected and met as far as possible. 
An individual plan of care, which includes food and drink, symptom 
control and psychological, social and spiritual support is agreed, 
coordinated and delivered with compassion’.  
 
 
Therefore, the End of Life Care Strategy, LCP with its failings and 
followings on from the Baroness Neuberger report, including the 
Ambitions for Palliative and End of Life Care 
(http://endoflifecareambitions.org.uk) individually and collectively 
enhance the significance of End of Life Care in England. Major 
achievements in end of life care have been made over the years with 
national policy documents constantly reviewed in response to public 
concerns (12). However, these documents highlight that policy, pathways 
and toolkits are by themselves inadequate. Gaps in service provision must 
be identified and addressed paving the way for remodeling of services, to 
meet individual preferences. End-of-life care services need to be 
appropriately designed to ensure that a majority can be looked after in in 




Public Health Perspectives on end of Life Care: Public health includes 
health improvement, health protection and improvement of services (13).  




from a public health strategy (Rao et at). This is due to the fact that 
illnesses and death are a significant burden on the individual and the 
community, causing significant suffering. It has adverse financial, health 
and social implications to those involved in their care. In addition the 
utilisation of health and social care services, increases in the last year of 
life, at a great cost to the health care system (14). The principles of public 
health can be used to measure perceptions of end of life care, provide 
health information and coordinate the efforts of end-of-life care providers 
to efficient use of resources to enable people achieve a good death (15). 
 
 
Individual characteristics and structure of social institutions impact on 
how people experience death and how a society responds to dying (16). 
The epidemiology, demography and the organisation of the health and 
social care system of England are a measure of this response (17). The 
ONS report shows that the population in England is increasing in size, 
ageing and becoming more ethnically diverse. Describing the 
characteristics of people who die using the principles of epidemiology 
can assist in end-of-life care planning. Indeed delivery of high quality and 
sustainable end-of-life care requires the causes of death, individual 
characteristics and future needs for care to be determined. For instance 
deprivation is associated with increased morbidity and mortality. To 
compete with other interventions for resource allocation, end-of-life care 
needs to establish an evidence base for sufficiency and cost effectiveness, 
is also subject to public perceptions and health system evaluation (18). 
End of life care can greatly benefit from public health approach, which 
values evidence and engages with wider societal issues such as health 




disparity in socio-economic status and postcode to assess variation in end 
of care for gynaecological cancer patients in England.  
 
 
This thesis aimed to comprehensively explore various aspects of end of 
life care of gynaecological cancer patients’ in England using primarily 
national routine data. The routine data was derived from two main 
sources: ONS Mortality data and Hospital Episode Statistics (HES) data 
held in national databases at Public Health England. This was used to 
explore what we can learn about the current end of life care services both 
in hospital and outside hospital for gynaecological cancer patients in 
England. It was envisaged that the work from this thesis would also help 
expand the current but very small evidence base on end of life care for 
patients with gynaecological cancer in England. The analyses included 
studying the trends in place of death, socio-economic variables that 
impact on patient experience such as emergency admissions and 
interventions in the last year and last month of life and regional variations 
in end of life care. The thesis also assessed some aspects of resource use 
by examining trends in the use of radiological examinations and surgical 
interventions in the last 12 months and reviewing the trends in patients 
who require drainage of their ascites in the last year of life over the study 
period, so that this evidence could provide a basis for recommending re-
configuration of service provision if needed. 
 
 
In 2010, the National End of Life Care Programme established the 
National End of Life Care Intelligence Network (NEoLCIN) as a result of 
recommendations made in the National End of Life Care Strategy. 




(SWPHO). In 2013 the hosting arrangement changed to Public Health 
England. The NEoLCIN supports National End of Life Care work at 
NHS England and provides data and intelligence to a wide range of 
stakeholders including, The Department of Health, NHSE, charities, 
Local Authorities, Clinical Commissioning Groups and researchers. The 
NEoLCIN has been the national repository for the End of Life Care 
Database, a linked ONS-Mortality-HES database. This database provided 
the person-linked data for analysis from which the results are derived. 
 
 
The aims of this thesis were to test two hypotheses: 
 
‘Is routine data useful to gain a better understanding of aspects of the End 
of Life Care for Gynaecological cancer patients in England?’ 
 
Having demonstrated the ‘usefulness’ of routine data in assessing the 
aspects of end of life care of patients with gynaecological cancer, the Null 
hypothesis tested was 
 
‘There is no difference in the end of life care for gynaecological cancer 
patients in England from a socio-demographic or geographical aspect as 
measured by routine data’  
 
Therefore the objectives of this thesis were to: 
 
• To establish the ‘usefulness’ of routine data sources to understand 
more about the end of life care for gynaecological cancer patients 




• To report on trends of place of death and the impact of socio-
demographic variables on the place of death of patients with 
gynaecological cancer in England 
To assess the various interventions received by gynaecological 
cancer patients in hospital in the last year of life and to evaluate the 
impact of these interventions in last month of life on death in 
hospital  
• To assess regional variations in EOLC for gynaecological cancer 
patients in England to include variations in hospital deaths, 
emergency admissions and emergency interventions in the last 
month of life. 
• To reflect on resource usage of ovarian cancer patients who require 
paracentesis in the last month of life in NHS hospitals and also to 
infer whether drainage in a hospital or hospice setting influences 
place of death.  
 
 
1.2 Plan of study 
 
 
This thesis explores the usefulness of routine data sources to provide 
insight into the various aspects of the quality and equity of end of life 
care for gynaecological cancer patients in England. The basis of the thesis 
plan is explained in the following paragraphs.  
 
 
The first section of the thesis uses routine data to report where 




that influence their death in hospital. The thesis focuses on the mode of 
presentation of patients either as an elective or an emergency, to evaluate 
whether either presentation impacts on death in hospital. This work is 
based on the lucidly described ‘quality indicators’ of end of life care such 
as emergency admissions in the last month of life by Earle et al (9). The 
outcomes of this analysis were based on the linked ONS-HES database 
and not from patient directed interviews.  
 
 
Emergency hospital admissions during the last year of life may be 
necessary but also distressing for the patient. They may affect care 
delivery resulting in avoidable investigations, which may further prolong 
stay in hospital and impact on hospital costs (6). In this thesis, it was 
hypothesized that emergency admissions impacted on death in hospital 
for gynaecological cancer patients (9, 19, 20). This led to the derivation 
of a predictive model to deduce the possible reduction in the number of 
deaths in hospital, if emergency admissions could be avoided in the last 
month of life.  
 
 
 Many patients may have several interventions and once admitted have 
prolonged stays in hospital (9). Cancer patients receive a number of 
interventions in the last year of life with varying intent some palliative 
and some curative (20). The aim of subsequent sections of the thesis was 
to explore the number of various procedures being undertaken to gain 
insight to the intent with which patients are managed at the end of life 
following an emergency or an elective admission in hospital. This 
information could be useful primarily as a surrogate marker of quality of 




end of life care for gynaecological cancers and begin to consider whether 
interventions are being undertaken inappropriately, although, from 
routine data at an individual level this may not be possible to tell. 
 
 
THE NHS ATLASES OF VARIATION IN HEALTH CARE show wide 
variations in levels of delivery and quality of health care 
(http://www.rightcare.nhs.uk/index.php/atlas/nhs-atlas-of-variation-in-
healthcare-2015). There is no data for gynaecological cancers 
(http://www.rightcare.nhs.uk/index.php/atlas/diagnostics-the-nhs-atlas-
of-variation-in-diagnostics-services/). The aim of the NHS Atlas is to 
identify and reduce unwarranted variation. An ‘unwarranted’ variation is 
when the variation cannot be explained by patient preference and usually 
arise from disparate organisational or professional practices. These 
concepts are expanded further in Chapter 7. The mid-section of the thesis 
explores whether geographical regional variations in end of life care exist 
for gynaecological cancer patients in England with regard to place of 
death, emergency admissions and number of interventions in the last 
month of life. 
 
 
 The final section of the thesis reports on the increasing need to consider 
the future expansion of palliative and end of life care services to be able 
to provide symptom relief in a timely manner, not only in NHS hospitals 
but to also consider alternative sites outside hospital, based on a review of 
recent trends. For the purpose of this thesis, paracentesis drainage in the 
largest subgroup of patients i.e. ovarian cancer patients was chosen as an 
important example. It was therefore intuitive to analyse the utilisation of 








1.3 Structure of thesis 
 
 
This first chapter describes the context in which the research took place. 
The scope of the study is also defined and the null hypothesis stated. The 
study plan is outlined with the intent of each chapter highlighted. 
 
 
Chapter 2 – Background. This chapter reviews the incidence of each 
gynaecological cancer and discusses the age related trends. The 
management of each advanced cancer type is discussed to highlight the 
range of possible interventions, including trial based treatments, that may 
be offered to patient’s in spite of a poor prognosis. The difference 
between palliative care and end of life care is described. A 
comprehensive and up to date literature review on end of life care for 
gynaecological cancer patients, relevant to place of death, interventions at 
the end of life and drainage of ascites is presented. 
 
 
Chapter 3 – Materials and Methods. This chapter describes the datasets 
used in particular, extraction of the linked HES-ONS database used for 
the study. The study population is described, the derivation of the 






Chapter 4 - End of life care in ovarian cancer. This chapter focuses on 
a descriptive analysis of the ovarian cancer patients. The ovarian cancer 
patients are the largest sub-group of gynaecological cancer patients with 
diverse presentations at the end of life calling for difficult management 
decisions to be made from a gynaecology-oncology perspective. This 
cancer group is therefore explored and reported on in detail. Another 
reason for this detail is that they are also the reference group for the 
multivariate analysis in chapter 5.  
 
 
Chapter 5 - Factors that impact on place of death on gynaecological 
cancer patients. This chapter reports on where gynaecological cancer 
patients die, the trends of the place of death and the impact of emergency 
admissions on place of death. A predictive model was derived following 
multivariate analysis to estimate the reduction of the number of deaths 
occurring in hospital, which might be achievable if physician-led 
interventions in the community could prevent emergency admissions. 
 
 
Chapter 6 – Geographical variations in the end of life care: A case 
mix analysis was performed to explore geographical variations in end of 
life care for gynaecological cancer patients. Variations in the number of 
hospital deaths, admissions, procedures and lengths of stay by 
geographical region (Strategic Health Authority) were assessed for the 
last month of life. Funnel plots were used to interpret the significance of 






Chapter 7 - Interventions in the last month of life of patients with 
gynaecological cancer. This chapter reports on the interventions 
gynaecological cancer patients are exposed to in the last year of life and 
their trends over the study period. The focus of the chapter is on the 
interventions performed in the last month of life and a multivariable 
analysis highlights those interventions that impact on death in hospital. 
 
 
Chapter 8- Ascites drainage at the end life. Three distinct cancer 
populations were analysed. The first section of this chapter focuses on the 
trends of ascites drainage of ovarian cancer patients and the socio-
demographic variables that impact on these trends and possibly death in 
hospital.  
The second section of this chapter focuses over a two-year period on all 
cancer patients admitted to NHS hospitals in England, their socio-
demographic characteristics and the median time to death was calculated. 
A comparative analysis is performed using a third distinct but similar 
group of patients treated at a local specialist palliative care unit to assess 




Chapter 9 - Discussion, conclusions and future work. This chapter 
places the findings of the research in context and examines the strengths 
and weaknesses of the studies. Proposals are made for future exploration 








2 Chapter 2: Background & Review of Literature 
 
 
This chapter begins with the description of the incidence; mortality, age 
related incidence and trends related to socio-economic status of each 
gynaecological cancer site. The management possibilities for advanced 
and recurrent disease for ovarian, endometrial, cervical, vulval and 
vaginal cancers are discussed in detail along with the treatments available 
for symptom control of advanced disease. The second part of the chapter 
highlights the current relevant published literature. 
 
 
2.1 Gynaecological cancer: incidence and mortality  
 
 
2.1.1 The Burden of disease 
 
 
Worldwide, it is recognised that cancer is at the root of a significant 
volume of morbidity and mortality. In 2012, GLOBOCAN reported 14.1 
million newly diagnosed patients with a malignancy, 8.2 million 
bereavements, secondary to cancer and 32.6 million cancer survivors 
(http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx). In the same year 
there were 6.6 million women worldwide reported a new cancer 
diagnosis, 3.5 million women died of cancer and 17.1 million women 
were living with cancer 




standardised incidence rates for all cancers over the last decade have 
increased (between 2001-2003 and 2010 to 2012) by 7% for all females 
(http://www.cancerresearchuk.org/cancer-info/cancerstats/incidence/all-
cancers-combined/; accessed 21/03/2016). Gynaecological cancers 
account for approximately 12% of these cancers and include endometrial, 
ovary, cervix, vulva, vagina and placental site tumours. Uterine and ovary 
cancer are two of the ten most common incident cancers in females in the 
UK (5% and 4% respectively).  
 
 
2.1.1.1 Cancer of the Ovary 
 
Worldwide, ovarian cancer is placed seventh as the most occurring cancer 
in women. In the UK, ovarian cancer is the sixth most incident cancer 
amongst women and responsible for 6% of all cancers deaths in women.  
The lifetime risk is 1:50 for women in the UK 
(http://publications.cancerresearchuk.org/downloads/Product/CS_CS_OV
ARY.pdf). The incidence of ovarian cancer increases with age 
particularly beyond the age of 40 years with a median age incidence of 
65-75 years.  Ovarian cancer is associated with a poor prognosis due to 
late stage diagnosis (21). Ovarian cancer presents major diagnostic 
challenges in the absence of recognised screening tools, with 70% of 
cases at an advanced stage presentation.  The five-year survival was 








2.1.1.2 Uterine cancer 
 
Worldwide, uterine cancer is the sixth most incident cancer and now the 
most common of all gynaecological cancers of women in the UK 
(http://www.cancerresearchuk.org/health-professional/cancer-
statistics/statistics-by-cancer-type/uterine-cancer/incidence#heading-
Five). As a result of increasing obesity and delayed family planning in 
urbanized countries, notably, North America and the UK, the incidence of 
uterine cancer has surpassed ovarian cancer more recently, as the most 
common gynaecological cancer. In 2013, in the UK, 9,022 new cases of 
uterine cancer were diagnosed (http://www.cancerresearchuk.org/cancer-
info/cancerstats/types/uterus/). The average age at presentation for 
endometrial cancer is 65 years (http://www.cancerresearchuk.org/cancer-
info/cancerstats/types/uterus/incidence/#source1). Uterine cancer tends to 
present at an early stage and 70% of tumours will be confined to the 
uterine corpus at presentation, thus amenable to surgical treatments and a 
more favorable prognosis.  
 
 
2.1.1.3 Cervical cancer 
 
 
Cervical cancer is the most commonly occurring female cancer in 
developing countries and globally is documented to be the second most 






2.1.1.4 Vulval cancer 
 
 
Vulval cancer, from a global perspective is a rare gynaecological 
malignancy. About 3% of all gynaecological cancers are of vulval origin. 
The five-year survival for the subset of patients diagnosed from 1996-
1999 was found to be 58% (http://www.ons.gov.uk/ons/publications/re-
reference-tables.html?edition=tcm%3A77-252716). The incidence of 
vulval cancer has a linear relationship to age. 46% of cases are diagnosed 
in those above the age of 75 (22). 
 
 
2.1.1.5 Vaginal cancer 
 
 
Vaginal Cancer accounts for about 0.2% of all newly diagnosed cases of 






2.2 Trends: Age, Socio-economic status and Mortality 
  
2.2.1 Age related incidence trends for gynaecological cancer patients 
 
  
 Ovarian cancer: The incidence of ovarian cancer ascends with age, with 
3 of 4 cases presenting in those above the age of 55 years in the UK. The 
age specific incidence rates escalate beyond the 35-39 years age group 
with incidence peaking for the age group 80-84 years 
(http://www.cancerresearchuk.org/cancer-
info/cancerstats/types/ovary/incidence/#source10 accessed 23/03/2016).  
 
 
Uterine cancer: The age specific incidence rates appear to rise beyond 
the age of 40 years with incidence peaking in the 70-74 years age group. 
The increase in obesity may explain the increasing incidence of this 
malignancy in the 50-74 years age group and the decline in incidence 
beyond that age group (23).  
 
 
Cervical cancer: The incidence corresponds to a bimodal age 
distribution. The first peak is in women aged 25-29 years of age when the 
age standardised incidence is 20 per 100, 000 women and then a much 
later peak in incidence between 80-84 years when the incidence is 12 per 
100,000 women (http://www.cancerresearchuk.org/health-
professional/cancer-statistics/statistics-by-cancer-type/cervical-




The earlier peak is related to many women becoming sexually active. 
Persistence of a high risk Human Papilloma Virus (HPV) infection is the 
main causative factor of cervical cancer, with a study of 1000 cases 
suggesting a very high prevalence of 99.7% (24). 
 
 
The age related incidence for cervical cancer has reduced for almost all 
age groups with the introduction of the national cervical screening 
programme in England. In a study where trends for cervical cancer were 
assessed and reviewed for 38 countries, it was found that countries that 
had had screening programmes in place for a long time were able to 
maintain low and stable detection rates of cancer in spite of adjusting for 
group specific risk factors (25). When the question of 2 or 3 yearly 
screening interval was studied it was felt that the cervical cancer 
mortality rates fell by 40% for the countries included in the analysis 
namely Australia, New Zealand and England. The incidence of cervical 
cancer fell by more than third for Australia and New Zealand and by 
approximately 20% for England. The findings did not support a more 
frequent 2-year screening interval (26).  
 
 
The incidence of vulval cancer has increased significantly by 18% from 
2.13 per 100,000 to in 1990-92 to 2.51 in 2007-2009 (22). The mortality 
rates have statistically significantly decreased by 25% from 0.85 to 0.64 
per 100,000 over a similar study period. Over the past 2 decades vulval 
cancer incidence has increased with increasing age. Most importantly 
there has been a statistically significant increase in the rate of new cases 




to HPV infection, which is the main cause of pre-invasive changes in 
younger women (27). 
 
  
2.2.2 Trends related to Socio-economic status 
 
 
Socio-demographic inequalities may lead to advanced stage presentation. 
Little geographic variation within UK and Ireland are reported for 
ovarian cancer, apart from a slightly higher incidence in affluent groups. 
This may be explained by a relatively higher incidence of reduced parity 
in more affluent women (28).  
 
 
The incidence of cervical cancer strongly correlates with age and socio-
economic status. A study from the southwest of Scotland, which included 
1762 cases of cervical cancer, highlighted that women from the poorest 
regions were three times more likely to develop the disease (29). 
 
 
Endometrial cancer presents early however there is some evidence to 
suggest that this cancer may be detected at an advanced stage in women 
of lower socio-economic strata due to lack of awareness and delayed 
interpretation of cancer symptoms (30). 
 
 
Cancers of the vulva and vagina are rare and there are no clear socio-
economic trends documented in the literature. However, the incidence of 




with HPV infection and the aetiology of vaginal cancers is also related to 
HPV with 30% of cases occurring in women with previously treated pre-
invasive disease of the cervix (31). 
 
 
2.2.3 Trends related to mortality from gynaecological cancer 
 
 
Ovarian cancer: The mortality trends for ovarian cancer have shown a 
small but consistent decline (http://www.cancerresearchuk.org/cancer-
info/cancerstats/types/ovary/mortality/#Trends). The improved survival 
over the last 35 years, primarily occurred in the 1980’s and 1990’s 
secondary to the use of platinum based chemotherapy, and the more 
recent improvement in five year survival rates since the year 2000, are 
probably due to centralisation of gynaecological oncology services in 
England, adoption of radical surgery techniques and advances in surgical 
techniques allowing successful treatment of recurrent disease (32). There 
is a noticeable decline in age related survival with younger patients 
performing better. For the period 2003-2007, the relative five-year 
survival was around 60% for the 40-49 years age group, but around 50% 
for those falling in the 50-59 years age group. Elderly patients probably 
present late with their symptoms and GP’s being late to recognise and 
refer these patients, probably contributed to a late diagnosis and survival 
in this age group (33). 
 
 
Uterine cancer: The mortality rates in the UK have decreased between 
1971 and 2005 by 27%, however, recently an increase in mortality rates 








Cervical cancer: The incidence of cervical cancer has decreased by 46% 
from 1975 to 2005, whereas the mortality rates have declined by 63% 
(from 7.5/100,000 to 2.8/100,000). 
 
 
Vulval cancer: The mortality rates have decreased significantly in the 
UK since the 1970’s by 43% between 1971 and 2012. This is mainly 
recognized secondary to increased awareness, early diagnosis and 





Vaginal cancer: The decrease in mortality rates by 47% between 1971 
and 2012 are primarily due to improved diagnosis and institution of early 
treatment. It is of note that the incidence rates have remained constant 
over this period (http://www.cancerresearchuk.org/cancer-
info/cancerstats/types/vagina/mortality/#Trends). 
 
2.3 Management of advanced gynaecological cancer 
 
 
This section of the thesis highlights the complexities of management of 




however minor a significance, are evidenced by various RCT’s and in 
many cases observational studies. With inaccurate prognostication, a lack 
of comprehensive integrated multi-disciplinary review at the end of life 
and poor communication, patients may find on offer a plethora of 
traditional and novel treatments available to them with possibly little 
survival benefit and the added risk of side effects and complications of 
treatment, further impacting on quality of life. This section outlines 




2.3.1 Ovarian cancer 
 
 
70% of women with ovarian cancer are diagnosed at a late stage i.e. stage 
3 and 4 disease (34). Thus presentation is often vague and nonspecific 
with most women complaining of abdominal distension, abdominal 
bloating or a concern about weight gain (35). The prognosis of ovarian 




The management of patients with advanced disease at initial presentation 
often depends on their performance status and thus their ability to accept 
chemotherapy or surgery upfront. Both modalities of treatment can be 
instituted and have an implied morbidity and mortality rate with an effect 






Often prior to commencing any treatment regime, many patients require 
simultaneous symptom control to achieve a transient enhancement in the 
performance status and quality of life. A small percentage of patients are 
unable to proceed to either treatment modality. Therefore, instituting 
early input from palliative care teams to improve the patient disease 
journey from diagnosis to the end of life is an essential aspect of the 
management of these patients.  
 
 
Ovarian cancer can be regarded mostly as chemo-sensitive disease. 
However, many patients relapse at varying intervals, often undergoing 
multiple cycles of palliative chemotherapy. For stage 3 to 4 disease, the 
cure rate or a 5-10% survival rate, following diagnosis at 5 years can be 
expected. The treatment intent for patients surviving with metastatic 
ovarian cancer is not only to prolong life but most importantly to palliate 
the symptoms from the recurrence whilst actively balancing possible 
future and current toxicities already acquired from previous treatments. 
The management of advanced ovarian cancer requires continued effective 
communication between oncologists, hospital palliative care, and 
specialist community palliative care and primary care physicians so that 
these patients can be managed as per their expectations in the place of 
their choosing.  
 








The management aim is surgical staging and endeavored complete 
debulking of all visible macroscopic disease to achieve nil residual 
disease either with upfront primary cytoreductive approach or following 
neoadjuvant chemotherapy (38). A radical approach to surgery is often 
adopted with the inclusion of peritoneal stripping, diaphragmatic excision 
or stripping, splenectomy or multiple bowel resections performed to 
achieve the surgical aim (39). The size of residual disease following 
surgery is regarded as an important prognostic indicator. The patients 
who have had complete cytoreductive surgery have a 2-year survival of 
80% in contrast to less than 22% for patients with lesions more than 2cm 
in diameter (40). This suggests that response rates to chemotherapy are 
improved by removing tumour tissue, which may be resistant to 
chemotherapy in parts, with improved delivery to smaller residual 
nodules of tumour. There are metanalysis to support this hypothesis 
although randomised trial evidence may be lacking (41). Thus, not only 
are patient symptoms alleviated such as pain, abdominal discomfort 
secondary to a pelvic mass or ascites and bowel obstruction but also 
progress towards treatment is made. However, primary surgery can be 
technically difficult and has an associated morbidity and mortality. The 
surgical aim may not always be achieved and some patients may have 
complications that ultimately significantly delay chemotherapy (42). 
Metastasis in the liver, small bowel mesentery, the presence of supra-
renal lymph node metastasis, disease in the lesser sac and in the porta 









70-85% cases of ovarian cancer show some response to first line 
chemotherapy (43). Response is assessed clinically, by improvement in 
symptoms such as resolution of ascites and reduction of the pelvic mass, 
resolution of poor appetite, weight loss, low albumin levels; 
radiologically by assessing changes in CT scan measurements of disease 
and reduction in the volume of ascites and biochemically by assessing 
improvements in Ca125. The Ca125 is regarded as a tumour marker for 
ovarian cancer and can be used to oversee the response to 
chemotherapeutic agents, being present in the serum of 85% of women 
with ovarian cancer (44).  
 
 
Paclitaxel and Taxanes are first line chemotherapeutic options often 
instituted in the treatment regime of patients with ovarian cancer. The 
ICON 2 study showed that carboplatin is at least equally efficacious as 
Cisplatin with respect to disease response (45). Unfortunately 
monotherapy or combination chemotherapy is associated with side 
effects, some transitory like anaemia, nausea and vomiting and some 
cumulative or irreversible such as neurotoxicity (46). Platinum 
compounds are associated with cumulative myelosuppression, 
neurotoxicity, and nephrotoxicity. Paclitaxel in combination with 
platinum compounds can cause granulocytopenia, anaemia, 
thrombocytopenia, and peripheral neuropathy apart from potentiating 
toxicity from the Platins, thus significantly impacting on quality of life of 
patients (47). A Cochrane systematic review assessed monotherapy with 




women with ovarian cancer were included. The review concluded that 
combination chemotherapy was more effective than monotherapy and 




Ideally, patients have 6 cycles of chemotherapy following upfront surgery 
or with the neo-adjuvant approach will have three initial cycles of 
chemotherapy followed by primary cytoreductive surgery, followed by 
another three cycles. Second and third line chemotherapeutic regimes are 
usually 6 cycles of chemotherapy with response assessment at cycle 3. 
The aim is to induce remission with the least possible side effects. The 
results of the ICON 8 trial will provide further information on whether 
dose intensity is more important than the total dose delivered over the 
treatment period (49). 
 
 
2.3.1.2 Management of relapsed Disease 
 
 
About 60% of patients will relapse after primary treatment, and 80% with 








There are limited indications for secondary cytoreductive surgery. 
Patients with progressive disease on chemotherapy are not suitable 
candidates for surgery. The patients who have a single or few sites of 
recurrence (as defined by imaging) and have had previous complete 
debulking surgery with at least a 12-month disease free interval may be 
considered for a second look laparotomy. The role of the current 
DESKTOP 3 trial is to assess the value of secondary cytoreductive 
surgery compared to chemotherapy (50).  
 
 
Exenterative surgery for ovarian cancer is often not a consideration due to 
the widespread peritoneal seedlings. 
 
 
2.3.1.2.1.2 Chemotherapy for relapsed disease 
 
 
The clinical decision making for the delivery of subsequent cycles of 
chemotherapy is based on the disease free interval, or the time to 
progression. Thus women who progress whilst on platinum therapy are 
classified as platinum refractory disease. Those who relapse within six 
months of platinum chemotherapy have platinum resistant disease and 
those who recur after 6 months are regarded as platinum sensitive 
(National Cancer Institute 2007). The likelihood of response to further 
lines of treatment following platinum based chemotherapy is associated 






The aim of chemotherapy in relapsed disease is to treat symptoms, restore 
quality of life, extend disease free interval and possibly improve survival, 
particularly in women with long intervals and platinum sensitive disease. 
The choice of treatment is often dependent on possible benefit, potential 
toxicity and patient choice. Patients with platinum sensitive disease 
benefit from a combination of carboplatin and paclitaxel as was shown by 
the ICON 4 trial(52), but may also benefit from gemcitabine/carboplatin 
combination where a similar benefit in PFS was shown (53). The 
CALYPSO trial showed that a combination of PLD (Pegylated liposomal 
Doxorubicin) and carboplatin provided a modest progression free 
survival (PFS) and was less toxic to the standard carboplatin/paclitaxel 
regime (54). Whilst these patients benefit from a carboplatin regime 
almost all patients after two to three cycles of chemotherapy develop 
resistance and non-platinum combination therapies may be of more 
benefit (55). More recently various PARP inhibitors have been included 
in the treatment option profile of patients with ovarian cancer.  These 
improve sensitivity of primary combinations and as maintenance therapy. 
Many of these drugs have shown benefit in improving PFS in early 
systematic reviews and a number of trials are on going such as the 
SOLO1 (http://www.cancerresearchuk.org/about-cancer/find-a-clinical-
trial/a-trial-of-olaparib-after-chemotherapy-for-advanced-ovarian-cancer-
with-change-to-brca-gene-solo1) and ICON9 
(https://clinicaltrials.gov/ct2/show/NCT03278717) trials (56). A recent 
Cochrane review assessed 8 trials (1644 women) and confirmed that that 
there was no evidence to suggest the use of platinum agents, Doxorubicin 
or Paclitaxel as maintenance therapy (57). Another effective drug for 
second line and subsequent use that have been proven to be of benefit 




effective as PLD and Paclitaxel, but is awaiting further assessment via 
trials (58). 
Antigen immunotherapy is currently being reviewed. So far a in a meta-
analysis which included 55 studies (RCT’s and Non-RCT’s) no benefits 






Platinum-resistant ovarian cancer patients have an estimated response 
rate of less than 25% to other chemotherapeutic agents, while platinum 
refractory patients have poor outcomes. The management of platinum 
resistant and refractory patients is difficult and depends on response, 
performance status, patient request and the treating oncologist. Single 
agent therapy is typically employed, as combination chemotherapy is 
often associated with additional toxicity without any survival benefit. 
Response rates of up to 60% have been reported with dose dense 
carboplatin, which is currently being explored. Single agent PLD in a 
meta-analysis of seven studies in patients with platinum resistant disease 
provided a PFS of 15 weeks and OS of 54 weeks (60). Other agents that 
can be considered are paclitaxel, docetaxel, topotecan,, gemcitabine, oral 
etoposide, tamoxifen and bevacizumab (https://www.cancer.gov/about-
cancer/treatment/drugs/ovarian). The results of chemotherapy in this 
population are poor. 
 
Thus from the above treatment options it can be concluded that ovarian 
cancer is a disease usually diagnosed and treated at a late stage in the 




disease is to palliate symptoms and achieve as long a disease free interval 
(DFI) as possible. Conventional treatment includes a combination of 
chemotherapy and cyto-reductive surgery. With advances in 
chemotherapeutic options ovarian cancer is now regarded as a chronic 
disease with the recent availability of maintenance therapy with anti-
VEGF factors and immunotherapy, all currently administered under the 
umbrella of numerous research trials with various standard combinations 
of chemotherapy. It is understood that some of these regimes have 
resulted in slight but variable improvements in DFI. Robust trials are 
needed to assess that treatments are truly palliative and that symptoms 
improve with various chemotherapeutic agents(36). Heterogeneous 
mutations are recognised amongst ovarian cancer patients and therefore it 
is thought that the future of these patients will benefit from personalised 
gene therapy (61) 
 
2.3.2 Management of Advanced Endometrial cancer 
 
 
Endometrial cancer tends to present early with postmenopausal or 
irregular bleeding, and more than 70% of patients present while the 
disease is confined to the uterus with an excellent prognosis (62). Most of 
these patients will have a hysterectomy with bilateral salpingo-
ophorectomy and a consideration for pelvic lymphadenectomy based on 
local treatment guidelines (63). Unfortunately, patients with advanced 
disease or a recurrence have a poor prognosis (64). 
 
 
When advanced disease, most patients present with both local and 




ascites suggestive of peritoneal metastasis, bone pains, shortness of 
breath and pain radiating down the back of the legs or bleeding from the 
urethra suggestive of bladder infiltration (65). 
  
 
Initial assessment involves ultrasound imaging and pipelle sampling to 
obtain tissue for histology. Some Centre’s in the UK, perform 
preoperative staging with MRI to assess the myometrial invasion to plan 
pelvic lymphadenectomy. In patients with symptoms of advanced disease 
and when metastasis is suspected a CT scan of the chest, abdomen and 






The most significant prognostic variable is disease stage. However, a 
number of factors may correlate with disease stage. The most important 
factors are grade of differentiation referred to as grade 1, 2 or 3, depth of 
invasion and histologic subtype. Age too, is an important prognostic 
factor as suggested by a study of 51,471 US patients with endometrial 
cancer. It was found that those diagnosed at 40 years or under, lived 
longer compared to older patients, when controlling for other clinico-
pathological factors (66). More than 85% of endometrial cancers are of 
the endometrioid variety and are related with survival rate of about 92% 
when compared to the non-endometrioid variety where the survival rate is 
nearer to 33%. This unfavorable group is associated with a lower survival 




surgical staging (67). Papillary serous carcinomas are associated with 
poor outcomes, even at an early stage of disease (68). A serous 
component of 25% is also associated with a poor prognosis and is linked 
with early intra-abdominal dissemination (69).  
 
 
When assessing outcomes, a strong correlation between grade of the 
tumour and degree of invasion of disease into the myometrium has been 
reported. In a study of 621 patients where grade 1 tumours were limited 
to the inner one-third of the uterine muscle wall, the incidence of pelvic 
nodal metastasis was under 3% whereas, high grade lesions involving the 
outer one-third, the incidence of positive pelvic nodes was 34% (70).  
 
The presence of lymph-vascular space invasion (LVSI) is a poor 
prognostic factor, increasing the risk of recurrence and death (71). The 
incidence of LVSI in stage 1 uterine cancer is 15% and increases with 
depth of myometrial invasion and grade of tumour (71). Positive 
peritoneal washings do not appear to worsen prognosis in the absence of 
other significant adverse prognostic indicators and is therefore no longer 
included in the FIGO staging (72). Patients who have a positive estrogen 
or progestogen receptor status have a better survival outcome than those 
who are not (73).  
 
 






Patients presenting with primary advanced endometrial cancer are 
uncommon. The treatment modalities may include surgery, radiation 
therapy, hormone therapy and or chemotherapy, either alone or 
sequentially to treat endometrial cancer.  
 
 
2.3.2.2.1.1 Radiation Therapy 
 
 
Vaginal radiotherapy significantly decreases the risk of vaginal vault 
recurrence. If patients refuse adjuvant therapy, then they should be 
offered careful follow up to allow early detection vault recurrences. 
External beam radiotherapy has shown to reduce vaginal vault and pelvic 
sidewall metastases. The PORTEC trial randomised 715 women to with 
grade 2/3 stage 1C endometrial cancers to surgery with or without 
adjuvant external beam radiotherapy. In addition, the GOG 99 trial 
randomised 448 women with stage 1B, 1C or II (occult) endometrial 
cancer to adjuvant or no further adjuvant radiotherapy. The study 
reported improved recurrence free intervals following adjuvant 
radiotherapy (HR = 0.42, 90% CI: 0.25-0.73, P = 0.007) but no 
improvement in survival figures (92% vs. 86%, P = 0.557)(62).  
Patients with pelvic lymph node metastases have a higher incidence of 
para-aortic lymph node metastases and should be offered extended field 
radiation. The failure rate of 15-20% in the para-aortic area has been 
reported for patients receiving pelvic radiation only. Radiation therapy is 
useful in early stage disease in patients with high risk of recurrence, to 





2.3.2.2.1.2 Hormonal therapy 
 
 
Hormonal therapy is reserved for use in advanced stage disease or 
patients with recurrent disease who are hormone receptor positive 
endometrioid adenocarcinomas (62). Progesterone is usually drug of first 
choice followed by tamoxifen as second line agent (74). Aromatase 





The of the value of adjuvant chemotherapy in patients with high-risk 
stage 1 disease is thought to be positive, however, it is thought the 
PORTEC 3 trial will answer this question. The PORTEC 3 was set up to 
compare adjuvant radiation therapy with adjuvant chemotherapy and 
pelvic radiation. The clinical implications of the results of the PORTEC -
3 trial are that chemo-radiotherapy possibly benefits patients with stage 3 
disease because of their high risk of recurrence (76). At least four other 
prior randomised controlled trials have compared various 
chemotherapeutic regimes with radiation therapy without a survival 
advantage although an advantage in progression free survival is observed 
(77). 
 






Variable response rates ranging from 40-70% have been reported(78). A 
possible progression free survival advantage of 6 months can be expected 
with a median overall survival of about 12 months for advanced stage or 
recurrent disease (79). In a meta-analysis of 14 eligible trials, the 
response to various chemotherapeutic regimes was reviewed for patients 
with recurrent or metastatic uterine cancer. The review concluded that 
whilst more intense chemotherapeutic regimes may benefit patients by 
improving PFS and OS, the most safe and beneficial regime was yet to be 
identified. Chemotherapy was found to treat distant metastasis; local 
prevention of recurrence did not occur (80).   
 
 
2.3.2.2.1.3.2 Second line chemotherapeutic agents 
 
 
There is an unmet need for second line agents. Currently one point of 
view is the emergence of resistance to current chemotherapeutic drugs 
resulting in a reduced clinical benefit.  
 
 
2.3.2.2.1.4 Novel agents 
 
 
The poor outcomes associated with patients of advanced or recurrent 
uterine cancer has potentiated the need for new treatment approaches 
amongst clinical oncologists. Epothilones are new class of microtubule-
stabilising agents (62). Ixabepilone when paired with capecitabine has 




A randomised open-label phase III study is to assess the response in 
women with locally advanced, recurrent or advanced uterine cancer of 
ixabepilone to paclitaxel or doxorubicin (81). 
 
 
2.3.2.2.1.5 Targeted therapies 
 
 
Targeted agents appear to have a potential role when used with second-
line and third line chemotherapeutic agents to target certain molecular 
abnormalities. mTOR inhibitors, EGFR tyrosine kinase inhibitors and 
VEGF inhibitors are being evaluated. The Cochrane Systematic database 
has put a working group in place to review the evidence base for the use 






The gold standard is total abdominal hysterectomy and bilateral salpingo-
ophorectomy 
(https://bgcs.org.uk/BGCS%20Endometrial%20Guidelines%202017.pdf 
). Some centres in the UK perform pelvic lymph node sampling to plan 
external beam radiotherapy. In a multi-centre US study that evaluated 
1577 patients with Stage II disease, patients who had a modified radical 
hysterectomy (379) followed by radiation therapy had a significantly 







Patients staged as IIIA disease i.e. involvement of the uterine serosa, 
tubes and ovaries, is surgically resectable with a favorable prognosis with 
or without adjuvant therapy. Only 0.6% present with stage IVA disease 
and treatment needs to be individualised. A modified pelvic exenteration 
may be an option. Patients with stage IV B disease have poor prognosis 
and the lung is the most common site of extra-pelvic disease. There may 
be individualised role for cytoreductive surgery, combined with 
chemotherapy and radiotherapy. 
 
 
2.3.3 Recurrent Endometrial Cancer 
 
 
Robust clinical trials are have been called for to improve the treatment 
paradigm for metastatic or recurrent endometrial cancer. Surgery, 
radiotherapy and chemotherapy can have a role in part or not for the 
management of recurrent disease. In a study of 379 recurrent endometrial 
cancer patients it was reported that about a third of women were 
asymptomatic at presentation, a third had had bleeding per vaginum and 
some had lower abdominal pain.  About half these patients had a local 
recurrence, less than a third had metastasis (29%) and in 21%, both local 
and distant metastases were present. The average time to recurrence was 
12-14 months for pelvic disease and distant metastasis usually occurred 






Isolated vaginal metastases are responsive to radiotherapy. For bulky 
lesions surgical resection prior to radiotherapy may improve local 
control. Pelvic exenteration may be considered in those patients who have 
a localised pelvic recurrence after radiotherapy. As part of patient workup 






Those with a long interval from primary treatment and of good 
performance status can be good candidates for surgical resection 
following an isolated recurrence in the lungs, liver or pelvis. 
 
 
2.3.3.1.1.2 Hormonal Therapy 
 
 
There is insufficient evidence to support a survival benefit from hormonal 
therapy and currently any treatment should be individualised (75). Up to 
a 15% response may be seen in those with estrogen receptor positive 








The administration of chemotherapy for metastatic disease applies to 
recurrent disease and is discussed in detail in the above section. The role 
of chemotherapy in recurrent endometrial cancer follows a careful 
consideration of the patients associated co-morbidities and history of 
previous pelvic radiation. The first line chemotherapy is often carboplatin 
in combination with a taxane or anthracyclines. There results are often 
short term with response ranging from 30%-60% in patients. The current 
response to second line treatment is disappointing. The GOG reported a 
response rate of 35% with paclitaxel and median duration of response of 
4.2 months. Newer targeted agents are being investigated such as 
sorafenib, bevacizumab and traztusumab.  
 
 
2.3.4 Management of advanced cervical cancer 
 
 
529,800 cases of cervical cancer were recognised worldwide with 
275,100 deaths in 2012 (http://www.cancerresearchuk.org/cancer-
info/cancerstats/types/cervix/incidence/uk-cervical-cancer-incidence-
statistics#world). The prognosis for stage 1 and stage IIA disease is good 
with five-year survival rates of  >90 and 85% respectively (84). The 
primary treatment for early cervical cancer is radical hysterectomy or 
chemo-radiation and on occasion using both modalities of treatment when 
the response to initial treatment is suboptimal or in the presence of high 
risk factors (84). Concurrent chemotherapy and pelvic radiotherapy in 
advanced cervical cancer (stage IIB-IVA) reduces the risk of recurrence 






Patients with advanced cervical cancer can have several patterns of 
failure of treatment to include persistent disease, local or distant 
metastases. The goals of treatment change from cure to palliation with the 
main aim being symptom control and reducing disease burden. 
 
2.3.4.1 Patterns of failure 
 
 
2.3.4.1.1.1 Local failure 
 
 
The most common pattern of recurrence is local failure and may follow 
primary treatment either surgery or chemo-radiation. Local recurrence 
may be central, or peripheral either in or outside the radiation field.  
 
 
The risk of a central recurrence is 7% for Stage IB and 15% for stage IIA 
disease. Of patients with stage III and IV disease, 20-35% may recur 
centrally(86). Occasionally, very few patients are suitable for a radical 
hysterectomy, however the treatment is a pelvic exenteration. The ‘cure’ 
rate following a pelvic exenteration is 25-80% and is dependent on stage 
at diagnosis, size and extent of lesion, and the interval from primary 
treatment to presentation (87). Patients with persistent disease and within 
six months of primary therapy have a poorer prognosis. These patients 
require an extensive clinical work up to exclude distant metastases and 




implications from a pelvic exenteration and patients need time and 
support from the team to come to terms with this procedure. 
 
 
Cancers that involve the anterior urogenital compartment, an anterior 
pelvic exenteration may be suitable and includes enbloc resection of 
uterus, parametrium, and bladder with formation of neobladder using a 
detached segment of ileum (89). Continent procedures are associated with 
longer operative times, higher peri-operative complication rates and 
higher rates of return to theatre. 
 
 
Posterior pelvic exenteration involves removal of rectum, with the uterus. 
Either exenterative procedure may extend above or below the pelvic 
floor. In cases where the exenteration is infralevator, the procedure may 
require removal of the urethra, clitoris, the vagina and anus. In such cases 
an end colostomy is formed and consideration is given to restoration of 
the pelvic floor with a myocutaneous flap (89). 
 
 
Complications include blood loss, infection, stoma problems, fistulas, 
flap necrosis and anastomotic leaks in the immediate postoperative 
period. The risk of death following this procedure is 3-10%(90). Patients 
can suffer from intestinal obstruction, diarrhea, malabsorption 







Patients who have not been previously irradiated can opt for radiation 
therapy. Radiation has its side effects on bowel and bladder and in those 
who have been previously irradiated and do not wish surgery in addition 
to the complications from radiotherapy these patients have an increased 
risk of fistula formation. 
 
 
2.3.4.1.1.2 Peripheral recurrence 
 
 
Recurrences occurring outside the radiation field can be treated with 
concurrent chemo-radiation. Advanced imaging techniques such as 
dynamic MR imaging and PET scan have enhanced treatment planning. 
Recurrence within the radiation field is incurable if the patient is not 
suitable for an exenterative procedure. These patients can be salvaged 
with chemotherapy. Response rate to single agent chemotherapy in phase 
II trials is 10-15% (92) and to combination chemotherapy is around 30-
60% (93).  
 
 
2.3.5 Presentation of recurrent disease 
 
 
Central recurrence may present with foul smelling discharge following 
tumour necrosis at the vaginal vault. Patients may present with renal 
failure secondary to a large central recurrence and subsequent ureteric 
obstruction. Peripheral recurrences can present as deep vein thrombosis, 




involvement of the obturator nerve or sciatic nerves or via pressure on 
these structures. 14% of patients can have severe bone pains, secondary 
to bone metastases or fractures and rarely leg weakness secondary to cord 
compression. 
 
2.3.5.1 Distant spread 
 
 
The predominant route for distant spread for recurrent cervical cancer is 
via lymphatics. The symptoms therefore may be pain, anorexia, weight 
loss or cachexia. The role of treatment is to palliate symptoms with 




The response to single agents/combination is variable and is dependent 
on a number of factors including age, performance status, histology, site 
of recurrence, number of sites of metastases previous treatment and 
interval from previous treatment. The most active agents described in the 
literature are carboplatin, paclitaxel and topotecan. 
 
 
GOG 179 compared cisplatin to cisplatin and topotecan. The response 
rate was 27% with the combination and 13% when patients were treated 
with single agent carboplatin, however the response was regarded as 
temporary (94). The use of carboplatin and paclitaxel is now regarded as 




role of targeted therapies is currently being investigated in phase 3 trials 
with promising results from phase 2 trial data (96).  
 
 
To conclude, the treatment of advanced cervical cancer is not without 
challenge. Women with recurrence are best investigated by PET CT, 
which has high sensitivity and specificity for the detection of local and 
distant metastasis (88). Biopsy of disease recurrence should be performed 
prior to initiating treatment. Chemo-radiotherapy is offered to those 
patients who have not been treated with radiotherapy in the past with aim 
of achieving cure(97). For those patients with a history of previous 
radiotherapy, surgery can be offered in the form of hysterectomy or 
pelvic exenteration, however these cases require careful selection and 
counseling due to high morbidity and mortality (98)with little randomised 
controlled evidence  supportive of such procedures (99). Chemotherapy is 
the modality of choice for the treatment of distant metastasis and 
platinum agents are more effective than non-platinum agents (100). 
 
 
2.3.6 Management of advanced or recurrent Vulval Cancer 
 
 
Vulval cancer is a rare gynaecological malignancy and accounts for just 
5% of presentations. Approximately, 33% of patients present with 
advanced stage disease (101). Most elderly patients present late, are 
reluctant to be examined and some primary care physicians are reluctant 
to examine, resulting in late referral (102). The cornerstone of treatment 
for most patients is a radical vulvectomy and bilateral inguino-femoral 




butterfly incision and although, cure was achieved, but at the cost of 
significant morbidity and mortality (103). Management is now towards 
an individualised approach with excision planned according to the size 
and site of tumour (104). Nevertheless, adequate disease free margin and 





Patients with advanced disease are complicated as these patients usually 
have large lesions often close to or impinging on the anus or urethra, 
complicating excision and on occasion continence. Furthermore, primary 
closure may be difficult leading to wound dehiscence, extensive scarring, 
disfigurement and loss of sexual function(105). Such patients need an 
extensive preoperative workup and counseling. Individualised care to 
include appropriate multi-disciplinary involvement from anesthetics, 
plastic surgeons, urologists, colorectal surgeons and oncologists must be 
undertaken. Physical and psychological morbidity may be considerable 
(106) if additional ultra-radical procedures need to be performed and 
postoperative mortality may be up to 20%. Radical excision or an 
exenterative procedure followed by plastic reconstructive surgery and 
bilateral groin node dissection can be followed by significant morbidity 
(107). It is imperative that patients of an advanced age are adequately 
counseled and the impact of procedures that may result in incontinence is 









The vulval skin is thin and delicate and extremely sensitive to high 
dosage radiotherapy. Acute skin reactions including inflammation, 
desquamation and erythema can be expected, and can be followed by 
subcutaneous oedema, fibrosis and narrowing of the introitus. These 
events can have a significant psychological impact especially on young 
patients. However, adjuvant radiotherapy is effective in improving 
outcomes in patients found with positive surgical margins (109). Another 
group thought to benefit from additional radiotherapy are patients with 
two or more malignant lymph nodes (110).  
 
 
2.3.7 Recurrent Disease 
 
 
80% of recurrences and about a third of patients will recur. These patients 
are usually elderly and require careful follow up to detect a recurrence 
early enough to ensure adequate management. Those patients who recur 
following a short interval from primary treatment, with nodal or distant 
metastases and with high-grade disease generally demonstrate poor 
prognosis. Management options depend on previous extent of surgery, 
previous radiotherapy, performance status and general health and wishes 
of the patient. Multi-disciplinary care with involvement of palliative care 
for symptom control and maintaining quality of life are usually the most 






Patients may be offered radical excision for single site local recurrence 
may be curative in a previously irradiated patient. Plastic reconstruction 
with flaps may be considered and effective. Five-year survival rates for 
isolated vulval recurrences following complete excision can range from 
50% to 70%. A unilateral or bilateral groin node dissection may be 
appropriate if not previously performed (111). Radiotherapy can be 
considered in a radiotherapy naïve patient with positive surgical margins. 
 
 
Palliative exenterative surgery may be considered in patients with locally 
extensive disease who have had a severe impact on their quality of life 
due to severely debilitating symptoms (101). The possible morbidities 
from such a procedure must be clearly and honestly explained to the 
patient. Nodal recurrences are extremely difficult to manage and although 
a combination of surgery, chemo-radiotherapy can be considered, 
outcomes are poor and treatment depends on previous modalities 






The lymph node status and stage of disease correlate with survival. Node 
negative patients had a 5-year survival of 80.7%, however if two or more 
nodes were positive it fell to less than 25% (108).  
 
 
To conclude, the management of vulval cancer warrants an individualised 




The aim is to excise disease with 1cms of healthy margins by performing 
a wide radical excision and a groin lymphadenectomy to assess spread, 
where depth of invasion is greater than 1mm (112). Sentinel lymph node 
mapping may help reduce the incidence of lymphedema formation, but is 
still only to be performed under the umbrella of clinical research trials 
(113). The role of chemotherapy is limited, however, neoadjuvant 
chemotherapy has been used to shrink disease with advanced 
presentation. There is limited evidence for this approach with no added 
advantage in survival (114). As described above, radiotherapy is 
beneficial to patients with positive disease margins reducing the risk of 




2.3.9 Vaginal Cancer 
 
 
2% of cancers of the vagina are a subset of primary gynaecological 
cancers (115). These are primarily squamous cell cancers, although 
melanomas, adenocarcinomas and sarcomas are also seen (116). 
Sarcomas of the vagina are occasionally seen after radiotherapy for 
cervical cancer. Vaginal cancer is often diagnosed in the seventh, eighth 
and ninth decade.  
 
 
The most common site of disease is the upper third of the vagina and is 
associated with abnormal discharge and bleeding. On occasion patients 






Experience with primary vaginal cancer is limited and treatment needs to 
be individualised. Treatment may involve surgery and or radiotherapy. 
Patients with stage 1 disease with an intact uterus may be suitable for a 
modified radical hysterectomy with bilateral pelvic lymphadenectomy 
(117). An upper vaginectomy and pelvic lymphadenectomy can be 
planned for patients with a previous history of a hysterectomy (118). 
Patients with a recto-vaginal or vesico-vaginal fistula may be suitable for 
an exenteration. 
 
Radiotherapy is the treatment of choice and comprises of a combination 
of external beam and brachytherapy (119). Chemo-radiation use is 
reported as per the cervical cancer regime, however experience with 
outcomes is limited (120). 
 
 
Complications with treatment are in the 20% range. Complications 
following radiotherapy include radiation cystitis, proctitis, fistula 
formation and rectal stricture formation. Radiation necrosis of the vagina 




The median 5-year survival is 40% for cancer of the vagina. Most 
recurrences are in the pelvis and salvage rates are very poor (117). 
 
Vaginal cancer is a rare gynaecological malignancy. Surgery for stage 1 
disease allows preservation of ovarian function and the avoidance of 




malignancy (121). Radiotherapy is the main modality of treatment for 
patients beyond stage 1 and are offered external beam radiotherapy and 
brachytherapy with curative intent. The survival rates for advanced 
disease are poor. 
 
 
2.4 Symptom control 
 
Women with advanced gynaecological cancer often present with 
distressing symptoms and the primary aim, prior to initiating treatment, is 
symptom control and comfort with an effort to maintain dignity and thus 
reduce distress at the end of life (117). Estimates of survival often 
underpin the clinical decision-making process especially for patients with 
advanced cancer and their symptom control. The considerations are often 
the performance status, symptoms of the cancer recurrence, previous 
treatment and disease free interval if any. In general effective anti-cancer 
treatments offer the best symptom control if deliverable and is guided by 
whether the patient is or has been responsive to treatment in the past. 
However, the futility of aggressive chemotherapy may result in a much 
poorer quality of life than that of an untreated patient. 
 
 
Symptoms may be a result of relapse, complications of treatment or from 
unrelated causes. The severity of symptoms can be variable for individual 
patients and some particular symptoms may have more of a psychological 






Patients with advanced gynaecological cancer, can present at the end of 
life with symptoms of or recurring symptoms of bowel obstruction, 
ascites, pleural effusion, urinary obstruction, pain, deep vein thrombosis 
or fistulae (8). The management of some of these symptoms are described 
in the next section. 
 
 
2.4.1 Refractory Ascites 
 
 
Ascites is ‘the build-up of fluid in the abdomen’ and can be the outcome 
of advanced ovarian or endometrial cancer (122). Assessment of these 
individuals requires careful consideration of physical, social, 
psychological and practical issues.  
 
 
The goals of treatment need to be carefully considered. Systemic or 
intraperitoneal chemotherapy may be options in patients with chemo-
sensitive disease.  In patients who are non-responsive to chemotherapy 
the aim is often symptom control. Paracentesis aims to reduce ascites and 
provide symptom control. The complications of repeated ascites drainage 
are hypovolemia, dehydration and loculation. When repeated paracentesis 
are required, consideration to implanted external catheters can be given 
which allow patients to drain the ascites at home and maintain comfort, 
rather than waiting for an appointment for drainage and can be performed 
under ultrasound guidance (123). There is no evidence on the timing of 
these catheters and when they should be best placed and no studies exist 
that compare the outcomes of the placement of these catheters with serial 




routinely performed due to the invasive approach and high complication 
rates.  
The role of diuretics is being explored in patients where the serum-
albumin gradient is greater than 11mg/dl.  
 
 
2.4.2 Malignant Bowel obstruction 
 
 
Malignant bowel obstruction (MBO) is multifactorial and in advanced 
disease and can be seen in up to 20% of ovarian cancer patients (124). 
Established bowel obstruction is associated with a median life expectancy 
of 4-5 weeks. The presenting symptoms may be abdominal pain, nausea, 
vomiting, loss of appetite and the inability to pass flatus. 
 
 
These patients need individualised management with careful 
consideration of treatment goals (125).  A metanalysis of 43 studies 
suggests the need for careful consideration prior to proceeding to surgery 
(126). Initial supportive therapy involves providing pain relief, anti-
emetics, corticosteroids and anti-secretary agents. It is unlikely that 
patients with MBO towards the end of life have a single site of 
obstruction. These patients usually have multiple sites of obstruction and 
surgery can be technically difficult. The decision to operate should not 
been taken lightly, with the patients’ wishes and anticipated survival 
discussed frankly prior to any intervention (127).  Most patients end up 
with a bypass procedure or a permanent defunctioning procedure. 
Recently, more focus has been given to colorectal stents especially if 






2.4.3 Urinary tract obstruction 
 
 
Obstructive uropathy may occur following pelvic, retroperitoneal or 
abdominal cancers. Bladder outlet obstruction is seen in advanced 
cervical cancer, vulval cancer or urethral cancers. 50% of cervical cancer 
patients die following urinary tract obstruction. Ureteric obstruction may 
be as a result of enlarged para-aortic nodes causing extrinsic compression 
from disseminated ovarian or cervical cancer. Rarely sarcomas can 
contribute to this presentation of late stage disease. 
The management is dependent on the site of obstruction, the patients’ 
general condition and estimated survival.  
 
 
A full assessment should include a complete history and discussion with 
the patient about her goals and priorities. Aggressive treatment of urinary 
obstruction may not always be appropriate and multidisciplinary care is 
required. In the terminal stages, symptom management may be all that is 
possible and or reasonable. Conservative management involves pain 
relief, fluid resuscitation and correction of electrolyte balance, and 
possibly an assessment of the site of the obstruction via CT or MRI if 
decisions on an intervention are to be undertaken.   
 
 
Drainage or relief of obstruction may involve placement of a urinary 
catheter or suprapubic catheterisation. Nephrostomy insertion is reserved 






More definitive procedures may involve implantation of the ureter into 
the other side, re-implantation of ureter into bladder following treatment 
of a distal ureteric stricture, or complete urinary diversion, which 
involves implanting ureters into the terminal ileum forming an ileal 
conduit which is brought to the surface as a urostomy. These are usually 
major procedures that require a good performance status and survival is 
anticipated.  
 
2.4.4 Management of Fistulae 
 
A fistula is ‘an abnormal connection linking two epithelial surfaces’. In 
the context of gynaecological malignancy most fistulae relate to abnormal 
connections between the vagina and bladder or rectum or between the 
bowel and skin surface. Fistulae can occur following radiotherapy or 
surgery or may be a primary presentation of advanced stage disease or 
disease recurrence.  
 
 
A multidisciplinary approach is helpful, as often patients will need 
psychological as well as physical support as well. Management is usually 
aimed at controlling symptoms and improving the patients’ quality of life. 
Unfortunately, the evidence is lacking on how best to manage this rare 
complication. The primary aim should be symptom control. For vaginal 
fistulae, a tampon can be considered to reduce discharge along with an 
indwelling catheter. Stents can be inserted to protect from ureteric 






Drugs to reduce effluents can be prescribed such as codeine phosphate for 
recto-vaginal fistulae and often patients will require barrier creams to 
protect the skin. The use of parental nutrition must be carefully 
considered in end of life care patients.  
 
 
Definite repair involves diversion of fecal or urinary stream with the aim 
of repairing the fistula. Most patients with advanced disease will not be 
suitable candidates for intervention and clinical decision making depends 
on the stage of disease, previous radiotherapy, projected survival and 
performance status. 
 
2.5 End of life Care: review of literature 
 
 
The purpose of the literature review was to identify published studies that 
describe the place of death for gynaecological cancer patients and assess 
the impact of socio-demographic variables and interventions in the last 
month of life on the place of death of gynaecological cancer patients. The 
work also tried to identify if any descriptions of variations in end of life 
care in England that had been studied for this set of cancer patients. 
 
 
The search terms, their synonyms and combinations there of used were -
‘gynaecological cancer’, ‘end of life care’, ‘palliative care’, ‘place of 
death’, ‘determinants’,’ quality’, ‘demographic’, ‘socio-economic’, 




‘variations’, ‘ascites’ and ‘paracentesis’ in search engines including 
PubMed and Medline for relevant literature. All abstracts in the English 





There are limitations of the search strategy. The terms ‘end of life care’ 
and ‘palliative care’ have been used interchangeably. Only articles in the 
English language were shortlisted for further study. The United States 
and Scandinavian countries have rich administrative databases and thus 
reports from developing countries on end of life care are hugely deficient. 
It was found that most studies included either cancer and or non-cancer 
patients with very few studies focusing on a specific cancer type and its 
specific issues at the end of life. With the issue of lack of standardised 
terminology, increased the inability to generalise results. 
 
 
2.5.2 Studies relating to place of death  
 
The search identified 6 systematic reviews and 41 other study results 
relevant to place of death, including some qualitative but primarily 
retrospective quantitative work. The key studies are highlighted below 
and in Table 2.1 and described below. 
 
 
The literature review highlighted a number of significant studies, 




to assess the place of death and the secondary outcome was to identify, if 
possible, the factors that impacted on place of death, if any and that were 
uniformly reported in a variety of studies. For the purpose of this research 
the author concentrated on the gynaecology oncology population.  
 
The study design of the majority of the studies was observational and 
retrospective where, only one study collected data prospectively, with the 
aim of assessing the impact of home based palliative care on the final 
place of death of 110 Canadian patients (129). All the described studies 
vary in quality and included many heterogeneous populations, the results 
of whom pertained to the general population, cancer and non-cancer 
patients, preventing generalizability of results. The participants included 
in the various studies ranged from 110 participants to 2.2million 
participants. The origin of the participants of most of the studies was 
from high-income countries. It is known that the quality of end of life 
care based on place of care for different countries is thought to vary 
significantly (130). The place of death continues to be regarded as a 
‘marker’ of the ‘quality of end of life care’ and it is reported that 
satisfaction with end of life care services improves if death occurs in a 
place of one’s choosing (131). However, it has been recognised more 
recently that with disease progression, preference with respect to place of 
death may become less important with other determinants, such as control 
of symptoms of disease prior to death and the availability of support for 
the same in the community taking priority (132, 133). An early 
systematic review which included 18 studies was published in the year 
2000, confirmed that for the majority, the preferred place of death was 
home followed by death occurring in a hospice for the general population 




change in trends for cancer patients in England with respect to their place 
of death included 1.3 million decedents. This study found that the number 
of deaths occurring in hospital had dropped significantly from 58% in 
1985 to 47% in 1994 with an observed surge in the number of deaths in 
hospices in England (135). Home, as the preferred place of death, 
continues to be reiterated in a fairly recent weekly statistics update from 
the USA, the proportion of hospital deaths fell by 25.7%, i.e. from 50.2% 
in 2000 to 37.3% in 2014. Further, in this update, it was reported that 
during the period 2000-2005, the proportion of demises in nursing homes 
or long-term care facilities were unaffected but fell by 10.1% over the 
next decade i.e. during 2005-2014. From the years 2000 to 2014, the 
proportion of home deaths increased to 29.5% and of particular 
significance was the increase in hospice deaths by 242.9%, from 3.5% in 
2000 to 12.0% in 2014 (http://www.cdc.gov/mmwr/index2016.html/ 
published 8/04/2016). Interestingly, in countries such as Italy, Japan and 
Taiwan the incidence of hospital deaths has increased possibly due to 
changing demographics and trends in availability of end of life care 
services(136).  Recently S Hoare et al challenged home as the preferred 
place of death having reviewed the literature concentrated on the UK 
population. They questioned the impact of missing preferences on place 
of death. From 2000-2015 they included 61 studies of varying evidence 
grade including grey literature. They concluded that when missing data 
was included in the analysis, the proportions for each place of death (e.g. 
home, hospice or nursing home) were suppressed. They admitted that the 
some of limitations of their study were that the heterogeneity of the 
studies precluded a robust meta-analysis. A number of public surveys 
were included in the study where the absolute number of participants 






 Many cancer patients choose to die at home or in familiar surroundings 
preferring to avoid an institutionalized death, however 54% of cancer 
patients of a study of 45 nations still died in hospital (138). This suggests 
a continued discrepancy between preferred place of death and actual 
place of death.. The results of a recent VOICES questionnaire suggested 
that in England less than 50% of terminal patients had their preferred 
place of death recorded, and that it was unlikely that a home death would 
be achieved. However, cancer patients would probably achieve their 
preferred place of death (139). Gomes et al also assessed this in a 
systematic review of 210 studies. This review included a number of poor 
quality studies, a heterogeneous population (the general public, cancer 
and non-cancer patients), and 8 qualitative studies, which included patient 
and caregiver transcripts. However, this systematic review concluded that 
4/5 patients were unlikely to change their preference with respect to place 
of death and that majority preferred a home death (140). In a secondary 
analysis of data from the National Survey of Bereaved People, advance 




Recently, studies on place of death in England have confirmed trends 
with respect to home death {Gomes, 2012 #5998}. This paper reports the 
incidence of home deaths, has steadily increased from 18.3% in 2004 to 
20.8% in 2010. It is however important to highlight that the incidence of 




The explanation for the increasing incidence of deaths occurring outside a 
NHS hospital may be the introduction of the ‘National End of life Care 
Programme’ in 2004 and the ‘End of Life Care Strategy’ in 2008. The 
impact of more recent measures such as the Amber Care Bundle, 
Electronic Palliative Care Co-ordination Systems and Rapid discharge 
and their contribution to the actual place of death are awaiting evaluation. 
Therefore with respect to place of death, the literature suggests that most 
patients wish to die at home, however a good number of patients continue 
to die in hospital and this was found to vary by country. 
 
Apart from small retrospective studies (141-143) three of the six 
systematic reviews (144, 145) & (146) aimed to investigate the various 
factors that impacted on the place of death. The determinants of a home 
death are believed to be multifactorial and relate to the broad categories 
of, the illness, individual factors and environmental factors that include 
level of social care and health care available prior to death (144). Gomes 
et al reported on the outcomes of a systematic review which included 58 
studies and more than 1.5 million patients more than 80% of whom had 
cancer. They found that their population was heterogeneous and that there 
was wide variation in the quality of the included studies, some with 
conflicting results. They arrived at a final model, with six factors 
associated with a home death: poor performance status, patient 
preference, pre-existing home care and its frequency, carer support at 
home. A more recent systematic review looked at the determinants of a 
home death and death occurring in a nursing home. This review included 
26 retrospective studies. The paper once again concluded that the causes 
of a death occurring at home or death in familiar surroundings were 




palliative care and or the support of a specialist home- based palliative 
care team, might improve the prospect of a patient dying where they 
choose (146). Rainford et al concluded that community palliative care 
significantly contributed to a home death. Another retrospective study 
observed in a German population of 439 deceased patients, found that 
52.2% had a home death, and 47.8% had a hospital or hospice death. The 
factors strongly impacting on a home death were a member of the family 
caring for the dying in the last days prior to death and intensive input 
from the GP when end of life was recognised. Patients with multiple 
comorbidities and poor performance status were less able to die at home 
(147). A recently reported study included patients from 14 countries; the 
place of death was assessed with respect to socio-demographic 
differences and the convenience of palliative care services. The study 
found a wide variation the proportion of patients dying from various 
causes and in the place of death. The study concluded that such large 
variations might be explained by variations in end of life care policies of 
various countries (148). A large retrospective study of English cancer 
patients showed that marital status and socio-economic status impacted 
on place of death (149). 
 
 
 The level of input received by patients who have access to home-based 
palliative care teams may predict a home death. This aspect of care was 
studied of the 1690 end of life care Belgium patients, some of whom had 
home based palliative care (141). In another study (by the same group) of 
3672 chronically ill patients, majority (63%) died in hospital. Of those 
residing in care homes, about one fifth also died in hospital. This study 




probably choose to die at home when compared to cancer patients who 
were of a lower socio-economic group (150). A Cochrane systematic 
review aimed to determine if home based end of life care reduced the 
possibility of a hospital death. The authors concluded that the availability 
of home based palliative end of life care programs would likely impact on 
the same (151). 
 
Qualitative surveys suggest that patients and their carers may give 
preference to alleviation from pain and distress over place of death. In the 
absence of specialist palliative care in the community, hospital may 
provide an environment of professional support (152). 
 
A more recent published study of patients with advanced cancer in Japan 
found that specific symptoms at the end of life might impact on place of 
death. This study used structured interviews; to assess symptoms that 
may have influenced a change in the preferred place of death of 123 of 
end-of-life cancer patients. The outcome measured was the place of death 
(Home/Hospital/Still surviving) and the independent variables were the 
patient's symptoms as a time-dependent variable. The study found that of 
all patients, 53 had a hospital death, 52 a home death and 16 still 
survived. When pain and dyspnea were present, patients preferred the 
hospital (adjusted sub hazard ratio [SHR]: 1.50 [95% confidence interval 
(CI): 1.23-1.83] and 1.71 [95% CI: 1.36-2.15], respectively); when 
delirium was present, a hospital death was less probable (adjusted SHR: 
0.64 [95%CI: 0.43-0.96]); The study recommended that pain and dyspnea 
in dying patients should be managed swiftly by allowing these patients 
easy access to hospital via a rapid admission system to either a 




palliative care input at home was required to prevent unnecessary 
prolonged admissions in hospital leading to death in hospital (133). 
Therefore, more recently the occurrence of a home death as an outcome 
measure of the ‘quality of end of life care’ for a country or community 
has been questioned with the need for more specific independent markers 
of ‘quality of end of life care’ and services. 
 
Strengths of search results: The studies on place of death concentrate 
from a number of high-income countries and intend to provide an insight 
to the place of death of various populations and inform on trends where 
possible. The data is predominantly derived from administrative 
databases, which allow for assessment of the influence of socio-
demographic factors and resource use on the ‘places of death’. A number 
of studies include a large number of participants increasing the strength 
of evidence. The results of these studies are important as they suggest that 
the place of death is still used as a proxy indictor of the quality of end of 
life care in many countries. The results of these studies may have 
impacted on local policy and the future development of end of life care 
services of various countries. 
 
Limitations of search results: The studies discussed above include both 
non-cancer and cancer populations. One systematic review included 
results from both quantitative and qualitative analysis. Due to the 
heterogeneity of the populations it is not possible to confidently report on 
outcomes and where missing data has not been reported. The definition of 
home, care home, hospice etc. is not standardised for all countries making 
comparison further difficult. It is not clear of the studies that explore 




the patient or carer and the added complication of missing data, which 
may have a significant impact on the interpretation of results, however 
both issues should be considered future foci of research.  
 
Interpretation:  Home remains the preferred place of death although a 
significant proportion die in hospital. The above studies suggest that a 
number of factors may influence place of death, the type of illness (i.e. 
cancer or non-cancer), availability of resources, availability of palliative 
care, severity of symptoms, socio-economic status, availability of support 
at home and the preference for a certain environment. Some of these 
factors require further investigation. A number of national campaigns 
such as Dying matters (https://www.dyingmatters.org/overview/about-us) 
encourages the public to talk about death and allows for ‘choice’ to be 
exercised at the end of life. It is clear that the current evidence is deficient 
and future research is required into place of death and the experience of 
dying. Moreover, for the purpose of this thesis, little evidence was found 
with respect to the place of death of English gynaecological cancer 
patients, the change in trends, if any and the factors that may influence 



















2.5.3 Interventions at the end of life and the impact on quality of 
care 
 
There are at least two aspects of resource use at the end of life; 
interventions, appropriate or inappropriate, undertaken to allegedly 
improve the quality of life at the end of life and the actual cost of these 
interventions with their collective impact on the individual and family, 
such as an emergency admission days before death. ‘Markers of quality 
of end of life care’ which are also markers of ‘aggressiveness of end of 
life care’ have been outlined by Barbera et al and are described as, 




hospital bed’, ‘visits to the emergency department in the last two weeks 
of life’ and ‘GP visits in the last two weeks of life’. 
The aim of the literature search was to identify studies, which had aimed 
to identify the impact of interventions especially via the emergency route 
on place of death for gynaecological cancer patients. 11 studies were 
identified of which only three in the published literature were specific to 
gynaecology oncology patients. One systematic review, included 78 
studies, reviewed resource utilisation of cancer patients and included 3.2 
million patients (153). Other studies were observational studies where 
administrative data has been reviewed retrospectively bar one prospective 
study (154). The outcomes studied were chemotherapy in the last month 
of life and the number of emergency admissions in the last month of life. 
These outcomes had been identified as ‘proxy indictors’ of the quality of 
end of life care (20). Of the three studies related to gynaecology oncology 
patients, one study reviewed resource use of 2040 ovarian cancer 
patients,, 4% of whom had a chemotherapeutic agent, 34% attended the 
emergency room and 27% were reviewed by their GP at home, 51% were 
admitted to and died in a hospital bed (155). By comparison, Fauci et al, 
explored in detail the quality of care issues of women with 
gynaecological malignancy at the end of life on 268 women in the USA, 
57.8% of who were diagnosed with ovarian cancer. In the last 180 days 
prior to death, 57% of patients had chemotherapy and many had multiple 
hospital admissions. This study also suggested a dearth of data on length 
of stay in hospital prior to death and the need to assess the potential 
financial impact of palliative care input at this stage whether provided at 
home or via specialist hospital palliative care teams (156). The third 
study by Lewin et al calculated the cost of hospice and non-hospice 
deaths of 84 ovarian cancer patients and their resource utilization in the 




chemotherapeutic agents was noted in the hospital group without a 
prolongation in life (19).    
 
 
Other studies highlight resource use at the end of life in other population 
groups. In a recent retrospective study conducted by Pataky, of 24,030 
colorectal, lung, breast and prostate cancer patients, the use of 
chemotherapy at the end of life had risen by 21% from 12-14 months 
prior to death to the last 3 months of life with no improved survival (157). 
In another study of 81 gynaecological oncology patients, the patients 
enrolled in hospice care (n=29) were less likely to undergo an invasive 
procedure when compared to those who were admitted to hospital for 
symptom control (158). This study stressed the need to assess increased 
use of hospice care, where symptom outcomes were believed to be at 
least similar, thus suggesting an improved quality of life with no gap in 
survival amongst the two groups. In a recent retrospective review of 536 
patients with cancer, 14 days prior to death, it was found that breast 
cancer patients (OR 23.7) and gynaecological cancer (OR 7.64) patients 
were more likely to have a consultation with the palliative care team than 
respiratory or haematological cancer (159). Furthermore, patients who 
had had a referral to palliative care had a lower probability of undergoing 
chemotherapy or being admitted to ITU. Wang et al recently published 
the trends of chemotherapy use and emergency admissions for 132,051 
cancer patients signed up to the Medicare Beneficiary Programme in the 
USA. The study reported that the proportion of patients receiving 
aggressive end of life measures had increased significantly with an 
increase in hospitalisations, ICU admissions and late hospice recruitment 
(160). Bekelman et al (Table 2.2) performed a study involving cancer 




lowest number of hospital admissions occurred in the USA and 
Netherlands; the USA had the highest healthcare utilisation and therefore 
costs attributed to the same in the last 180 days of life (161).  
 
 
Strengths of search results: The above studies provide the first insight 
into the current resource use of patients at the end of life. The use of the 
‘proxy quality markers’ of end of life care i.e. chemotherapy and 
emergency admissions in the last month of life, allow benchmarking 
exercises to be performed amongst various patient populations. 
Observational studies using health administrative data has the ability to 
inform on future policy and end of life care.  
 
 
Limitations of search results: The percentage of patients receiving 
chemotherapy or undergoing an emergency admission has been assessed 
at different times of the end of life (six months, 1 month, two weeks prior 
to death), thus making it difficult to collate results and effectively report 
on outcomes which would have allowed judgments on resource use and 
discussions on quality of end of life care. The studies are reported from a 
small number of high-income countries with relatively well-developed 
palliative care programs, which precludes any generalizability of results.  
 
 
Interpretation: The above studies suggest that resource use in hospital 
increases at the end of life. There are only three small studies specific to 
gynaecological oncology patients that have investigated the use of 
chemotherapy at the end of life and imply that patients continue to 




cancer patients other than those with gynaecological cancer also suggest a 
recent increase in chemotherapy use at the end of life. It is clear from the 
above studies that further research into the interventions experienced by 
patients at the end of life and where they occur are required to understand 
the impact on place of death if any but to also further the development of 




















12 original research papers were identified that related to gynaecological 
cancer patients and various facets of end of life care during the study 
period (Table 2.3). Zakhour et al assessed the impact of end of life care 
discussions on ‘quality indicators’ of ‘aggressiveness of end of life care’. 
Of the 79 who had EOLC discussions as an inpatient, 27 (34%) died in 
hospital. In another retrospective study of 100 gynaecological cancer 
patients, those patients who had end of life care discussions (49%) had 
significantly lower aggressiveness of end of life (ACE) scores indicating 
less aggressive interventions and lower inpatient costs towards hospital 
stay in the last month of life. The hospital costs for the last 30 days of life 
was insignificant for patients with planned reviews, $0 (range 0-28,019) 
compared to emergency reviews, $7729 (0-52,720), p=0.01(162). A few 
studies have assessed the quality of end of life care with respect to place 
of death and interventions at the end of life, Barbera et al assessed 2040 
women with gynaecological cancer native to Canada and found that of 
those who died in hospital, 4% had had chemotherapy in the last 14days 
prior to death and 34% attended the emergency department (155). In 
another retrospective study by Brown et al of 183 women with 
gynaecological cancer, 93% of patients had some adjuvant treatment in 
the 180 days prior to death and majority had some invasive intervention. 
They also reported death in hospital for 22.4% of patients Brown, 2014 
#7139}. Nevadunsky et al found that of a 100 patients, 75 patients had 




in the 42days prior to death. Another paper from Alabama looked at 
palliative care use by 268 women with a gynaecological malignancy in 
the 180 days prior to death (156). The cancer journey of 62 EOL patients 
with cancer of the ovary is charted by von Gruenigen et al highlighting 
the most common symptoms encountered by this subset of patients 
during this time of their lives and therefore the medical services that they 
are mostly likely to require as a result of (8). Two small studies review 
resource utilisation and the costs of gynaecological cancer patients in 




 All these publications include a relatively small numbers of patients. 
Whereas the cohort studied for the purpose of this thesis includes 72,246 
patients over more than a 12-year period. There are no publications 
specific to the United Kingdom and gynaecological cancer patients have 
been studied in this thesis in significant detail. Currently the majority of 




There are no published studies that explore the specific determinants of 
the place of death for patients with gynaecological cancer in England, or 
explore their recent trends of place of death or reports on whether 
regional variations of end of life care exist especially in England. The 
studies outlined in Table 1, highlight those studies that have aimed to 
explore the factors that impact on place of death but none are specific to 














2.5.5 Ascites drainage at the end of life 
 
 
Ascites is the commonest complication of ovarian cancer at the end of 
life, with up to almost a third of patients encountering this problem (5). 
Literature on this common problem is significantly scarce with no study 
comprehensively assessing the impact of this symptom on the quality of 
life on gynaecological cancer patients in detail. During the last 6 months 
of life this complication tends to increase in frequency and requires 
multiple hospitalisations signaling the need for increased input (8). The 
approach to symptomatic relief involves the current goals of care and 
may involve intermittent paracentesis, indwelling catheters, palliative 
chemotherapy and targeted therapies. Patients may prefer, if given the 
option of avoiding admission into hospital, access to care in specialist 
palliative care units (SPCU’s) providing outpatient drainage of ascites 
(163). One aspect of this thesis work has been to identify drainage of 
ascites as the most commonly used intervention in the last year of life for 
gynaecological cancer patients. An attempt has been made following this 
to assess the socio-demographic factors that may impact on drainage of 
ascites in hospital and to assess further whether this in turn influences 





The objective of this chapter was to update the reader on the incidence of 




range of treatment options for advanced stage or recurrent gynaecological 
cancer.  Whilst standard algorithms for the management of 
gynaecological cancer are relatively well defined, this chapter also 
highlights the numerous palliative options available to patients, especially 
with advanced ovarian cancer at diagnosis. These patients can maintain a 
‘stable’ disease status with various anti-VEGF factors and have a number 
of trials available to them with newer agents introduced as advances in 
research occur. Patients with recurrent endometrial and cervical cancer 
can be re-challenged with chemotherapy and be offered radiotherapy if it 
has not formed a part of their initial treatment. Recent advances in 
radiotherapy allow treatment of vital areas such as the brain or lung 
metastases with apparently minimal side effects.  In addition, anti-VEGF 
factors are also being trialed in these sets of patients. These patients can 
also be offered pelvic clearance with various diversion techniques if all 
else fails, in spite of limited evidence. Robotic surgery has helped 
improve outcomes by reducing morbidity. It is clear that oncologists have 
a number of options available to them, as do patients who wish to prolong 
life. It is however also evident that most treatment responses for 
metastatic cancer are disappointing and results achieved are only 
transient. Often may treatment regimes are toxic and can significantly 
impact quality of life. Whilst it can therefore be derived from the initial 
section of this chapter that much can be done to extend the life of 
gynaecological patients, it also follows that many of these treatments are 
being offered to patients near the end of life. This is confirmed to some 
degree by the search strategy performed in the later half of this chapter. 
Many patients receive chemotherapy in the last year of life and are 
admitted to hospital as an emergency. The literature on gynaecological 
cancer patients is sparse and therefore one aim of this thesis has been to 




at the end of life and thus to assess resource use and understand the 
services they require. This may inform on the future development of 
palliative or end of life care services in hospitals and outside hospital. 
These issues are further explored in Chapters 7 and 8. 
 
 
The second section of this chapter reviews the current literature on place 
of death and the interventions received by gynaecological cancer patients 
at the end of life. Many observational studies have used health 
administrative data to inform on various end of life care issues. However, 
there is a dearth of literature with respect to where gynaecological 
patients die, the interventions received by these patients and the impact 
that these interventions have on place of death. The most significant 
limitation of the studies performed so far are that the populations 
included are heterogeneous, which has compromised the ability to draw 
firm conclusions. Having thus identified the gaps in the literature as 
detailed above, this thesis describes ovarian cancer patients as the largest 
homogenous gynaecological cancer patient population in detail with 
respect to their place of death and their socio-demographic factors 
(Chapter 4). The ovarian cancer group forms the reference group for 
multivariable analysis performed for all gynaecological cancers to assess 
(Chapter 5) the impact of emergency admissions on the place of death. 
This allows one to compare and contrast the variations in place of death 
of the individual gynaecological cancer sites. It may thus be possible that 
certain gynaecological cancer patients need more focus with respect to 
their end of life care. The analysis further intends to identify the most 
common interventions undergone by gynaecological patients to inform on 
the future planning of resources and perhaps where that may need to be 





3 Chapter 3: Design and Methodology 
 
 
3.1 National End of Life Care Intelligence Network 
 
The analyses for this thesis were undertaken at the National End of Life 
Care Intelligence Network (NEoLCIN). The National End of Life Care 
Intelligence Network was established in 2010 as part of the ‘National End 
of Life Care Strategy’ for England (http://www.endoflifecare-
intelligence.org.uk/resources/publications/what_we_know_now_2014). I 
held an honorary contract and having complied with all the appropriate 
information governance protocols, I was able to analyse the linked HES-
ONS dataset. Public heath England Knowledge and Intelligence (South 
West) hosts the analytical team for the National End of Life Care 
Intelligence Network which in turn supports the work of the National End 
of Life Care Programme at the Department of Health. In addition to 
maintaining End of Life Care profiles online, the NEoLCIN has issued a 
variety of reports on emerging end of life care issues related to cancer and 
non-cancer disease groups. 
 
3.2 Ethical Permission  
 
This study was undertaken as part of the normal public health intelligence 
function, for the purpose of service improvement, provided by NEoLCIN 
in discharging its contractual obligations (NHS Health Research 





Only secondary analysis of routine data sources was performed in this 
study and the use of the data followed the national HES protocol that 
explicitly allows user organisations (including NEoLCIN) to use the data 
for epidemiology and health research whilst abiding by the appropriate 
codes of conduct. 
3.3 Information Governance 
 
The author, whilst on site at the NEoLCIN, obtained access to the linked 
ONS and Hospital Episode Statistics. Authorisation was obtained through 
an honorary contractual arrangement and agreement of internal 
information governance arrangements. The NEoLCIN provided 
pseudonymised extracts from the main database that included all deaths 
in England for gynaecological cancer for the period of study to include 1st 
of January 2000 to 31st of December 2012. 
 
All querying and analysis of the data used in this research was undertaken 
in NEoLCIN offices under the appropriate information governance 
policies and procedures. The Information Commissioner approved record 
linkage for the ONS mortality and HES datasets utilised by NEoLCIN. 
Small numbers, where present, in the final analysis have been suppressed 
in line with the ONS and HSCIC information governance policies to 
further protect clinical confidentiality. At no time was it possible for the 




This chapter describes the study design, the study population and the 




assess the quality of end of life care of gynaecological cancer patients. It 
describes in detail the HES and ONS databases and the merits of linkage 
of national administrative bases from which the study population is 
derived.  An overview of the statistical analytical methods described at 
the end of the chapter completes the methodology. This study is the 
largest worldwide to examine patterns of end of life care of 
gynaecological cancer patients and is also the first to look at interventions 
in detail.  
 
 
The aim of this study has been to establish that routinely collected 
hospital administrative data is a valid source for measuring aspects of the 
quality of healthcare, for the purpose of this thesis, end of life care of 
gynaecological cancer patients and, to describe variations in this aspect of 
care. In order to explore these questions, a quantitative approach has been 
adopted for this study; using the ONS and HES ‘linked database’ 
recorded for gynaecological cancer patients for over more than the past 
decade.  The HES database provides routinely collected person linked 
data whereas the ONS routinely collects death data, including the cause 
of death. These sources of data are described in detail in this chapter. 
Their use has allowed the analysis of the annual trends of the place of 
death of gynaecological cancer patients, emergency admissions, 
interventions and identification of the impact of these factors on a 
hospital death. Also, in this thesis, geographical variations in the place of 
death are highlighted and the reasons have been explored in detail to test 
the null hypothesis ‘There is no difference in the end of life care for 
gynaecological cancer patients in England from a socio-demographic or 
geographical aspect as measured by routine data’. This analysis has been 




life indicators) such as the number of deaths occurring in hospital, the 
number of emergency admissions and number of procedures performed 
as an emergency, by SHA. Furthermore, the linked database has allowed 
the analysis of the last year of life with respect to the specific type and 
number of interventions performed allowing insight into recent hospital 
resource use. A further detailed analysis of the last month of life with 
respect to the interventions received following an emergency admission 
was performed to assess the quality of end of life care of gynaecological 
cancer patients and it’s impact on place of death. An informative example 
of the need for the future provision of services resulted in a descriptive 
overview of the increasing number of patients who require drainage of 
ascites in the last month of life.  
 
 
3.4.1 Study Design 
 
 
The study design is outlined with the help of figures 3.1 and 3.2. In order 
to address the research objectives after a literature review, the 
methodological approach adopted was exploratory data analysis (EDA) 
of the linked database derived from routine person linked data from the 
HES and ONS national administrative databases. The recognised 
advantages of EDA are twofold, that it permits description of the data and 
model formulation (164). The first stage of EDA, after the quality check 
for any outliers is to assess the structure of the data for the number of 
observations, the variables to be examined, and whether they were 
continuous, binary or qualitative. Most importantly an understanding of 
the background of the variables, allows development of the model. 




range distribution of certain variables and a trend analysis to understand 
how the variables changed over the study period. Following preliminary 
analysis, the relationship of two or more (multiple) variables was tested 
by univariate or multivariate analysis. Multiple regression aims to seek a 
relationship between a dependent variable. For the purpose of this thesis 
and for most of the analyses the outcome was defined as ‘death in 
hospital’, with independent variables such as age group, socio-economic 
status or postcode at the time of death used in the model. Model 
validation, is an important aspect of model building and, was performed 
by calculation of residuals and the results were represented by scatter 
plots and this is described in the specific chapters. Suitable visual 
representation of data to understand the results was also performed by 
construction of bar charts, histograms and line charts. The interpretation 
of the results and the visual reporting allowed recommendations for 
future policy.  
Figure 3.1: The ‘linked database’ was derived from the HES and ONS database 


























3.4.2 Data Sources  
 
 
The National End of Life Care Intelligence Network has unique access to 
a dataset, which links ONS mortality statistics to inpatient HES data that 
allows analysis of patterns of inpatient care, at an individual level prior to 
death. This section of the thesis describes these two administrative 




Routine data is the information that is routinely collected through 
population observation (National Census), surveillance of disease (e.g. 
Notifications of Infectious Diseases), identification and follow up of 
cancers (Cancer Registries) notification of deaths (ONS mortality data) or 
whilst providing healthcare and community care or other public services 
(e.g. Hospital Episode Statistics and GP disease registers). These datasets 
contain routine demographic data along with clinical information based 
on statistical coding classifications. Disease specific data is not handled 
discretely either. The advantages to the use of this data however, are 
manifold. Data on large populations are easily available for extraction, 
inexpensive and are amenable to computerized analyses via statistical 
software (165). This allows the generalizability of results. The limitations 
of the data include: bias arising from a retrospective analysis, the 
completeness of clinical coding (often performed by an individual with a 
non-clinical background) and the variation in data quality between health 






For this thesis concentrating on end of life care in gynaecological cancer, 
the bulk of the analyses presented have been undertaken from the linked 
HES-ONS mortality database. One comparative dataset on a subset of 
cancer patients who had their ascites drained in a local specialist 
palliative care unit was obtained from the lead clinician of a local 
hospice, and is described in relevant chapter 8.  
 
3.4.3 Hospital episode statistics (HES) 
 
HES aims to collect a detailed record for each hospital ‘episode’ of 
admitted patient care delivered in England either by an NHS hospital or 
commissioned by the NHS but offered in the private sector 
(http://www.hscic.gov.uk/hes). This data not only allows all hospitals to 
be financially remunerated for the care they deliver but also allows a 
principal secondary use for the analysis and investigation of health care 
and its outcomes. More recently it has been observed that studies’ using 
HES have driven significant changes in health care delivery and is 
regarded as an important source of evidence (167). The inpatient data is 
most often used for public health intelligence and has allowed outcomes 
to be defined outside of specialist units feeding into clinical trials. 
 
3.4.3.1 Structure of HES 
 
The ‘finished consultant episode’ (FCE) is the elementary component of 
the data and includes ‘the continuous period during which the patient is 
under the care of a consultant’. These are linked into ‘spells’ or 









3.4.3.2 Limitations of HES: 
 The HES data quality is based on a variety of variables comprising the 
information included in the patient notes by the attending clinician, 
interpretation of the notes by the clinical coding team at the hospital, 
choice of diagnostic and procedural codes recorded by the coders 
including the order of the coding and the query scripts used in the data 
analysis. In the past, the accuracy of HES data has been questioned due to 
suspected inaccuracies in clinical coding, however there is evidence that 
coding has improved over time and inaccuracy is minimized by looking 
at the most general level of diagnostic code (168). 
 
Patient activity data in HES can be used to identify if death occurred in 
hospital. The main diagnosis, for which the patient was being treated, 
may form the basis for analysis of deaths occurring in hospital. However, 
this data alone cannot be used to determine the underlying cause of death 
as specified on the death certificate. Another limitation of HES is the 
inability to record deaths occurring outside hospital. Linking HES with 
ONS data helps overcome these two issues allowing for a more robust 
mortality analysis (169). 
 





For the analyses, several strategies were employed to improve the 
robustness of the HES data used. Running code frequencies for each 
position illustrated where the majority of target codes are found. We 
found that the first 6 codes were likely to be relevant. For example those 
codes that lay in later positions and were likely to imply an unrelated 
procedure to a patient were excluded, for example cataract operations.  
 
The value of HES can be further developed by linkage of data. Internal 
linkage allows tracking of patients over time and institutions, using the 
unique identifier code assigned to individual patients. The unique codes 
in a target population allow one to identify multiple admissions over the 
study time frame. HES can also be linked to external sources such as the 
ONS mortality database and this linked database is described in the next 
section. Data from cancer registries, networks and audit can also be 
linked with patient identifiable data within the HES dataset. 
 
3.4.3.4 Significance of HES data analysis and its publication: 
 
Dissemination of specific results from HES data analysis is aimed 
primarily at healthcare providers and commissioners. The data is used to 
set budgets, evaluate tariffs, service planning and spotlighting health 
services. From a research perspective it is used to monitor healthcare 
trends, assess outcomes and perform epidemiological studies. HES allows 
measurement of performance amongst various levels of healthcare. 
 






The ‘Office for National Statistics’ (ONS) compiles mortality data 
routinely from death certification and registrations. Individual person-
level records for every registered death in England and Wales, including 
date, location, underlying cause of death and contributory factors (Office 
for National Statistics, 2012c) are available and the ONS is responsible 
for the quality of this data. ONS usually produces summary reports 
covering updated mortality data, which provides a high level analysis of 
trends in deaths by major disease group (Office for National Statistics, 
2012b). 
 
The mortality data is coded using standard, internationally recognised 
classification systems (WHO, 2007) and selection processes that identify 
the underlying cause of death according to established rules.  
 
From time to time, the classification and selection systems are updated. 
The classification system was recently updated in the UK from ICD-10 
version 2001.2 to version 2010. This has impacted on mortality data 
interpretation. 
 
The death certification system in the UK has been widely criticised in a 
variety of studies and a Home Office ‘fundamental review’ labeling it 
‘not fit for purpose in modern society’ (Home Office, 2003). However it 
continues to provide information, which is invaluable for public health 
and healthcare policy makers. 
 
Fairly junior doctors often complete death certificates and whilst ONS 
guidance on death certification is available (Office for National Statistics, 





death on death certificates (170). An audit of 1000 death certificates 
recorded in an acute NHS trust reported that 25% of death certificates 
were incomplete and that another 20% were either inappropriately of 
illogically completed (171). The inclusion of training and updates on 
completion of death certification during undergraduate learning has not 
been associated with an improvement in quality. When consultant 
pathologists were involved in advising junior doctors in certifying deaths 
in a hospital setting, a large proportion of certificates still did not meet 
ONS standards. The 2009 Coroners and Justice act has suggested that 
medical examiners would need intensive training in the coding and 
selection criteria used, to meet standards in certification before reliability 
would be seen to improve (Fernando, Oxley & Nottingham, 2012). 
 
For all deaths registered with ONS, the underlying cause of death is 
derived from the series of medical conditions resulting in death. The 
death certificate also records other conditions that the patient was 
diagnosed with at the time of death, which may or may not have directly 
contributed to the cause of death. 
 
HES-ONS linked mortality data: Clinical information such as 
treatment, diagnosis, and admission following an elective or emergency 
presentation, cause of death in hospital are available from HES. The ONS 
database holds information on death including data on underlying cause 
of death, which takes into account information provided by the coroner or 
physician. Analysis of deaths in and outside hospital can be made more 
robust by linking HES and ONS databases for all those patients that are 
recorded in HES. Thus outcomes of hospital care such as postoperative 






The linkage process involves the ONS mortality data being linked to HES 
by matching person identifiable data, based on eight different criteria, in 
the ONS mortality dataset with patient identifiers in HES (the HESID 
index). Thus a unique HES patient identifier (HESID) is assigned to the 
ONS death record. The HESID exists in all HES datasets ensuring that 
patients can be tracked in a confidential manner.  Only those ONS 
records that successfully match to a patient in HES are included in the 
linked dataset. ONS records that cannot be matched are rejected and an 
attempt is made to match these every subsequent month when the latest 
death registrations from ONS are available. An annual refresh of ONS 
data is collected every year to provide a finalised position on the monthly 
data. For the year 2009, it was observed that there was a less than 1% 
difference when the data were finalised implying that the coverage and 





The advantages of the linkage of routine healthcare datasets is a reduction 
in missing data and enables reporting of additional comprehensive 
adjusted measures of performance that allow more robust comparisons 
between regions and cancer networks. Hospitalisation frequency and 
associated mortality can be described in much greater detail. Linking 
routine datasets to national audits and registries represents a feasible, 
cost-effective and enlightening new way to evaluate services and assess 





the English NHS. The results can help inform on end of life care 
intelligence, the need for future service provision and health policy. 
 
 
3.5 Study Population 
 
 
This section of the thesis describes the extraction of all deaths from 
gynaecological cancer in England from the HES-ONS linked database 
from 1st January 2000 to 1st of July 2012. The following sections describe 
the study variables chosen for analysis to assess the impact on proxy 
indicators of quality of end of life care i.e. death in hospital or number of 
emergency admissions in the last month of life. The derivation of the 
variables was based on Earles’ quality markers for end of life care (9). He 
defined aggressive markers as ‘chemotherapy in the last two weeks of 
life’, ‘death in hospital’, ‘emergency admissions in the last six months of 
life’. The work in this thesis modified and simplified these to the 
following outcomes:  
• Death in hospital 
• Emergency admissions in the last month of life  
• Chemotherapy administration in the last month of life  
to allow extraction and analysis over the study period.  
 
 
It was assumed that all interventions in the last month of life were of 
palliative intent. The impact of socio-demographic variables was assessed 
to predict the equity of end of life care, at the end of life and, to detect 










Data was extracted for all women who died of gynaecological cancer 
from 1st January 2000 to 1st of July 2012 who were resident in England. 
During the selected period 71,891 patients died of gynaecological cancer 
in England. We excluded from the analysis (0.98%) of patients with 
missing deprivation status. Thus details of 71,269 were subject to 
analyses. This included 93% of all gynaecological cancer deaths for the 
study period. Death from gynaecological cancer was defined, irrespective 
of place of death, where the underlying cause of death was recorded as 
ovarian (ICD-10 code C56 and C57.0-C57.4), endometrial (C54 and 
C55), cervix (C53), vulva (C51) and vaginal (C52), or placental (C58) 
site cancer (ICD-10, International classification of diseases, 10th 
revision). Table 3.1 shows the number of gynaecological cancer patients 
by site. Information on age, year of death, postcode, and number of 
hospital visits and length of stay in hospital in the last month of life, and 
place of death were extracted for each gynaecological cancer death and is 










Table 3.1: Number of deaths due to underlying gynaecological cancer diagnosis 
over the study period (1.1.2000 to 1.7.2012) 
 
 
Source: HES-ONS database extract 
 
 




Place of death 
Nationally accepted definitions were used in the analysis of place of 
death in this research: 
‘Hospital’ included ‘all acute and community hospitals/units but not 
psychiatric hospitals or institutions’ 
‘Home’ included “the place of usual residence where this is not a 
communal establishment’;  
‘Care home’, which includes both ‘Local Authority/private residential 
homes and NHS/private nursing homes’;  
‘Hospice’ – whilst most hospices are ‘free standing’ some are based on 
NHS hospital properties. At present ONS classifies the ‘place of death as 





premises’. Thus there is likely to occur a slight under-reporting of 
hospice deaths  
‘Other places’ such as ‘communal establishment (including psychiatric 
hospitals) or a private address other than normal place of residence or 
outdoor location or nil recorded’ (NHS National End of Life Care 
Programme, 2012). 
 
The term ‘deaths in usual place of residence’ (DiUPR) used within the 
thesis correlates to the national end of life care ‘Key Performance 
Indicator (KPI)’ of the same name (End of Life Care Intelligence 
Network, 2012). End of life care in England is now one of the 
Department of Health’s ‘Quality, Innovation Productivity and 




Cause of death 
This was used to identify the dataset of gynaecological oncology cancer 
patients as an exploratory variable for the proxy outcomes.  ‘The World 
Health Organisation’ (2007) defines ‘the underlying cause of death’ as 
‘the disease or injury that initiated the train of events directly linked to 
death; or the circumstances of the accident or violence that produced the 
fatal injury’. The Office for National Statistics derives the ‘underlying 
cause of death’ for each patient from the death certificate and uses the 
‘International Classification of Diseases (ICD-10) system’ (table below) 
for the same. The nomenclature used for the classification of 





analyses and has been used regularly throughout the thesis. The groups 




Vulva / vulval cancer 
Vagina / Vaginal cancer 
Trophoblastic tumours / Placental site tumours 
Gynaecological cancer of unknown origin 
 
Table 3.2 Classification of disease categories by coding 
 
Source of table: ICD 10 World Health Organisation. Version 2010. 
 
For the purpose of the study and subsequent analysis, ovarian cancer 
included cancer arising from the ovaries, fallopian tube cancer and 
primary peritoneal cancer and thus alluded to C56 and C57. The 
proportion of deaths by gynaecological cancer site is shown in table 3.2. 
 






The number of emergency admissions for each year from 2000-2012 has 
also been investigated as an outcome. The trends in the number of 
emergency admissions are described in chapter 4 for the ovarian cancer 
patients and in chapter 5 for all gynaecological cancer patients. HES 
provided data on the proportion of emergency admissions and elective 
admissions for the year before death. The length of stay in the last month 
of life was extracted following an admission into hospital. To aid analysis 
the number of admissions and lengths of stay were grouped as follows: 
The length of stay in the last month of life for all elective and emergency 
admissions was grouped as: no stay, one day, two to six days, one to two 
weeks of length of stay and greater than two weeks and up to 30 days. 
The number of elective and emergency admissions was grouped into: 
none, one, two and three or more admissions in the last month of life. 
Admission details for patients, who died in the year 2000, were included 
for the year before (1999), to allow interpretation of trends. More than a 
single admission in the last month of life can be regarded as a negative 
predictor of care in the community (172). The distribution of the 








The postcode at which death occurred is documented by the ‘Office of 
National Statistics’ (ONS) using a number of communal establishment 





‘hospice’, ‘nursing home’ or ‘residential home’, and ‘other’. The 
patients’ postcode was used to assign each patient to a Strategic Health 
Authority, which existed until April 2013. These were large geographical 
areas with a population of several million, and there were 10 in England. 




Gynaecological cancer is a diagnosis that dominates in those of a more 
advanced age group. For the purpose of analysis 8 age groups were 
formed. The first group included those aged between 0-44yrs due the low 
likelihood of such a cancer diagnosis in that particular age range 
subsequent to a low incidence. Subsequent age groups were at intervals 
of a decade. As expected, we found that age at death for gynaecological 
cancer resulted in a skewed distribution with just less than one-third of 
deaths (28%) occurring in the 75-84 years age group due to this age range 
being the commonest age of presentation. The distribution of the 





The distribution of the proportion of deaths by socio-economic quintile 
for England over the study period is shown in table 3.3. This is based on 
the understanding that each death was allocated to a ‘Lower Super Output 
Area’ (LSOA) by the person’s residential postcode. LSOAs are small 
geographical areas, which were defined by the ‘Office for National 





statistically valid for comparison than parishes or wards. The average 
population is about 1,500 people. LSOAs are arranged into quintiles 
based on the rank of their income deprivation score in 2007 such that 
each quintile has a matching population of residents. This allows each 
individual to be assigned into an income deprivation quintile based on 
residence. The income deprivation score 2007 was published by the 
Department of Communities and Local Government (173 ) and is the 
‘proportion of households in the LSOA defined as income deprived; 
based on unemployment and disability benefits claimed’.  
 
Year of death 
 
To assess annual trends of the place of death of gynaecological cancer 
patients by cancer site and to review the impact of national programmes 
on place of death, the deaths were distributed at yearly intervals for 
analysis. The distributions of the proportion of deaths, for each year of 
study are shown in Table 3.3. For the year 2000, all hospital episodes and 
the resultant interventions were included for the prior year. Similarly for 
the year 2012 (up to and including, 1st of July 2012) details of all patients, 
including their admissions and interventions for their last year of life are 
included. The data is therefore complete for the twelve and a half years of 
study. In addition, the subsequent six months of 2012 (1.7.2012-
31.12.2012) used for model validation. The reader is advised to interpret 
trends with caution for the year 2012 as the data extends (for the year 
2012) to the 1st of July 2012. Univariate analysis was performed where 
possible to confirm trends. For the purpose of publication, trends for the 






Table 3.2 Variables and their distribution by place of death. 














3.5.3 Statistical Analysis: Justification & Outline 
 
This section of the thesis provides an overview of the statistical methods 
employed in each of the analysis chapters. A variety of methods were 
used, and specific methods are described in each chapter. The HES-ONS 
linked dataset provided the ability to assess various aspects of end of life 
care of the dying patient on a national level. This work concentrated on 
assessing the influence of socio-demographic characteristics and hospital 
admissions on those gynaecological cancer patients who died in hospital 
and assessed whether this varied by geography. Regional variations in the 





and interventions were explored to understand equity in availability of 
end of life care services. The ovarian cancer group is the largest 
homogenous group of gynaecological cancer patients and is the reference 
group for regression analysis and therefore, the characteristics of this 
group are described in detail in chapter 4. Regression analysis allowed 
one to identify subtle differences, if any, between the different 
gynaecological cancer sites with regards to factors that impact on death in 
hospital, but also was the start in identifying the existence of variation if 
any, and is described in detail in chapter 5. An attempt has also been 
made to understand the needs of these patients to inform on future 
resource planning, following an elective or emergency admission in the 
last month of life and at the end of life, by detailing the interventions 
received. Paracentesis or drainage of ascites, the most common procedure 
identified at the end of life and is described in chapter 8. Geographical 
variations at the end of life for gynaecological cancer patients have been 
explored by performing a case mix analysis thus allowed exploration of 
the possible existence of regional differences in number of emergency 




Place of death 
 
Place of death continues to be regarded as a ‘proxy marker’ for the 
quality of end of life care in spite of recently inviting much debate.  
Contingency tables were constructed and logistic regression analyses 
were performed to identify any patterns, and to predict the impact if any 





hospital.  The predictor variables measured were year of death, age 
group, income deprivation quintile, Strategic Health Authority of death, 
gynaecological cancer site, and number of emergency and elective 
admissions into hospital and their respective total duration of stay. 
Multivariate logistic regression analyses allowed identification of those 
variables that impacted on death occurring in hospital. Subsequent 
modeling involved the elimination of those predictors no longer found to 
be associated with death in hospital. Residuals and deviance were 
calculated to assess the quality of the model. Calibration of the model 
was assessed by Hosmer-Lemeshow statistics to quantify expected and 
observed deaths in hospital. We assessed discriminatory power of the 
model with receiver operating curve analysis. The potential for 
interaction of predictors was tested for by introduction of new variables 
derived from the product of the variables being tested.  
 
 
Interventions in the last month of life 
 
 
Descriptive statistics were used to explain the data on admissions and 
interventions performed. Univariate analysis was performed to study the 
trends of the procedures performed in the last month of life over the study 
period, to assess an increase or decrease in resource use and to identify 
those interventions than inform on future healthcare planning. 
Multivariate analysis was performed to identify those interventions that 
significantly predict death in hospital having adjusted for age, year of 
death, socio-economic status, cause of death and place of residence at 







Variations in End of life care 
 
 
Case-mix adjustment analysis was performed to confirm regional 
variations in end of life care in England with respect to place of death, 
emergency admissions in the last one-month of life and the number of 
interventions performed either as an elective or as an emergency. Funnel 
plots were constructed for data representation and interpretation. 
 
 
Ascites drainage at the last month of life: 
 
 
Descriptive statistics were used to show the data on admissions. 
Univariate analysis was performed to study the trends of the number of 
procedures performed in the last month of life over the study period. 
Multivariate analysis was performed to identify those factors that 
significantly predict death in hospital following drainage of ascites 
having adjusted for age, year of death, socio-economic status, cause of 
death and place of residence at time of death. 
 
 
A sub-analysis involved comparison of all patients with any cancer 
diagnosis, who had paracentesis performed in a local hospice as an 
outpatient procedure over a two-year period to those with a cancer 





of time. The aim was to compare Kaplan Meier survival curves to assess 
the median time to death from first tap when performed in a hospice or in 
a hospital. 
 
3.6 Software  
 
 
SQL Server Management Studio was used to query the data extract 
provided by SWPHO and the resulting tables were imported into Excel 
for analysis and the construction of charts and drafts. STATA was used to 
explore the distribution of specific fields including hospital admissions 
data. Confidence intervals for statistics were calculated using guidelines 
from the Association of Public Health Observatories (APHO) (Eayres, 
2008). 
 
3.7 Constraints of the Study Data 
 
 
This study used the most recent available data from the first of January 
2000 onwards in each data source. For mortality data, this included 2000 
to 1st July 2012, and was linked with Hospital Episode Statistics for the 
purpose of analysis and comparison. All incomplete records (7%) 
following linkage were extracted with the help of a senior data analyst at 
the NEoLCIN from the final analysis and data quality assurance was 
processed at the observatory. Co-morbidity data was not linked into this 
study, due to it’s incomplete recording (54% missing values). 





retrospective nature. The results therefore relate to large populations and 
lacks reference to individual experiences and vignettes of ‘a patient-
centered approach’. The use of population based statistics rather than 
representative samples increases the reliability of the data used in this 
study. This is probably the largest study in the world using routine data 


































This chapter focuses on the ovarian cancer patients, which is the largest 
subgroup of the study database. The purpose of this chapter is to establish 
the feasibility of the linked database to provide a descriptive overview of 
the largest gynaecological cancer site i.e. ovarian cancer patients at the 
end of life. A number of factors may interact and impact on the place of 
death and these may be specific to a particular cancer site. This chapter 
aims to explore the relationships between age, socio-economic status, 
postcode, the number of hospital admissions and procedures on the 
patterns of place of death of 41,227 women at the end of life with an 
underlying diagnosis of ovarian cancer in England, over a twelve and a 
half year period. This population is also the reference cancer for the 
multivariable analysis described in Chapter 5. With a clear understanding 
of the end of life events of this single cancer site, comparisons and 
contrasts can be drawn with other gynaecological cancer sites as 
described in the next chapter. 
 
 
To begin a quantitative assessment of various factors that may impact on 
various aspects of end of life care of cancer patients it was found easier to 
begin with data that does exist as notably suggested by the national care 





life-care-audit-dying-hospital). Therefore, this chapter commences the 
exploration of the ‘quality’ of end of life care of ovarian cancer patients 
by exploring the complex interactions of age, socio-economic deprivation 
status, post code at time of death on place of death for this cancer site. 
This is the first study to explore and describe the frequency of emergency 
and elective admissions and the number of interventions over the last of 
year of life of a single large group of cancer patients to provide a 
foundation of understanding on how these events may impact on the 
patterns of the place of death at the end of life. 
 
 
4.2 Materials and Methods 
 
 
The derivation of the linked database is described in detail in Chapter 3. 
Briefly, this study used person-linked routine inpatient, day case and 
mortality data. The HES database provided information on number and 
type (emergency or elective) of admissions in the last year of life and the 
interventions undertaken by the population subset under study. The ONS 
database provided data on place of death. 
 
 
4.2.1 Study Population 
 
 
Data was extracted for all women who died of ovarian cancer from 1st 
January 2000 to 1st of July 2012 who were resident in England. Such an 





cause of death was recorded as ovarian cancer and included ICD-10 code 
C56 and C57.0-C57.4 according to the ICD-10, International 
classification of diseases, 10th revision. Information on age, postcode, 
and number of hospital visits, type of admission, length of stay in hospital 
in the last month of life, place of death and number of interventions 
received in the last year of life were extracted. This included extraction of 
data for the year 1999 to ensure the details of those patients who died in 
the year 2000 was complete. In order to describe a full picture of the 
trends of the number of emergency and elective interventions received by 
ovarian cancer patients the last year of life (i.e. in the twelve months prior 
to death), was charted as ‘time periods’ prior to death. These were 
classified as, 1 month prior to death, months 2-3 prior to death, months 4-
6 prior to death and months 7-12 prior to death. The data extracted was 
exclusive to these time frames to provide a clear understanding of the 
frequency of elective and emergency interventions as the time of death 
drew closer over the last year of life. The specific interventions are 
described in detail in Chapter 7. In order to assess geographical 
variations, London was regarded as the reference standard and 
comparisons were drawn with this SHA, with the same format is 
followed throughout the thesis work. The derivation and subgroups of 
each variable are described in detail in chapter 3 and once again, the same 
format adopted for all analysis throughout the thesis.  
 
 
Complete data for 41,227 (99.7%) ovarian cancer patients was available 
of the total 41,331 ovarian cancer extract. Due to missing socio-economic 








4.2.2 Statistical Analysis 
 
 
Cross tabulations were used to identify temporal changes in patterns of 
the place of death. In order to determine any significance of the change in 
trends a univariate analysis was performed. A descriptive analysis of the 
year of death, age group, income deprivation quintile, Strategic Health 
Authority of death, and number of scheduled and unscheduled admissions 
into hospital for ovarian cancer patients and their respective total duration 
of stay was performed. 
 
 
4.3  Results  
 
 
This section of the thesis describes the results from the analysis of the 
ovarian cancer population with respect to where ovarian cancer patients 
die and the trends of their place of death, over a twelve and a half year 
period from the year 2000 to July 2012. Care has been taken to interpret 
trends, as the data for the year 2012 was inclusive of but till the 1st of 
July 2012. At the time of analysis this was the most recent date up to 
which data was available. Some trends relating to elective and emergency 
admissions and the respective lengths of stay are only depicted for the 
period 2000-2011 to allow adequate interpretation of trends. A 
descriptive analysis of age, socio-economic status, and postcode at the 





ovarian cancer patients is described. Also detailed are, the number of 
emergency and elective admissions and the number of interventions 
performed as inpatient or as day case over the last year of life to 
understand any interactions between these events and the place of death. 
These results have been used to also indicate the dominant routes of 
presentation of these patients into hospital and their subsequent level of 
resource utilisation, when symptom relief is sought.  
 
 
A total of 41,227 women with ovarian cancer died over the study 
duration. The proportion of patients who died from ovarian cancer has 
varied over the study period as shown in Table 4.1. 6% of all women died 
from ovarian cancer in the year 2000, and the highest proportion of 
deaths were noted in 2002, and reported as 8.6%. The proportion of 
ovarian cancer deaths slowly decreased to 7.8% in 2011. 4% of women 
died of their ovarian cancer diagnosis in the first half of 2012. This is in 
stark contrast to the rise in the number of cancer related deaths in 
England from ‘all causes’ from 25% in the year 2000 to 28% in the year 














Table: 4.1 Number of deaths from ovarian cancer, recorded as the ‘underlying 
cause’ of death and as a proportion of all female deaths and all cancer related 






4.3.1 Place of death 
 
 
This section of the thesis first describes where ovarian cancer patients 
died over the study period. Figure 4.1 shows that on average 43.5% of 
ovarian cancer patients died in hospital over the study period i.e. from 1st 
of January 2000 to 1st of July 2012. This is lower than the calculated 
English average for all causes of death, over the study period, which was 





hospital is mirrored by an increase in the number of deaths occurring at 
home and in hospices, with a proportionate increase in the number of 
deaths occurring in care homes also noticed (Figure 4.1b). The number of 
hospital deaths dropped from 49% to 32% from 2000 to 2012, whilst the 
number of deaths occurring in a home or hospice increased in a similar 
fashion from 22% to 28%. 
 
 
The trends of the place of death for all deaths (cancer and non cancer 
related) for England are shown in table 4.3 for correlation. When the 
trends of the proportion of ovarian cancer ‘care home’ deaths are 
compared to deaths from ‘all causes and all ages’ it was observed that 
although the proportion of deaths occurring in care homes had increased 
for this cohort (10% in 2012 from 6% in 2000) this was lower than the 
English average for the number of care home deaths for ‘all causes and 
ages’ for the study period (18%). We found that the likelihood of death in 
a hospice (28% in 2012) was higher for ovarian cancer patients compared 







Figure 4.1: Place of death of ovarian cancer patients expressed in percentage 
 




Table 4.2: The total number of cancer and non-cancer related deaths 
per year, from the year 2000 onwards for the study period 
 



























When trends were further explored, we found that the place of death for 
this subset of patients varied by postcode. The analysis of the regional 
variations of the place of death for ovarian cancer was performed with 
London being the reference SHA. We found that 57% of ovarian cancer 
patients died in hospital in London in 2000 and this dropped to 39% in 
the first half of 2012 by 18% (Table 4.4). The average number of women 
dying in a care home (6.5% vs. 7%) or at home (18% vs. 23%) was lower 
in London when compared to the overall average for the English 
population and for all regions. Regional variations with respect to place 
of death for ovarian cancer patients are explored in detail in a further 
section in the chapter. On univariate analysis the odds of dying in hospital 
have significantly reduced, irrespective of postcode. The odds of dying in 
hospital in London were 0.95 for each most recent year (p <0.001; CI 
0.93 -0.96) with similar odds outside London of 0.95 for each most recent 
year (p <0.001; CI 0.94 – 0.95) over the study period.  
 
Table 4.3: Number of deaths (all causes and all ages) by data year and place of 






(Source: ONS-HES extract) 
Figure 4.2: Chart representation (Table 4.3a) of the proportion of ‘all causes of 
deaths’ by year and place of death, describing trends for England. 
 
(Source: Linked HES-ONS extract) 
 
 
Table 4.4: Proportion of ovarian cancer deaths by year of death in England, 











Figure 4.3: Chart representation (Table 4.4) of the proportion of ovarian cancer 
deaths by year and place of death, describing trends for England. 
 
 
(Source: ONS-HES database) 
Table 4.5: Trends of the place of death (percentage) of ovarian cancer patients 
living in London over the study period 
 









Figure 4.3: Chart depicting the trends in place of death for ovarian cancer 
patients in London.  
 
 
 (Source: ONS-HES linked database) 
 
 Impact of age on place of death 
 
 
This segment of the chapter examines the impact of age on place of 
death. The incidence of hospital deaths increased with increasing age of 
ovarian cancer patients. 38% (422) of the 0-44 years age group died in 
hospital, which increased to 46% (5131) for the patients aged between 
75-84 years and rose further to 49% (422) for the 95 -104 years of age. 







Table 4.6: This table shows number (percentage) of women with ovarian cancer 
with respect to age group and place of death. (Source: ONS-HES database) 
 
(Source: ONS-HES linked database) 
 
 
Table 4.6 shows, that proportion of ovarian cancer deaths in care homes 
also rose significantly with increasing age and 3.8% deaths were noted 
for the 65-74 years age group, which rose to 34.2% for the 95-104 years 
age group. This was mirrored by a significant reduction in the number of 
deaths happening at home (26% to 8.8%) or in a hospice (33% to 6.5%) 
with advancing age (Table 4.5 and Figure 4.2). The incidence of home 
deaths dropped from 26% (928) in the 55-64 years age group to 14% 
(671) in the 85-94 years age group. Similarly the incidence of hospice 
deaths dropped from 31% (2652) to 13% (587) for the same age groups.  
 
Of interest were also noted variations in the place of death with respect to 
age when comparing regions. When compared to regions outside London 
the percentage of deaths in London, in hospital, fell sharply from 58% to 
23% beyond the age of 85 years (Figure 4.3). The 85 years and beyond 
age range also saw a rise in the number of deaths occurring at home from 
13% to 19% in London (Figure 4.2) whereas, the same age group outside 
London demonstrated a lower likelihood of a home death. The proportion 
of people dying at home fell from 16% to 6% with deaths more likely in a 







Figure 4.2: Visual representation of place of death with respect to age group for 
the English population. 
 
 
Source: ONS-HES linked database) 
 
 
Figure 4.3: Visual representation of place of death with respect to age 








(Source: ONS-HES database) 
Figure 4.4: Visual representation of place of death with respect to age group for 
women with ovarian cancer who live outside London. 
 
Notes: X-axis: Age group at death; Y-axis: Percentage of deaths 
(Source: ONS-HES database) 
 
Table 4.7: This table is derived from Nomis (14th October 2013) and shows 
marital and civil partnership status by sex by age (all household reference 
persons). 
 







4.3.2 Socio-economic deprivation status and place of death 
 
 
This section of the thesis describes the interaction of socio-economic 
quintile with place of death for ovarian cancer patients. 
Socio-economic deprivation status was found to strongly correlate with 
place of death for patients with ovarian cancer with clear trends 
identifiable with change in socio-economic quintile status. When the least 
deprived population was compared to the most deprived population the 
percentage of deaths occurring in hospital increased from 39% to 46%. 
The reverse was observed for deaths occurring at home or in a hospice 
with the percentage of deaths at home (24% vs. 21%) or in a hospice 
(28% vs. 23%) higher in the least deprived quintile when compared to the 
most deprived quintile and clear downward slope recognised in the 







Figure 4.5: Place of death for ovarian cancer patients with respect to socio-
economic status (as per quintiles). Note: 1st quintile- least deprived group. 
 
(Source: ONS-HES database) 
 
 
 Regional variations in place of death 
 
 
This section of the thesis explores the relationship between the postcode 
and place of death.  
 
Table 4.8: This table shows the variations in place of death of ovarian cancer 







(Source: ONS-HES database) 
 
 
Variations in the proportion of patients and their place of death were 
observed when different Strategic Health Authorities were compared. The 
widest variations in place of death by geographical region were observed 
for hospice deaths. The highest proportion of hospice deaths were 
observed for the South East region of England (37%) and the lowest 
percentage of hospice deaths are observed for the North East (17%). 
Home deaths vary between 18% in London and 26% for the North East. 
The lowest number of deaths occurring in hospital over the study period 
was noted for the South East region in comparison to London where the 
number of deaths in hospital was noticeably higher (35% vs. 49%).  
 
 
4.3.3 Number of Emergency admissions in the last month of life 
 
 
This section describes the frequency of emergency admissions in the last 
month of life and reports on any changes of the proportion of ovarian 
cancer patients who presented as an emergency over the study period. An 
emergency admission in the last month of life was understood to occur as 
result of a complication of end stage disease and can be regarded as a 
negative quality marker of end of life care. The proportion of ovarian 
cancer patients who had an emergency admission in the last month of life 
was plotted as a function of time to assess for any trends over the twelve 
and half year study period. The results suggested that the percentage of 





found to have linearly increased from 45% in 2000 to 49% in 2011 and 
this was regarded as a significant result (p = 0.005; figure 4.6).  
 
 
Figure 4.6: The histogram below shows the percentage of patients who had at 
least one emergency admission in the last month of life over the study period. 
The linear trend line shows an upward trend. 
 
(Source: ONS-HES database) 
 
 
In the year 2000, 6% of the total number of ovarian cancer patients in the 
last month of life had an admission, which increased to 9% by the end of 
2005 and remained stable at 8% till the end of 2011. The data also 
suggested that not only had there been a noteworthy rise in the proportion 
of women with ovarian cancer who had been admitted at least once as an 
emergency (p=0.001) from the year 2000 to 2011, but also that an 
absolute increase in the percentage of patients re-presenting for a second 





who had a second admission was from 5% in 2000 to 8% in 2011. This 
result was found not to be statistically significant. We, also found that 
over the last month of life an emergency admission could also lead to the 
need for multiple admissions (i.e.>2) and these were significantly more 
likely (p = 0.002). The percentage of patients who had had three or more 
admissions (4% in 2000 to 11% in 2011; p<0.0001) was noticed to have 
significantly increased over the study period (Figure 4.7). Furthermore, 
on univariate analysis the odds of a hospital death following an 
emergency admission in London (OR = 4.7, CI 4.1-5.3; p < 0.001) was 
higher compared to if an emergency admission were to occur outside 
London (OR = 4.1 CI 3.9-4.2; p < 0.001) with a quadrupled risk of death 
in hospital irrespective of postcode.  
 
 
Figure: 4.7: This chart shows the proportion of emergency admissions for all 
ovarian cancer patients’ in the last month of life. 
 
 
Note 1:  1- single admission; 2- two admissions; 3- Three or more than 





(Source: ONS-HES database) 
 
 
Table 4.6: Unadjusted odds of a hospital death following an emergency 
admission in and outside London for ovarian cancer patients in the last month of 
life. 
 
(Source: ONS-HES database) 
 
 
4.3.4 Number of elective admissions in the last month of life 
 
 
This section of the thesis examines the proportion of ovarian cancer 
patients who were admitted electively over the study period. The 
proportion of ovarian cancer patients who had an elective admission was 
plotted over the study duration to analyse trends. The percentage of 
women who had at least one elective admission in the last month of life 
had decreased (Figure 4.8), but, not significantly between the year 2000 
and 2012 (from 19% to 17%; p=0.2). Whilst again, there was a moderate 
but insignificant increase in a second elective admission, the number of 
patients who then presented a third time appeared to have significantly 
increased from 3% (17) of patients being admitted thrice in the last month 
of life in 2000 to 9% (48) of patients in 2011 (p = 0.008). The trends of a 
third elective admission demonstrate an increase from 3% in 2000, of the 





10.4% in 2008, followed by a decline in the number of elective 
admissions to 9% in 2011. 
 
Figure: 4.8: Proportion of elective admissions for all ovarian cancer patients’ (y 
axis) in the last month of life by year of death (x axis). 
 
 
Note 1: 1- single admission; 2- two admissions; 3- Three or more than 
three admissions in the last month of life. 






Figure 4.9: Percentage of patients who had at least one elective admission in the 
last month of life over the study period. The linear trend line shows a downward 
trend. 
 
(Source: ONS-HES database) 
 
 
 Length of stay of ovarian cancer patients following an emergency or an 
elective admission in the last month of life 
 
 
There was a significant increase in the proportion of elective and 
emergency 23hr stays (patients seen in A&E and admitted as day case 
with under a total of 23hr stay) over the study period. The proportion of 
elective one day stays increased from 13% to 19% of all elective 
admissions (Figure 4.10). Figure 4.11 shows that the total number of the 
23hr stay emergency admissions also increased from 19% to 34% over 








Figure 4.10: The proportion of elective 23hr admissions of all admissions in the 
last month of life. 
  








Figure 4.11: Of the total number of admissions this histogram shows the 
proportion (yaxis) and  trend (x axis) of emergency day admissions in the last 
month of life. 
 




The proportion of emergency lengths of stays for a 7-14 day period 
increased from 24% to 32% during 2000 to 2005 in the last month of life 
(Figure 4.12a) and then fell to 22% by 2011.  Those whose length of stay 
equaled 2-6 days (Table 4.7) increased moderately from 5.5% to 8.4% (p 
<0.0001). This length of stay contributed to 27% to 31% of all emergency 
admissions of ovarian cancer patients in the last month of life (Figure 
4.12a). Of the total number of emergency lengths of stays the proportion 
of emergency admissions that stayed in for 15-30 days declined from 
24% to 18%. The proportion of patients who stayed in for 15-30 days 








Figure: 4.12: The proportion of ovarian cancer patients’ each year and their 
respective length of stay following an emergency admission in the last month of 
life. 
 
Note 1:1: single 24hr admission; 2: two-six day stay; 3: seven-fourteen 







Figure: 4.12a: The proportion of all emergency admissions of ovarian cancer 
patients’ each year for their respective lengths of stay in the last month of life.  
 
Table 4.7: shows the absolute number of ovarian cancer patients and the 
proportion of all ovarian cancer patients with their respective emergency lengths 































The proportion of women requiring an elective length of stay overall 
appears to have declined over the study period (Table 4.8). However, the 
proportion of elective one-day stays had been noticed to increase from 
13% to 19% of all elective admissions as described already (Figure 4.10). 
The proportion of patients who stayed in for the duration of 15-30 days 
following an elective admission in the last month of life decreased from 
8% in 2000 to 5.3% at the end of 2011. The proportion of women who 
stayed in for 7-14 days following an elective admission decreased from 
6.7% to 5.1%. Figure 4.13 shows that of the total number of admissions, 
the 23hr stay elective cases saw a moderate percentage increase and an 
upward linear trend over the past decade (p<0.05).  
 
 
Figure: 4.13: Proportion of ovarian cancer patients’ by year of death and the 
proportion of the respective lengths of stay following an elective admission in the 
last month of life. 
 
 
Note 1: 1 Single day admission; 2:two-six day stay; 3: seven-fourteen day 







Table 4.8: Absolute numbers of ovarian cancer patients and the proportion of all 
ovarian cancer patients with their respective elective lengths of stay for the year 
of death.  
 
 
4.3.5 Frequency of procedures performed by admission type for 
patients with ovarian cancer over the last year of life 
 
 
This section of the thesis describes the trends of the average number of 
interventions over the last year of life performed either as a day case or 
inpatient. These results further inform on whether these interventions 
occurred following an elective or emergency admission type or via 
another route of referral such as from the GP. The purpose of this 
segment was to understand the final year of life of ovarian cancer patients 
with respect to their dominant mode of presentation and the frequency of 
attendances for an intervention for symptom control. This indicates the 





the last year of life. Ovarian cancer patients are likely to be subject to a 
number of interventions due to the symptomatology of advanced disease, 
for example, shortness of breath due to excessive ascites and pleural 
effusion, nausea, vomiting and abdominal pain secondary to impending 
bowel obstruction (8). In order to trace the number of admissions and 
interventions in the last year of life and to provide an over view of the 
whole year prior to death, the year was divided into sections. These were 
studied as, interventions and admissions occurring in the last month of 
life, months 2 and 3 prior to death, months 4, 5 and 6 and finally 
frequency of interventions and admissions in months 6-12, prior to death. 
 
 
Tables 4.9 a-d show the frequency of procedures ovarian cancer patients 
are exposed to in the last year of life as inpatient or day case and the route 
of referral i.e elective, emergency or via other routes such as the GP. 
Table 4.9a shows that in the last month of life following a referral, 
majority of patients had a single intervention [69% (21303/30819)] 
following an admission via all routes, with 31% undergoing multiple 
interventions. The interventions were more likely to be performed as 
inpatient rather than as a day case (26,141 vs. 4678), in a ratio of 6:1. 
Inpatient interventions were more likely to occur following an emergency 
admission rather than an elective admission (ratio of elective to 
emergency inpatient interventions 0.2). Of all elective admissions, 36% 
(3008/8398) of patients had a single intervention during an elective 
inpatient stay whereas 46% (3844/8398) following an elective day case 
admission. Following an emergency admission 60% of patients (12, 594/ 
21,054) had a single intervention whereas; only 3% had an intervention 





patients had 1 or more interventions following referral in via other routes 
e.g. GP referrals, local hospices and other departments such as radiology 
or palliative care, performed primarily as inpatient [97% (1339/1367)].  
 
 
For months 2 and 3 prior to death (Table 4.9b), we found that 61% 
(27,195/ 43972) of patients underwent a single intervention with the 
remaining undergoing multiple interventions following an admission via 
all routes. Of all elective admissions where an intervention was 
performed, 31% (5,755/ 18,607) had a single intervention whilst inpatient 
and 33% as daycare (6,180/18,607). Following an emergency admission, 
53% (12, 893/ 24,320) of ovarian cancer patients had a procedure as 
inpatient whilst 6% underwent an intervention as a day ward attender. 
The ratio of elective to emergency inpatient procedures was 0.32, 
whereas the ratio of elective to emergency daycare procedures was 6.6 
for this period. 2% of patients had a single intervention following an 
elective admission via other routes of referral and 0.2% as emergency. 
 
 
For months 4, 5 and 6 (Table 4.9c) we found that 58% (22456/39028) of 
ovarian cancer patients had a single intervention following admission into 
hospital, with the remainder requiring multiple interventions. 
Of all elective admissions 24% (5,277/ 22,114) had a single intervention 
as inpatient and 29% (6,372/ 22,114)) as daycare stay. Of the patients 
who had had 2-4 elective procedures, 7% followed an inpatient stay and 
29% (6346/22,114) were performed as daycare admission. Following an 
emergency admission, 54% (8,779/16,265) had a single intervention as 





elective to emergency inpatient procedures was 0.5 and for daycare 
procedures was 9.1. 
 
 
For months 7-12 prior to death (Table 4.9d), we found that 61% of 
ovarian cancer patients had a single intervention and therefore 39% of 
ovarian cancer patients had multiple interventions following an 
admission. Of all elective admissions, 24% (7,415/ 30,538) had a single 
intervention as inpatient and an equal percentage as (24%) as daycare. In 
addition, 7% had 2-4 interventions as inpatient and 23% (6948/ 30538) as 
daycare following an elective admission. Of all emergency admissions 
49% had a single intervention as inpatient and 14% as daycare. In 
addition 33% of patients had 2-4 procedures as inpatient and 1% as 
daycare following an emergency stay. 
 
 
Table 4.9a: Number of procedures performed by route of referral, elective, 
emergency or other routes of referral (for e.g. via GP) and admission type i.e. 










Table 4.9b: Number of procedures performed by route of referral elective, 
emergency or other routes of referral (for e.g. via GP) and admission type i.e.  






Table 4.9c: shows the number of procedures performed per admission method, 
elective, emergency or other routes of referral (for e.g. via GP) and duration of 













Table 4.9d: shows the number of procedures performed per admission method, 
elective, emergency or other routes of referral (for e.g. via GP) and duration of 









A detailed descriptive analysis of the patients with cancer of the ovary 
with respect to trends of the place of death and a preliminary exploration 
of the impact of socio-demographic variations and hospital admissions on 
place of death in the final month of life has been possible by use of the 
linked database. This is significant, as thus far, most published studies 
have explored patients with cancer as a group or countries with advanced 





2006 #5999). These results are important as they demonstrate the 
feasibility of this type of study and show that this type of analysis using 
the linked database can be extended to other cancer sites individually as 
well as specific groups such as pelvic cancers to understand the effect of 
baseline socio-demographic characteristics and admission details on place 
of death. In addition, the trends of the frequency and type of hospital 
admissions are charted for the final year of life over the duration of the 
study, indicating the level of hospital resource use required by this subset 
of patients. This investigation informs on the need for future service 
provision for ovarian cancer patients whilst simultaneously charting 
current trends and permits the recognition of the impact of recent national 
initiatives by the identification of changes in patterns of place of death. 
 
 
‘Hospital’ continues to be identified as the most common place of death 
for ovarian cancer patients. A recently published, large international 
study (1.3 million patients) investigated the ‘place of death’ of cancer 
patients from 14 countries and reported a large variation in the place of 
death by country, over a single reference year, 2007 (175). The range of 
hospital deaths varied from 26% in the Netherlands to 87% in Korea 
whereas home deaths ranged from 12% in Korea and 56% in Mexico for 
the year 2007. The proportion of cancer related hospital deaths for 
England were reported as 44% in the study. The explanation for the 
variation in the place of death appeared to be related to the individual 
healthcare resources of each country and its’ organisation of end of life 
care services. The importance of the ‘place of death’ is currently under 
debate with evidence, such as results from the recent VOICES survey 





death with adequate control over symptoms was more significant than the 
actual place of death itself. Therefore, it was assumed that, a better 
quality of ‘care of the dying’ could be achieved in hospital rather than at 
home with the input of professionals trained to provide end of life care 
(176). This would hold true, till such services were set up in the 
community with adequate resources. The expenses incurred following the 
use of hospital resources at the end of life including the possibility of 
inappropriate tests and interventions to diagnose the end of life are the 
current arguments in favour of a ‘home death’, ‘death in the usual place 
of residence’ or other familiar environments such as care homes or 
nursing homes, allowing the dying individual to achieve death in their 
place of choosing, surrounded by loved ones. Currently, in the United 
Kingdom, ‘home’ continues to be regarded as the ‘preferred place of 
death’ and a ‘quality marker’ of care at the end of life. 
 
  
This study reported on the increase of the proportion of hospice and care 
home deaths over the study duration. This is reflective of national trends 
of the place of death, where the incidence of hospital deaths has gradually 
and significantly decreased over the past decade, mirrored by an increase 
in the number of deaths occurring at home or in a hospice (177). This 
must be correlated with the awareness of improving survival for ovarian 
cancer patients and preferred place of care prior to death.  Recent 
National strategies such as ‘Dying matters’ stress on the significance of a 
‘good death’ achieved at the place of one’s choosing with advance care 
planning setting out directives advising on how to achieve a good death 







Increasing age is a significant factor, impacting on death in hospital (177) 
was confirmed by the results.  The incidence of hospital deaths rose with 
increasing age. Whilst relatively more young patients were more likely to 
die in hospices or at home, there was a noteworthy rise in the number of 
ovarian cancer patients dying in care homes. The differences in the actual 
place of death by age may be influenced by the marital status of the 
individual. Table 4.8 is for reference and derived from Nomis, which is a 
derivative of the ONS database.  This table provides a snap shot of 2011 
and the marital status of males and females by age suggesting that with 
increasing age more men remain married compared to women.  78% 
(1,170, 667/1,487,103) of men remained married between the age of 65 to 
74 years compared to 22% of women and 80% (696,711/863,972) of men 
remained married in the subsequent decade compared to just 20% 
females. Gao Wei et al in a study of 2,281,223 cancer deaths found that 
patients with haematological cancer had a higher likelihood of a hospital 
death when aged over 75 years and lived alone (149). Most importantly 
the place of death varied by cancer type and marital status was found to 
be the second most influential factor (149). Although this work was 
unable to directly take marital status under consideration, it has been 
shown that this study population had a higher probability of dying in 
hospital rather than outside hospital, confirming that the cancer type and 
resultant complications of advanced incurable disease possibly also 
contributed to the place of death and that this population therefore 
required an individual analysis. In addition to age, it can be inferred from 
the data that regional variations in availability of community palliative 
care and varying availability of hospice beds may further significantly 





study of 3,140 US counties looking at hospice density and their use 
inferred that, beyond 65 years, wealth of a nation, density of the 
population and ethnicity may impact on hospice utilisation and death in 
hospices (178). According to the Office of National Statistics, the UK is 
an aging population with the incidence of ‘home deaths’ or ‘deaths in the 
usual place of residence’ rising in those aged 85years and beyond, with 
the proportion increasing from 11% to 13% and care homes deaths too 
have reportedly increased since 1974 in those aged beyond 85 years, 
although this is more difficult to quantify (177). In the study population, 
the ratio of deaths at home or in a hospice for those beyond the age of 65 
years significantly decreased with a steep incline in the percentage of 
deaths occurring in care homes. We have already noted that marital status 
may contribute to these results with some evidence to suggest that male 
partners are less equipped to efficiently care for the dying at home (179). 
Geographical variations in the place of death when age was considered 
was apparent especially for those aged 85 years and above for those who 
lived in London, compared to those who lived outside London. There was 
a significant decline in the proportion of hospital deaths in London 
beyond 85 years of age in spite of an equal contribution of each age 
group to either population of 12%. This may reflect preferences for and 
variations in availability and accessibility of end of life care in places 
other than a hospital. 
 
 
Preferences with respect to place of death were also not taken into 
consideration due to its size and retrospective nature of this study over a 
period of 12 years. However, other studies report that no more than 20% 





(140). Similar results were available from a recent National Patient and 
Family Survey, the outcomes of the VOICES survey, which reported that 
cancer patients were significantly more liable to achieving their preferred 
place of death (139). 
 
 
Gao W et al have also shown that people with cancer and of a deprived 
socio-economic status had a lower probability of dying at home or in a 
hospice (149). Similar significant trends with observed for patients 
included in this study. Women with ovarian cancer have a higher 
likelihood of a hospital death with each quintile increase in socio-
economic deprivation status. This was trend was imitated in the reverse 
for hospice and home deaths. A recent systematic review suggested that 
specialist palliative care input could impact on place of death by reducing 
disparities in accessing end of life care services arising as a result of 
socio-economic differences (180). A large British cross-sectional study of 
hospice patients (446, 615 deaths) showed an increased likelihood of 
hospice patients belonging to the most affluent quintile (OR=1.25) further 
suggesting that socio-economic status and equal availability of end of life 
care services in hospital and hospices required further study (181). 
 
 
In the study results, geographical variations with respect to the proportion 
of deaths occurring in and outside hospital was observed, when different 
SHA’s in England were compared. Particularly, with reference to London 
which was regarded as standard for comparison. We found that with 
respect to London and the ovarian cancer patients above the age of 85 





than in hospital. We also found that it was more likely that death occurred 
in hospital following an emergency admission in London when compared 
to outside London (4.7 vs. 4.1) Barriers to death occurring at home were 
noted in a qualitative study following the comparison of two hospital 
trusts in England after analyses of taped interviews of district nurses. The 
results suggested that the discrepancy in the accessibility of community 
palliative care contributed to variations in hospital admissions at the end 
of life and death in hospital (182). Variations in place of death can be 
regarded as a probable surrogate indictor of the level of available 
palliative and end of life care in the community (144). In this study 
population, the lowest percentage of hospital deaths was noticed in the 
South East region of England, which may be due to a larger availability 
of hospice beds and denser community palliative care network. The 
highest proportion of hospital deaths over the last decade was in the 
London region. One of the reasons for London to stand out may be due to 
variability in the ease of available community palliative and hospice care. 
Ovarian cancer patients in the final month of life were 2.5 times more 
likely to present as an emergency admission. The results from this study 
suggest that there has been a significant rise in the proportion of 
emergency admissions in the last month of life over the period under 
study. The high proportion of emergency admissions observed at months 
7-12 are probably secondary to the onset of symptoms secondary to a 
recurrence and the need for symptom control followed by progression of 
disease and a failed attempt at palliative treatment. The proportion of 
emergency to elective admissions appears to be equivalent at month 3 and 
2 and this may be due to an awareness of the poor prognosis by both 
patients and physicians and subsequent initiation of the involvement of 





allows optimisation of symptom control at home with the support of the 
community palliative care nurses and the GP. The proportion of 
emergency admissions were found to significantly increase in the last 
month of life again, probably secondary to worsening of symptoms at the 
end of life and the need for comfort to be sought in the final days. Thus 
the hospital often becomes the preferred place of care. There have been 
recent attempts in various regions of the country to set up 24-hour 
emergency oncology helplines providing telephonic advice and direct 
access into oncology wards. The numbers of emergency admissions in the 
final months of life possibly reflect the extent of palliative care available 
in the community. There is also a certain acceptability of de-
institutionalisation of care at the end of life, with the placement of 
advanced care plans, on a background of individual and environmental 
factors, which may determine place of care at the end of life and place of 
death. Where excellent care in the community is evidenced, multiple 
admissions with short hospital stays may still occur, especially if 
symptom control measures are set up better in a specialist environment, 
converse to the original aim of initiating, supporting and maintaining end 
of life care in the community. The level of palliative care available in 
localities, the density of affordable care homes or NHS hospice care 
remains an unquantified entity in England at present and therefore, 
emergency admissions continue to serve as a surrogate negative marker 
of end of life care. In a published report of 133,055 people in England 
beyond the age of 75 years, 89.6% had some hospital care in the year 
prior to death, with those accessing social care services more likely to 
attend for hospital service provision (174). The results from our data 
show that in spite of the introduction of the ‘National End of Life Care 





admissions has increased in the last month of life, with a proportionate 
rise in the number of patients staying in hospital for 7-14 days in the last 
month of life. In  2013, 40% of acute care trusts in England joined the 
‘Transforming End of Life Care in Acute Hospitals Programme’ 
originally launched on September 11. The five ‘key enablers of end of 
life care’ defined via this Programme were integration with the 
‘Electronic palliative care co-ordination system’, ‘Advance Care 
Planning model’, the ‘Amber Care Bundle’, ‘Rapid discharge Home to 
Die Pathway (RDHP)’ and ‘Liverpool Care Pathway for the Dying’ 
patient.  Early analysis revealed that with advanced care planning (ACP) 
hospice patients were unlikely to be admitted in hospital and or spend 
less time in hospital (183). Thus with the introduction of the above key 
enablers, there were reports of less time spent as inpatient, enhanced 
primary care input from GP’s and community palliative care services 
allowing earlier connection with people at the end of life. These 
processes facilitated dying in a preferred location (What we know now, 
2013). Therefore further careful monitoring and evaluation of the clinical 
indications for elective and emergency hospitalisations in the last year of 
life and any current unidentified barriers to the adoption of the above five 
key enablers needs to take place to allow for assessment of future 
planning of resources at the primary and secondary care level. 
Assessment of patient preferences and gaps in physician-level education 




This work is the first to trace the type and numbers of interventions 





work concluded that the emergency route was the dominant route of 
presentation, for patients seeking an intervention for symptom control 
and, of all ovarian cancer patients requiring an intervention. We also 
found that about two-thirds underwent a single intervention in the last 
year of life and just under one third, multiple interventions. Interventions 
were more likely to be performed as inpatient rather than as a day case 
admission. As the time to death approached the ratio of elective to 
emergency procedures decreased with a decline in the number of elective 




There are limitations to this analysis. It is acknowledged that the details 
for the year 2012 extend to July, 2012 and therefore there may be some 
end of year effects and thus caution must be exercised when interpreting 
the data. However, every attempt has been made to describe trends 
inclusive of 2000-2011. Marital status and comorbidities have not been 
taken into consideration for each individual. High co-morbidity scores 
may have impacted on the need for a hospital admission rather than 
complications from the cancer diagnosis for some patients. The analysis 
was therefore focused primarily on the period of the last month of life, 
prior to death, when admissions were assumed to be secondary to the 
cancer diagnosis. Information on the clinical reasons for admission and 
the preferences of the patient and relatives are also not available for 










The linked database permits an exploratory analysis of the baseline socio-
demographic and hospital admission characteristics of ovarian cancer 
patients at the end of life. The most common place of death for patients 
with ovarian cancer is the hospital. However the proportion of hospital 
deaths is reducing with more patients preferring to die in care homes and 
hospices or at home. Important socio-demographic differences were 
noted in this population in contrast to other studies on place of death. 
Increasing socio-economic deprivation increased the incidence of deaths 
occurring in hospital suggesting that deprived groups need more focus at 
the end of life. It has been suggested that improving the accessibility and 
availability of specialist palliative care may improve the quality of life at 
the end of life for the more deprived groups. Advancing age, place of 
residence, marital status and the number and length of emergency 
admissions also impact on place of death. Hospitalisation at the end of 
life may be essential to achieve symptom control and to progress the 
quality of life at the end of life. The clinical reasons for the increase in 
the number of emergency admissions along with tracing of patient 
pathways is required to understand how physician led interventions in 
primary and secondary care can help improve end of life care irrespective 
of preferred place of care or death. The future impact of the changing 
socio-economic structure of the population must be factored in for 







5 Chapter 5: Factors that Impact on Place of Death of 






In England the proportion of patients achieving death in their usual place 
of residence (or DIUPR), has been designated a key performance 




version-v2.pdf). The data on ‘place of death’ can be obtained from the 
ONS. Data for this KPI has shown a rise in the number of deaths 
occurring both at home and in care homes, suggesting that patients are 
achieving their preferred place of death. However, world wide and 
including the UK, recent evidence suggests that the median percentage of 
deaths occurring in hospital amongst 45 countries was 54% (138). Thus, a 




The National Survey of Bereaved People (VOICES 2014) reported that 
only 3% of those who responded on behalf of their loved ones, stated 
‘hospital’ as the preferred place of death. However, 7 of 10 respondents 
felt that death should have occurred in hospital. This survey further 





hospital deaths when compared to death occurring at home, in a hospice 
or care home (http://www.ons.gov.uk/ons/rel/subnational-
health1/national-survey-of-bereaved-people--voices-/2014/stb-voices-
2014.html). In an environment of fiscal constraints the ‘value’ of 
healthcare received has never been more important. Some qualitative 
studies have postulated the constraints of enabling a home death (149, 
O'Brien, 2010 #5976), however to our knowledge, apart from this study, 
no large population-based studies effectively examine socio-economic 
factors and the impact of hospital admissions at the end of life on place of 
death for gynaecological cancer patients.  
 
 
 One aspect of achieving a  ‘good death’ is dying at the place of one’s 
choosing be it at home or in the usual place of residence, such as a care 
home or residential home (189). The hospital setting is often regarded as 
lacking in being able to provide an ‘alternative to home’ environment at 
the end of life to patients and their families, as the environment is more 
‘clinical’ and formal and the attitude is geared towards prolonging life 
and offering advanced therapies (190). However, in certain circumstances 
the safety of professional clinical care and specialist end of life care may 
provide reassurance to the patient and the family and, the patient may 
wish to change his or her decision towards a hospitalised death at the end 
of life (191). The second to most recent VOICES (2011) survey reported 
that pain control achieved, was more effective for patients in hospices 
than in hospitals (http://www.ons.gov.uk/ons/dcp171778_370472.pdf). 
Therefore, contradictions continue to exist as to what might be regarded 
as the ‘ideal place of death’ (192). The availability of hospital beds for 





be factored into the future planning of end of life care resources not 
excluding the additional expertise, especially with respect to the UK 
aging population (193). 
 
 
The focus of research on ‘place of death’ has focused on ‘home deaths’ 
and more recently death occurring in usual place of residence, in keeping 
with national preferences and national policies directed towards 
achieving this directive. This chapter focuses on ‘hospital deaths’ and 
explores the factors that impact on death in hospital from a socio-
demographic view but also investigates how the modification of these 
factors may finally influence future service provision. Cancers of the 
female reproductive tract are a heterogeneous group, requiring multi-
professional and multi-disciplinary input throughout the disease 
trajectory. They remain less well studied compared to other cancers. With 




The analyses have involved the use of a large linked database, the linkage 
performed from two national administrative databases. This lead to the 
derivation of 13 years of person-based, linked hospital and mortality data 
to report on trends on where gynaecological cancer patients die in 
England and to determine the contribution of age, year of death, 
deprivation, cancer site, geographical region, and length and type of 







To elucidate, the aims of this chapter were to assess the ‘usefulness’ of 
the routine linked database with respect to proxy outcomes with 
particular reference to the key performance indicator ‘place of death’. 
Based on previous research, which has highlighted that most patients 
prefer not to die in hospital {Pivodic, 2015 #7105, Cohen, 2015 #7118}, 
this analysis focuses on those factors that influence death in hospital 
compared to outside hospital (i.e. home, hospice and care home). This 
methodology has been widely used in the past and more recently 
({Barbera, 2008 #6025}, {Higginson, 1998 #6796}, Gomes, 2018 
#7186}.  The predictors used are hospital-based variables derived from 
the comprehensive, accessible, national linked ONS-HES database. This 
work establishes the incidence and describes the trends of the ‘place of 
death’ of gynaecological cancer patients in England and explores the 
impact of socio-demographic factors and emergency admissions on death 
in hospital. This study further investigates how modifying the number of 
emergency admissions can diminish the number of deaths in hospital, 







The derivation of the linked database is described in chapter 3. The first 
step was to identify where gynaecological cancer patients die and to study 
the trends of the place of death. As discussed in chapter 3 the independent 
variables were derived based on death having occurred in hospital were 





and admission details. Multivariable analysis was performed to identify 
those factors that significantly impacted on death in hospital. This 
modeling exercise was validated by a separate dataset of gynaecological 
cancer deaths occurring over a subsequent 6 month period. This work 
attempted to predict the reduction in the number of hospital deaths after 
postulating a halving of the proportion of emergency admissions, which 
could be undertaken by implementing change in policy to increase 
community palliative care services.  
 
 
5.2.1 Participants and procedures 
 
Data was extracted for all women who died of a cancer of gynaecological 
origin from 1st January 2000 to 1st of July 2012 who were resident in 
England. This included 93% of all gynaecological cancer deaths for the 
study period. Such an event was defined, irrespective of place of death, 
where the underlying cause of death was recorded as ovarian (ICD-10 
code C56 and C57.0-C57.4), endometrial (C54 and C55), cervix (C53), 
vulva (C51), vaginal (C52) or placental (C58) site cancer (ICD-10, 
International classification of diseases, 10th revision). Information on age 
groups  year of death, postcode, and number of hospital visits and length 
of stay in hospital in the last month of life, and place of death were 
extracted. Place of death is recorded by the Office of National Statistics 
using a number of communal establishment codes, which were grouped 
into five broad groups: home, hospital, hospice, nursing home or 
residential home and other. The type of presentation for admission 
(emergency or elective) is recorded by the hospital completing the 









5.2.2 Statistical Analysis 
 
 
During the selected period 71,891 patients died of gynaecological cancer 
in England. We excluded from the analysis (0.98%) of patients with 
missing deprivation status. Thus details of 71,269 were subject to 
analyses. The patients were grouped into eight aggregate groups by age 
(Table 3.1). Each tumour site of gynaecological cancer was identified 
using the ‘underlying cause of death’ on the death certificate. Ovarian 
cancer is the reference tumour site for analysis being the commonest 
cause of death amongst all gynaecological cancers (99). London was 
chosen as the reference Strategic Health Authority for analysis due to the 
highest reported incidence of hospital deaths, the largest city and the 
capital of England. The length of stay in the last month of life for all 
elective and emergency admissions was grouped as: no stay, one day, two 
to six days, one to two weeks of length of stay and greater than two 
weeks and up to 30 days. Where there was more than one admission in 
the last month of life the data was aggregated. The number of elective 
and emergency admissions was grouped into: day case, one, two and 
three or more admissions in the last month of life.  
 
 
Cross tabulations were used to analyse and present data. Logistic 





predicted death in hospital. The predictor variables included in the 
analyses were year of death, age group, income deprivation quintile, 
Strategic Health Authority of death, gynaecological cancer site, and 
number of scheduled and unscheduled admissions into hospital and their 
respective total duration of stay. Multivariable logistic regression 
analyses were used to develop the model predicting death in hospital. 
Modeling involved the removal of those predictors, which were not 
significantly associated with death in hospital. Residuals and deviance 
were calculated to assess the quality of the model. Calibration of the 
model was assessed by Hosmer-Lemeshow statistics to quantify expected 
and observed deaths in hospital. We assessed discriminatory power of the 
model with receiver operating curve analysis. The potential for 
interaction of predictors was tested for by introduction of new variables 
derived from the product of the variables being tested. 
 
 
All analyses were performed using STATA version 10 
 
 
5.2.3 Model Validation 
 
 
To validate the predictive model we applied it to a different data set of 
2,808 women derived from the same linked database of hospital 
admissions data (HES) and Office of National Statistics deaths. This 
included all those women whose death certificate described 









In order to use the model to predict the effect of altering variables, we 
selected a subset of patients from the development dataset who attended 
as an emergency to predict their risk of dying in hospital. The patients 
were classified into four subgroups according to their number of 
emergency admissions. Their relative risk of death in hospital compared 
to the preceding group was calculated. The groups comprised those who 
had no emergency admissions; one emergency admission; two emergency 
admissions; three and more emergency admissions. We predicted the 
number of deaths that could be avoided in hospital if half the number of 
emergency admissions was avoided through improved assessment and 
support in the community. The basis of postulating a 50% reduction in 
emergency admissions was based on work performed on avoidable 
emergency admissions (194) and avoidable hospital deaths in England 
(195). According to O’Cathain et al, on average 22% of emergency 
admissions were avoidable, with a 3-fold variation recognised across 
hospitals in England. 53% of these admissions could be explained by 
routine data. Such admissions were defined by identifying ambulatory 
and primary care- sensitive conditions where emergency admissions 
could be prevented through intervention in primary care (194). Avoidable 
death is defined as those with 50% avoidability in view of trained 
medical reviews (195). Therefore, based on the above, to allow for 
interpretation of the analyses, a 50% reduction of emergency admissions 
was assumed as credible and the author thought could be used as a basis 










This section of the thesis describes where gynaecological cancer patients 
die and the trends of their place of death. This allows interpretation of 
where care needs to be focused, in keeping with changing trends and 
national end of life care policy. The impact of socio-demographic 
variables and emergency admissions is assessed on death in hospital for 
this subset of patients in England. This aspect of the analysis provides 
insight into some of the societal factors that impact on place of death and 
possibly reflects on the changing preference of place of death based on 
age, deprivation status, cancer site and postcode at the time of death. 
Based on this modeling practice, the impact of reducing the number of 
emergency admissions on deaths in hospital is postulated. This may have 
implications for implementing changes in end of life care policy. 
 
 
Results of the analysis of data on 71,269 women who died of 
gynaecological cancer during the study period are described. During the 
study period 30, 642 (43%) died in hospital, 15, 356 (22%) at home, 17, 
295 (24%) in a hospice, 6, 740 (9%) in a care home and 1, 236 (2%) in 
other places. Figure 5.1 describes the trends of the place of death for 
gynaecological cancer patients with a significant downward trend in the 
number of deaths occurring in hospital (2001/ 4278 or 47% in 2000 to 
991/ 3093 or 32% in 2012) mirrored by a rise in the number of deaths 





hospices (961/4278 or 22% in 2000 to 809 /3093 in 2012 or 26%) with a 
slight increase in the number of deaths occurring in care homes. A 
decline in the number of hospital deaths can be observed on the chart to 
begin after 2004, possibly following implementation of The End of Life 
Care Programme in 2004 and the End of Life Care Strategy in 2008. 
Logistic regression analysis confirms the significant reduction in the odds 
of a hospital death with each recent year (Table 5.1). Table 3.1 (chapter 
3) gives the baseline demographic data and inpatient details including 
frequency and duration of length of stay following an elective or 
emergency admission in the last month of life as a function of place of 
death (Table 3.1). The table also describes the candidate variables 
considered in the model that predict death in hospital: year of death, age 
group, tumour site, income deprivation quintile, geographic region, 
frequency of elective and emergency admissions in the last month of life 
and their respective lengths of stay.  
Figure 5.1: The trends of the place of death for gynaecological cancer patients in 





A higher proportion of deaths in the advanced age groups reflected the 
incidence of gynaecological cancer. Less than one-third of deaths (28%) 
of the gynaecological cancer population was concentrated in the 75-84 
years age group reflecting a skewed age distribution, in keeping with age 
related incidence. Age group proved to be a significant predictor of place 
of death as suggested by concordance of the univariable and 
multivariable analysis with the odds of dying in hospital increasing by 
18% for every decade of advancement in age, when other socio-
demographic and admission details were controlled for. The proportion of 
patients having at least one emergency admission in the last month of life 
was found to have steadily risen over the past decade from 43% in 2000 
to 48% in 2011 (Figure 5.4). The odds of an emergency admission in the 
last month of life, controlling for socio-demographic variables, over the 
study period was found to have more than doubled (OR 2.4, p < 0.001) as 
confirmed on multivariable analysis. An increase of the proportion of 
women (13% to 17%) whose inpatient stay extended from seven to 
fourteen days in the last month of life following an emergency admission 
is shown in Figure 5.5, whereas the proportion of patients who stayed in 
for 15-30 days prior to death had declined. Multivariable analysis 
confirmed that the lengths of stay following and emergency or an elective 











Table 5.1: Adjusted and unadjusted odds ratio after multivariable logistic 
regression analysis using backward elimination techniques 
 
 


















Figure 5.5: The percentage increase in length of stay for patients with 





Following multivariable analysis, the statistically significant determinants 
of increased odds of death in hospital were: less recent year of death; 
advancing age group; a diagnosis of cervical cancer, cancer of unknown 
gynaecological origin or placental site tumours; increasing income 
deprivation quintile; resident of London SHA; and the increasing number 
and duration of length of stay of both elective and emergency hospital 
admissions. Death was less likely to occur in hospital for women dying of 
cancer of the vulva or vagina. This suggested that the symptoms of end of 
life stage of this advanced group age group were different than other 
gynaecological cancer sites and were possibly managed well in the 
community. Table 5.1 gives the details of the final model. The only 
variable excluded was endometrial cancer, which did not significantly 







A probability cut off of 0.4 for classifying a hospital death gave the best 
sensitivity and specificity (75% and 72%, respectively, Table 5.2) for the 
developmental model. Figure 5.6 and 5.7 show the receiver operating 
curves for the developmental dataset and validation dataset respectively. 
The area under the curve for the developmental dataset of 0.78 and for 
the validation dataset of 0.71 confirmed the power of the predictive 
model. In each case the residuals plot shown in figure 5.8, demonstrate 
that the distribution of the variances of the error term is random and 
hence the model is not biased in the accuracy of fit with time. To assess 
the calibration of the predictive model we plotted the degree of 
correspondence between the observed and expected numbers of patients 
who died in and outside hospital across the range of predicted 
probabilities of death, by dividing the data in both datasets into 10 groups 
each. The expected and observed numbers were derived using a Hosmer-
Lemeshow goodness of fit test. A high degree of accuracy of predictions 
was demonstrated for both the models (scatter plots, figure 5.9 and 5.10). 
As a result of the large sample size of the models they were powered to 
detect the small differences between the observed and expected values 
within each group. Therefore, the Hosmer-Lemeshow test detected a 
statistically significant degree of miscalibration in both models. This is a 







Table 5.2: Predictive power of the model for death in hospital  
 
 









































We used the developmental data set to estimate the impact of dying in 
hospital on the use of resources. 18,072 women had one emergency 
admission in the last month of life. The odds ratio of dying in hospital 
derived from the model was 2.85 times the group with no hospital 
admissions. Assuming that half these emergency admissions are 
avoidable, 5,861 deaths in hospital could be avoided. If half the 
admissions in every admission group were avoided there would be a 
reduction of 6,031(16%) deaths in hospital in total (Table 5.3).  The mean 
percentage of deaths in hospital during the period was 43% and thus a 
16% reduction equates to a total of 27% of deaths occurring in hospital.  
We estimated that duration of emergency admissions in the last month of 
life equated to four wards being used full-time for one year (a ward-year), 
if 20 beds were included in a ward. 
 
 
Table 5.3: Comparison of number (percentage) predicted hospital deaths, if 50% 
of emergency admissions are reduced from each group, applying the risk ratio 










Table 5.4: The total number (percentage) of cancer and non-cancer related 
deaths for the study period for England for both sexes. (Reference table; data 




Figure 5.10: Trends of the place of death for all cancers in England over the 










The results suggest that the linked HES-ONS database allows 
investigation of the place of death of various cancer sites and for the 
purpose of this study, gynaecological cancer. It also allowed an 
investigation of the impact of emergency admissions on place of death, 
which can be considered as reflective of the quality of care at the end of 
life. The trends of the place of death can also be described, confirming 
the utility of the database. The percentage of gynaecological cancer 
patients dying in hospital has significantly decreased whereas the 
numbers of home deaths have increased in in keeping with national trends 
for all causes of place of death (Figure 5.1 and Figure 5.9). It was 
observed that the increase in the number of gynaecological cancer deaths 
in hospices did not mirror national trends with respect to trends of all 
cancer-related deaths, which remained unchanged over the study period. 
It must be noted that overall, the total number of cancer related deaths 
have increased for England (Table 5.4). It can therefore be speculated that 
gynaecological cancer patients, a small subset of the total cancer deaths 
are being referred for hospice care at the end of life, suggesting that this 
is likely a preferred place of care and death at the end of life. Hospice 
care, with respect to symptom control, especially pain control, has been 
reported by patients and their families to be more efficient than hospitals 
in the most recent VOICES survey.  The predictive model derived used 
objective data (year of death, age, income deprivation quintile, SHA of 
residence, gynaecological cancer site, and number of scheduled and 
unscheduled admissions into hospital and their respective total duration 
of stay) in a logistic equation to identify predictors of increased risk of 





Increasing age increased the risk of death in hospital. Elderly patients 
were also more likely to live in residential care homes and the incidence 
of deaths occurring in the usual place of residence to include care homes 
and nursing homes were observed to have significantly increased when 
compared to deaths occurring at home. Overall, the total number of 
cancer patients dying in care homes has been noticed to increase for 
England recently, as shown in figure 5.7. It therefore appears that care 
homes are increasingly a preferred place of care and death for 
gynaecological cancer patients of advanced age at the end of life. In a 
English study of 2, 281, 223 cancer deaths (from 1993-2010) Gao et al 
showed that patients were less expected to choose a home or hospice 
death if they were beyond the age of 75 years, single, widowed or 
divorced and therefore perhaps needed emphasis for better care and 
support at the end of life {Gao, 2013 #5988}. Thus assessment of 
changing patterns of social structure for cancer patients is recommended 
to ensure adequate appraisal and responsiveness to enable support in the 
appropriate place of care or death at the end of life. The Care Quality 
Commission is responsible for the assessment of care homes to ensure 
that national standards of social care are maintained.  Their strategy is to 
enable care providers to deliver high quality compassionate care to 
consumers. They also aim to provide ‘ratings’ of services for each 




The proportion of patients spending 7-14 days in hospital in the last 
month of life prior to death has increased. These subset of patients require 





of life care status, investigations performed whilst inpatient, and the 
proportion of patients for whom a rapid discharge pathways were 
employed to facilitate death in their preferred location.  
 
 
Among patients in the data set used to develop the model, the risk of 
dying in hospital following one emergency admission more than doubled. 
The incidence of emergency admissions in patients with gynaecological 
cancer in the last month of life appears to have risen with just under half 
of patients having an emergency admission. More than a single 
emergency admission in the last month of life can be regarded as a 
negative predictor of care in the community {Hu, 2013 #5980}. The rise 
of emergency admissions is likely to be multi-factorial, inevitable and 
possibly variable, depending on need for symptom control at an 
individual level at the end of life, the age distribution of the population, 
social status, marital status and the accessibility and availability of 
specialist palliative care services, which is known to be patchy in the 
community. In a study, which included 131 acute care hospitals in 
England over a three-year period, concluded that high avoidable 
admission rates occurred in hospitals with higher number of emergency 
beds per unit population (per 100,000), which in turn was related to 
surrounding areas of deprivation {O'Cathain, 2013 #7174}. This suggests 
the need for further exploration of the relationship between local hospital 
resources especially in areas of low deprivation and the impact on place 







The variation in the quality of end of life care in hospitals requires further 
exploration, and is analysed in chapter 7. In a study of 105, 157 hospital 
discharges in the United States from 2003 to 2007 of cancer patients, 
42% died on ICU, however by comparison this percentage was 
significantly reduced when consultation by the palliative care team was 
arranged for the patient whilst in hospital than when not {Wallace, 2015 
#7107}. There are clear differences in how patients present in England 
when compared to the United States, however, it can be speculated that 
some emergency admissions may be necessary, whilst some preventable. 
The necessary but ‘good emergency’ admissions may provide a 
compassionate way by which some symptoms of the end of life are dealt 
with in a swift and efficient manner. In addition the provision of some 
cost effective palliative care services as ‘day care’ such as drainage of 
ascites or a pleural effusion could prevent a prolonged stay in hospital, a 
concept that needs to be adopted by more hospitals and hospices. GP’s 
would need to have arrangements in place for referring patients in, for the 
organisation of imaging or a ward assessment unit. Both studies suggest 
that, whilst some patients may have uncontrolled symptoms that require 
admission into hospital, early institution of palliative care and appropriate 




Patients with vulval or vaginal cancer had a significantly lower likelihood 
of dying in hospital (Table 3.1). This is in spite of the fact that these 
patients are usually of advanced age. This subset was found more likely 
to die in care homes, hospices or at home i.e. their usual place or 





There may be several reasons for this; Gao et al have already shown that 
the cancer site is the most important reason for where cancer patients die 
followed by socio-demographic factors {Gao, 2013 #5988}. These 
patients are less likely to present with ascites or bowel obstruction and 
therefore are less likely to present themselves as a surgical emergency, 
which differs from other gynaecological cancer types. It can therefore be 
speculated that advance care planning is more effective in these patients 
helping them to achieve their preferred place of death. This subset 
requires further detailed exploration in future studies and exploration of 
their issues at the end of life.  
 
 
A major strength of the study is its large sample size, which allowed 
profiling of the more rare gynaecological cancer sites, suggesting 
dissimilarities in the end of life care journey of the various cancer sites.  
 
 
There are also limitations to the routine data. The purpose of this analysis 
was to specifically assess the impact of emergency admissions and 
lengths of stay on death in hospital. To explain the possible determinants 
of a hospital death i.e. the same has been compared to death outside 
hospital i.e. home, care home, hospice and elsewhere. However, in spite 
of simplifying outcomes, the predictive model confirmed a good 
predictive power (ROC 0.78). The co-morbidity data is not routinely 
recorded in HES with a high proportion of missing data. The presence of 
limiting medical conditions may affect the suitability of a patient to 





hospital. Also the actual preference of place of death was not available 
due to the retrospective data analysis.  
 
 
This aspect of the thesis does not explore the specific reasons leading to 
an emergency admission to allow clinical judgments to be made, however 
the question remains if care could alternatively be provided in the 
community, and if so, whether this would impact on place of death. 
Chapter 8 describes a separate subset analysis of 28 cancer patients 
(including non- gynaecological cancers) who had their paracentesis 
drained over a two-year period in a hospice in England and this subset 
was compared to 12,452 cancer patients who had their ascites drained in 
hospital. Of the 28 cancer patients well known to the hospice, 53% died 
at home and 29% in the hospice, whereas of the 12,452 cancer patients 
who had their ascites drained at hospital, 42% died in hospital (in press). 
Of the patients who had their ascites drained in hospital 20% were 
ovarian cancer patients and were the most common of the 68 analysed 
different cancer types in the hospital subset of cancer patients.  
  
 
The multivariate model was not designed to predict the individual risk of 
patients dying in hospital based on their individual socio-demographic 
characteristics or type of hospital episodes. The purpose of the model was 
simply to explore the impact of socio-demographic parameters, hospital 
episodes and the possible existence of regional variations with respect to 
death in hospital and question whether all patients of various 
gynaecological cancer sites had the same risk of dying in hospital. The 





at time of death impact on place of death for patients with gynaecological 
cancer. Social inequalities may reflect a lack of awareness of facilities 
and support available in the community and the inability to engage with 
hospital and community palliative care including inaccessibility of care, 
which may further impact on advance care planning. In addition, 
variations in availability of care in the community may impact on 
preferred place of care and death at the end of life. These variations must 
be understood to plan appropriate allocation of resources. This was also 
suggested by a recent study, which looked at the variation in the place of 
death in 14 countries over 4 continents by study of death certificate data. 
They concluded that hospital or home deaths varied by country primarily 
due to availability of hospital beds and general practitioners in the 
community {Cohen, 2015 #7108}. Our results were also applicable to the 







Limited resources exist for most countries. The incidence of hospital 
deaths is gradually reducing in the USA and Canada, with the United 
Kingdom closely following, however the majority of deaths in Europe 
still occur in a hospital or in an institution in spite of a preference for a 
home death. The linked database confirmed that the majority of 
gynaecological cancer patients die in hospital, however this trend is 





hospices and care homes suggesting a changing pattern in where 
gynaecological cancer patients die.  
 
 
The numbers of emergency admissions appear to be rising and this 
significantly impacts on a hospital death, almost trebling the risk of death 
in hospital after an emergency admission. Our modelling exercise 
suggested that a 16% reduction in deaths in hospital could be achieved by 
preventing half of the inappropriate emergency admissions in the last 
month of life. This would however need confirmation by a prospective 
study. This also suggests that physician-led interventions need to be 
offered in the community and in specialist palliative care units in order to 
effect change so that inappropriate referrals into hospital can be avoided.  
 
 
Patients with a less recent year of death; advancing age group; a 
diagnosis of cervical cancer, cancer of unknown gynaecological origin or 
placental site tumours; increasing income deprivation quintile; resident of 
London SHA; and the increasing number and duration of length of stay of 
both elective and emergency hospital admissions were ore likely to die in 
hospital. The model confirms that variations in number of deaths in 
hospital exist with respect to postcode. There is a variation with respect to 
the quality of end of life care available to patients as a result of disparities 
of age, socioeconomic status and response to end of life care situations by 
length and number of hospital admissions in the last month of life. Our 
predictive model supports the fact that improved services are required in 
the community to prevent both planned and unscheduled hospital 





hospitalised patients. This information would inform STP’s  
(Sustainability and Transformation Plan) on setting out practical plans to 
improve end of life care services for patients in all areas. Thus, allocation 
of health resources and public health care policy must focus on bridging 





























6 Chapter 6: Geographical Variations in the End of Life Care of 






Examination of geographical variations in healthcare: 
Local populations may vary with respect to their healthcare outcomes. 
These differences may be explained by variations in treatment choice or 
local demographics, for example, a more elderly population being less 
likely to accept a radical treatment option. These variations may be 
regarded as acceptable and can be explained. When these variations are 
examined over large population sizes, they can be adjusted for or would 
be expected to even out. 
 
 
An ‘unwarranted’ variation is when it cannot be explained by patient 
preference and does not disappear when adjustments are made in the 
case-mix analysis. As exampled by significant differences in mortality 
rates between two tertiary hospitals, when evidence-based treatment 
options are made available to both populations. Identification of 
‘unwarranted’ variations allows healthcare professionals and 
commissioners to question the reasons for such differences and adopt 
procedures and processes that would help improve outcomes and 







 In order to measure differences in outcomes, like must be compared by 
like.  
Adjusting for differences in hospital population characteristics allows the 
quality of patient care to be measured and is described as a case-mix 
analysis. In addition, using evidence-based clinical indicators or ‘quality 
markers’ of care allows comparison of populations using uniform 
measures of outcomes. 
However, interpretation of outcomes requires careful reflection, as 
statistically significant variations in outcome may not directly be 
regarded as clinically significant. This is referred to the phenomenon of 
‘over dispersion’, which can in turn be explained by the use of a poor 
choice of indicator or that appropriate adjustment did not occur. Ranges 
of results are more safely interpreted than a single target result. The next 
section describes the background of the study of geographical variations 
in end of life care for gynaecological cancer patients in England.   
 
 
Examination of geographical variations of the quality of end of life care: 
 ‘Equitable’ end of life care is central to ensuring each individual receives 
high quality care at the end of life. The existence of regional variations in 
the accessibility of end of life care in England has already been 
acknowledged in national policy documents such as the ‘End of Life Care 
Strategy’ (DH 2009), however these variations are yet to be formally 
quantified and more specifically for gynaecological cancer patients in 
England. These differences are further compounded by inherent social 
variations in regional populations such as differences in age and socio-





status is another cited confounder (144). Thus the quality of end of life 
care available in a region is probably dependant on a number of factors 
specific to the individual or population in an area and factors related to 
the needs of that region such as the density of hospices, the availability of 
community palliative care, accessibility to specialist palliative care units 
and the expertise of involved general physicians. Data on the 
performance of community palliative care services is currently not 
quantifiable for England in the absence of centralised databases. 
The aim of the updated NICE guidance on Supportive and Palliative Care 
issued originally in March 2004 was to strengthen the NHS Cancer Plan 
for England with regard to safeguarding patients with cancer by offering 
access to the best support and treatment available throughout their cancer 
journey (http://www.nice.org.uk/guidance/csgsp/documents/2004015-
new-guidance-will-improve-supportive-and-palliative-care-services-for-
adults-with-cancer-2). This included specialised palliative care services 
with face-to-face contact during routine hours seven days a week. The 
‘End of Life Care Strategy’ (DoH 2008) ensured accessible 24/7 care 
including visiting and rapid response services for patients in the last year 
of life. Sue Ryder proposed the concept of a co-ordinated and integrated 
service by promoting the Bedfordshire Partnership for Excellence in 
Palliative Support  (PEPS), which involved setting up a central electronic 
register for the area to improve communication and ensure that patients 
received a holistic assessment, consistency in information delivery, 
offered an advance care plan and appropriate treatment irrespective of 












The ‘markers for quality of end of life care’ as described by Earle are 
currently regarded as ‘number of deaths occurring in hospital’, ‘number 
of emergency visits/admissions in the last two weeks of life’, 
‘chemotherapy in the last two weeks of life’, ‘home care in the last six 
months of life’ and ‘physician house calls in the last two weeks of life’ 
(9). As a result anticipated services were home care visits and hospice at 
home whereas, non-desirable outcomes were emergency department 
visits and chemotherapy in the last two weeks of life. Thus followed the 
hypothesis that, geographical variations in end of life care services result 
in heterogeneity in the quality of end of life care. A study into the 
variations in end of life care in a region may not only serve to identify 
variations in performance, but also those factors that have contributed to 
significant improvement or are a probable deterrent in improving quality 
of care. These could be areas of focus when service development and 
resource allocation is planned. 
 
 
Benchmarking the performance of regional healthcare especially with 
regards to the end of life care of gynaecological malignancies is complex 
when the heterogeneous mix of a population by age, socio-economic 
status, postcode and diagnosis is taken into account. The significance of a 
case mix analysis is that it allows such data to be compared to allow 








The commitment from all levels of healthcare must extend to providing 
information on the available pathways for patients for symptom control in 
hospital and in the community including accessibility to specialist 




The aim of this work has been therefore to assess whether the use of 
routine patient linked data can be used to examine geographical 
variations in end of life care. Secondly, if these variations quantitatively 






This section describes the case-mix analysis performed by using routine 
person-linked administrative data to assess variations in end of life care 
and the use of funnel plots to aid result interpretation. 
 
 
In order to measure regional performance by SHA, for end of life care, 
we controlled for socio-demographic factors. The quality indicators used 
to benchmark end of life care for the 10 strategic health authorities 
(SHA’s) of England are modified from Earle’s markers of 





the percentage of deaths occurring in hospital, number of emergency 
admissions in the last month of life, number of elective admissions in the 
last month of life and their respective lengths of stay following an 
elective or an emergency admission. The baseline data was derived from 
a linked database of two national administrative databases: Hospital 
Episode Statistics (HES) and Office of National Statistics (ONS) deaths 
data from the 1st of January 2000 to 1st of July 2012. The details of the 
derivation of each variable and variable grouping are as described in 
chapter 2.  
 
6.2.1 Risk Adjustment 
 
 
Risk adjustment was performed by judgement-based modelling 
procedure.  The covariates that may explain between-region variability of 
quality of end of life care were selected to include percentage of deaths 
occurring in hospital, number of elective or emergency interventions in 
the last month of life, number of emergency admissions in the last month 
of life, number of elective admissions in the last month of life and the 
respective lengths of stay following an elective or an emergency 
admission. Multivariable logistic regression (logistic or regress command 
was used in STATA, the logistic command was used for the ‘procedures’ 
data as it was a continuous variable) was performed to sequentially 
include year of death (to factor in changes in the number of deaths 
occurring in hospital over the study period), socio-demographic factors 
(age, socio-economic quintile, postcode) and cancer diagnosis (Ovarian, 
Endometrial, Cervical, Vulval, Vagina and Gynaecological cancer of 





of elective and emergency admissions were factored into the model. 
Either calculating the area under the curve or plotting residuals checked 
the quality of the model. The observed number of events and predicted 
number of events were aggregated by region to calculate the 
observed/expected ratio of events (SMR). These were then interpreted by 
constructing funnel plots. 
 
 
6.2.2 Funnel plots 
 
 
‘Funnel plots are a form of scatter plots in which the observed area rates 
are plotted against area populations, the control limits represent the 
expected variation in rates assuming that the only source of variation is 
random’ (198). The funnel plots of risk-adjusted event rates (hospital 
deaths, emergency procedures in the last month of life, emergency 
admissions in the last month of life, emergency or elective length of stay 
following an admission) against expected number of events for the 
population were created using an online tool offered by the Public Health 
Observatories’ Analytical Tools for Public Health: Funnel plots for 
indirectly standardised ratios 
(www.apho.org.uk/resource/view.aspx?RID=47242). Each SHA was 
identified across the funnel plot that was an outlier to understand the 
possible reasons for variability. It was assumed that on the basis of 
statistical sampling error that 95% of SHA’s would lie within the 95% 









This section of the thesis aims to determine statistically significant 
geographical variations in the number of deaths in hospital and the 
number of emergency admissions, emergency lengths of stay, emergency 
and elective procedures undergone by this subset of gynaecological 
oncology patients. The finding of statistically significant variations of 
healthcare outcomes by SHA, questions whether these variations can be 
explained and if clinically relevant should change be suggested. 
Clinically significant variations, supported by statistical significance, 
indicate a possible effect on the quality of care afforded to patients. 
 
 
The data for 71,440 women who died of a cancer of gynaecological 
origin was available for the study period. The socio-demographic data 
and details of admission of the whole study cohort are detailed in table 1, 
chapter 2. Table 6.1 shows, for each SHA, the number of hospital deaths, 
emergency admissions, procedures and lengths of stay whilst Table 6.2 
shows the same for the elective admissions following admission into 









Table 6.1: Absolute number of hospital deaths, emergency admissions, 
emergency procedures and emergency lengths of stay (days) in the last month of 




Table 6.2 Absolute number of elective procedures and lengths of stay (days) in 
the last month of life for each SHA 
 
 
6.3.1 Variation in number of deaths occurring in hospital by SHA 
 
 
The total number of deaths that occurred in hospital for the duration of 
the study period was 30, 340 (42.5%). On multivariable logistic 
regression analysis for hospital deaths the factors that significantly 
SHA Hospital deaths Emergency admissions Emergency procedures Emergency lengths of stay
North East 1695 1761 1068 20613
North West 4144 4576 3149 49929
Yorkshire & Humber 3213 3385 2130 37389
East Midlands 2929 3086 2210 34185
West Midlands 3440 3727 2225 41484
East of England 3385 3682 2388 50681
London 3348 3491 2113 48629
South East 2451 2705 1974 28265
South Central 2247 2408 1486 26771





predicted death in hospital were increasing socio-economic deprivation, 
increasing age, diagnosis of either cervical cancer, endometrial cancer, 
gynaecological cancer of unknown origin or choriocarcinoma, an elective 
or an emergency admission and an increase in the respective length of 
stay following an admission of either type in the last month of life. 
Ovarian cancer and London were the reference standards for comparison. 
Reduced risk of death occurring in hospital was associated with most 
recent year of death and a diagnosis of Vulval or Vaginal cancer (Table 
6.3). The model yielded a good discriminatory power with the area under 
the receiver-operating curve of 0.78, suggesting that the percentage of 
deaths occurring in hospital was a good predictor of regional quality of 
end of life care (Figure 6.1). If the model predictions are accurate the 
points will lie close to the line of equality. The range of observed/ 
predicted percentages of deaths (94%-111%) in hospital are shown for 
each SHA in table 6.4. The absolute difference between the predicted and 
observed percentage of hospital deaths was (-2.4% to 4.8%).  
 
Table 6.3: Adjusted odds ratio, p values and confidence intervals following 
multivariable analysis to assess the impact of the socio-demographic, diagnosis 









Figure 6.1: Receiver operating curve (ROC) following regression analysis shows 





Table 6.4: Case mix analysis: ratio of observed vs. predicted number of hospital 
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A SHA was considered an outlier if the risk adjusted hospital death rate 
was more than three standard deviations (s.d.) from the mean. There were 
two outlier SHA’s (one above and one below) and one other SHA beyond 
the 95 per cent control limit. London clearly had the highest number of 
observed deaths occurring in hospital over the study period and was 
placed beyond the 3 s.d.’s control limit for expected variation, whereas, 
the South East of England had the lowest number of observed deaths 
occurring in hospital over the same duration of study and was placed 3 
s.d.’s below the expected variation.  
 
 
Over the study period the proportion of hospital deaths for women with 





analysis increased the range of the observed/expected number of hospital 
deaths by 17% (94%-111%). The proportion of deaths occurring in 
hospital varies by SHA, and is unexplained, although one might be able 
to speculate that the availability of specialist palliative care services, the 
density of hospices and the level of expertise offered by general 
physicians at the end of life may all contribute to some variation (16, 199, 
200). It is not possible to comment whether these differences are 
clinically significant for SHA’s or judge the performance of district and 
tertiary level hospitals within a region based on these results. It may be 
that all levels of healthcare are performing appropriately within an 
acceptable range based on available resources and patient preference. The 
multivariable model (Table 6.3) describes which patient characteristics 
increase the risk of death in hospital.  
 
 
6.3.2 Variation in the number of emergency admissions by SHA 
 
 
32,564 patients with gynaecological cancer had at least one emergency 
admission in the last month of life. In the last month of life the proportion 
of gynaecological cancer patients whom had an emergency admission 
varied by SHA from 35% to 47%. Multivariable analysis was performed 
to understand those patient characteristics that significantly predicted an 
emergency admission to hospital in the last month of life and may explain 
how patients vary in their presentation to hospital. These were death 
having occurred in hospital, a recent year of death and increasing socio-
economic deprivation (Table 6.5). Patients with ovarian cancer were 





compared to patients with cervical, endometrial, vulvar or vaginal cancer. 
Younger patients were more likely to present as an emergency (Table 
6.5). The discrimatory power of the model was good with an area under 
the ROC curve of 0.75 (Figure 6.3). 
 
 
The ratio of observed /expected number of emergency admissions are 
shown in table 6.6.  The observed/expected percentage of emergency 
admissions ranged from 94% to 118% suggesting a wider range of 
variation amongst SHA’s after risk adjustment (24%). A SHA was 
considered an outlier if the risk-adjusted number of emergency 
admissions in the last month of life for that SHA was more than 3 s.d’s 
from the mean. There were three outlier SHA’s, two above and one 
below the 99.7 per cent control limit. The South East and the North West 
were placed 3s.d beyond the expected emergency admissions control 
limits where as London was placed below the 3s.d expected control limit 
when assessed for variations in observed emergency admissions in the 
last month of life (Figure 6.4).  
The results above indicate that variations in emergency admissions 
amongst SHA’s are statistically significant. The range of variation of the 
predicted emergency admissions is greater than the range of variation of 
predicted hospital deaths for SHA’s (24% vs. 17%) after risk adjustment 
suggesting that this may be a more dominant factor. Again, whilst the 
variations in the patient characteristics explain the variations in the 
number of emergency admissions in the last month of life for a SHA, 
variation of emergency admissions by SHA remain unexplained.  





engagement and expertise along with previous patient experiences may 
be some of the factors that contribute to the relative increases observed.   
 
Table 6.5: Multivariable analysis of socio-demographic factors and type of 





Figure 6.3: Receiver operating curve (ROC) following regression analysis for 



















0.00 0.25 0.50 0.75 1.00
1 - Specificity






Table 6.6: Case mix analysis: ratio of observed vs. predicted (relative difference) 







Figure 6.4: Funnel plot show the distribution of number of emergency 









6.3.3 Variation in the number of Emergency Procedures by SHA 
 
 
33,004 patients had an intervention in the last month of life over the study 
period. Of these 21,232 (64%) patients had a procedure performed as an 
emergency. 23,830 of these patients were diagnosed ovarian cancer 
(60%). Multivariable analysis was performed to identify the patient 
characteristics that accounted for variations in the number of emergency 
procedures undergone by gynaecological cancer patients hospitalised in 
the last month of life. Younger patients, who had a more recent year of 
death and eventually passed away in hospital, were more likely to have 
undergone an emergency procedure in hospital prior to their death. In 
addition patients with cervical, vulval, vaginal and endometrial cancer 
were significantly less likely to have undergone an intervention compared 
to ovarian cancer patients (Table 6.7). This can be explained on the basis 
that end stage ovarian cancer patients are more likely to present with 
gastro-intestinal symptoms such as sub-acute bowel obstruction resulting 
in abdominal distension and symptoms such as pleural effusion or ascites 
causing shortness of breath. This results in acute on chronic distress 




The socio-economic status of the patient did not influence an emergency 
intervention. It has been reported that patients of a lower socio-economic 





possibly die in hospital (201). It can be speculated that socio-economic 
status does not appear to effect medical decision-making. The residuals 
plot shown in figure 6.5, demonstrate that the distribution of the variances 
of the error term is random and hence the model is not biased in the 
accuracy of fit with time. The R-square value was 75.5% suggesting good 
discriminatory power of the model. 
 
 
The ratio of observed /predicted numbers of procedures for each SHA are 
shown in table 6.8. The percentage of observed/predicted emergency 
procedures varied widely from 89% to 113%. An SHA was considered an 
outlier if the risk-adjusted number of emergency procedures in the last 
month of life for that SHA was more than 3 s.d’s from the mean. There 
were three outlier SHA’s on either side of the 99.7% control limits. The 
South East, East Midlands and the North West ranked above the 3s.d 
expected control limit while West Midlands, London and South Central 
coast were placed below the 3s.d’s expected control limits Figure 6.7. 
This wide variation in the number of emergency procedures by SHA 
could not be explained for, having adjusted for patient characteristics. 
There appears to be a link between the variation in the number of hospital 
deaths, emergency admissions and emergency procedures for London and 
the South East who are constant outliers. London is an outlier with 
respect to a higher proportion of observed to expected hospital deaths, a 
lower proportion of emergency admissions and lower proportion of 
emergency procedures. The South east of England is an outlier with 
respect to the lowest proportion of observed to predicted hospital deaths, 
a higher proportion of emergency admissions and emergency procedures. 





of presentation into to hospital for the South East of England, 
gynaecological cancer patients at the end of life seeking symptom control 
via an intervention are more likely to die at home rather than in hospital. 
Whereas in London, although emergency admission rates and 
interventions are significantly low, once admitted to hospital, death is 
more likely to occur in hospital. This link may have some clinical bearing 
with regards to the availability of specialist palliative care teams in 
hospitals, communication amongst teams and the availability of such 
services in the community. 
 
Table 6.7: Multivariable logistic regression analysis to predict which socio-









Figure 6.5 Residual plot analysis shows the difference between the observed and 





Table 6.8: Case mix analysis: ratio of observed vs. predicted number of hospital 









Figure 6.7: Funnel plot show the distribution of the number of emergency 





6.3.4 Variation in the number of Elective Procedures by SHA 
 
 
33,004 patients had a procedure in the last month of life over the study 
period. Of these 11,772 (36%) patients had a procedure performed as an 
elective intervention. Multivariable analysis was performed to identify 
those patient characteristics that accounted for variations in the 
proportion of elective interventions performed on gynaecological cancer 
patients hospitalised in the last month of life (Table 6.9). It was found 
that younger patients, increasing socio-economic deprivation, patients 
with cervical, endometrial, vulval or vaginal cancer were significantly 
less likely to undergo an elective intervention. Patients who had had a 
more recent year of death were more likely to have undergone an elective 





residuals plot shown in figure 6.8, demonstrates that the distribution of 
the variances of the error term is random and hence the model is not 
biased in the accuracy of fit with time. The overall p-value (F statistic) 
for the model was significant at <0.0005 however, the adjusted R-square 
value was noted as 31%, which may not reflect the quality of the model 
as some patients may have had more than one intervention. The ratio of 
observed to predicted numbers of elective procedures are shown for each 
SHA in table 6.10. A SHA was considered an outlier if the risk-adjusted 
number of elective procedures in the last month of life for that SHA was 
more than 3 s.d’s from the mean. There were five outlier SHA’s, three 
above and two below the 99.7 per cent control limit. The North East, 
Yorkshire and Humber and East Midlands, placed 3 s.d beyond the 
expected control limits where as London and South Central were placed 
below the 3 s.d.’s expected control limit when assessed for variations in 
observed elective procedures in the last month of life (Figure 6.9). There 
appears to be an ‘over dispersion’ of the SHA’s with respect to the 
proportion of elective procedures, suggesting a wider variation than 
predicted. This may be secondary to the fact that certain patients may 
have had multiple elective interventions or that the number of elective 













Table 6.9: Multivariable logistic regression analysis to predict which socio-





Figure 6.8:  Residual plot analysis shows the difference between the observed 
























Table 6.10: Case mix analysis: ratio of observed vs. predicted (relative 





Figure 6.9: Funnel plot show the distribution of the number of elective 








6.3.5 Variation in emergency length of stay by SHA 
 
 
32,656 lengths of stays were recorded as an emergency in the month prior 
to death. Multivariable analysis was performed to identify those patient 
characteristics that explained patient variations with respect to an 
emergency length of stay in hospital. It was found that, advancing age 
group and multiple emergency admissions were considerably associated 
with increasing duration of stay after an emergency admission. A more 
recent year of death, and increasing frequency of elective admissions 




 The residuals plot shown in figure 6.10, demonstrate that the distribution 
of the variances of the error term is random and hence the model is not 
biased in the accuracy of fit with time. The overall p-value (F statistic) 
for the model was significant at <0.0005. The ratio of observed to 
predicted emergency lengths of stay are shown for each SHA in table 
6.12 and varied widely from 96% to 128% having adjusted for patient 
demographics and admission characteristics. A SHA was considered an 
outlier if the risk-adjusted length of emergency stay in the last month of 
life for that SHA was more than 3 s.d.’s from the mean. There were five 
outlier SHA’s, three above and two below the 99.7 per cent control limit. 
The North East, Yorkshire and Humber and East Midlands, placed 3s.d 
beyond the expected control limits where as London and South Central 
were placed below the 3 s.d.’s expected control limit when assessed for 





6.11). The range of variation of the observed to predicted proportion of 
emergency lengths of stay was the widest for all SHA’s when compared 
to the proportion of hospital deaths, emergency admissions and 
procedures. London and the South East were outliers with respect to the 
proportion of emergency lengths of stay. Whilst statistically significant a 
link between the variation in the proportion of hospital deaths, emergency 
admissions and emergency procedures may suggest clinical relevance i.e 
that once admitted to hospital in London as an emergency, patients are 
most likely to stay in hospital till death.   
 
 
Table 6.11: Multivariable logistic regression analysis for emergency length of 
stay to predict whether death in hospital, socio-demographic variables and 









Figure 6.10 Residual plot analysis shows the difference between the observed and 





Table 6.12: Case mix analysis: ratio of observed vs. predicted (relative 

















The methodology used allowed SHA’s to be compared and contrasted   
by the use of the routine person-linked database. Assessment of the 
performance of end of life care by risk-adjusted measurement of the 
number of deaths occurring in hospital, emergency admissions, 
emergency length of stay and number of emergency procedures was 
achieved for the last month of life. The results indicate that statistically 
significant variations by SHA with respect to the proportion of patients 
dying in hospital, hospitalised as an emergency, undergoing an 
intervention either electively or as an emergency or having an emergency 





used (20) are regarded as ‘quality markers’ or ‘clinical indicators’ of end 
of life care it can be determined that regional variations in the quality of 
end of life care exist in England. Risk adjustment increased the 
proportion of expected numbers for each quality marker studied. These 
differences are ‘unwarranted’ and cannot be explained and therefore 
further study is required to understand the reasons for these differences. 
However, it must be remarked that there appears to be a clinically 
relevant link between these variations, in particular to certain outlier 
SHA’s such as London and the South East of England. It is understood 
that whilst statistical significance has been derived these results can only 
be regarded as significant if clinical implications are evident. 
 
 
If clinical importance is established, then this ‘quality measure-based’ 
case mix, undertaken to produce adjusted measures of regional 
performance of end of life care, could be thought to influence resource 
utilisation, future allocation and policy-related issues (202). This chapter 
has explored whether the outcome measures studied were indicative of 
the quality of end of life care and describe national variations in end of 
life care, serving as a benchmarking tool.  
 
 
The respective four multivariable models explain the variations in the 
patient characteristics that predict death in hospital, an emergency 
admission, an intervention and an emergency length of stay within a 
population in the month prior to death. The model on death occurring in 
hospital highlights the significant patient characteristics that might 





that a more recent year of death (p< 0.001), advancing age (p< 0.001), 
increase in socio-economic deprivation status, an elective or an 
emergency admission (p<0.001), increasing length of stay (p< 0.001) and 
a diagnosis of cervical cancer, endometrial cancer, cancer of unknown 
gynaecological origin or choriocarcinoma increased the risk of death in 
hospital for all SHA’s.  Similarly, the model variables that significantly 
predicted an emergency admission in the last month of life for patients 
with gynaecological cancer were younger age group (p = 0.89), a more 
recent year of death (p =1.05), increasing socio-economic deprivation (p 
= 1.02) and a diagnosis of ovarian cancer. Most importantly, a hospital 
death was seven times more probable in the last month of life following 
an emergency admission (OR = 7.12; p < 0.001). The discrimatory power 
of this model was also regarded to be good (AUC = 0.75). The third 
model, with good predictive power, highlighted those patient 
characteristics that increased the emergency length of stay. Advancing 
age (p < 0.001) and multiple emergency admissions (p < 0.001) increased 
the length of an emergency admission. The longer the lengths of stay 
following an emergency admission the greater the probability of dying in 
hospital (OR = 2.3; p < 0.001). The model for predicting emergency 
procedures suggested that the younger patients (p < 0.001), more recent 
year of death (p < 0.001) were more likely to have undergone an 
emergency intervention prior to death in hospital in the last month of life.  
 
 
Therefore younger patients were more likely to present as an emergency 
admission, be exposed to an emergency intervention but less likely to 
prolong stay in hospital and thus less likely to die in hospital. Increasing 





emergency admission and also an increased risk of death in hospital. 
Compared to ovarian cancer, patients with cervical, endometrial, vulval, 
and vaginal cancer were significantly less likely to present as an 
emergency or be exposed to an intervention in the last month of life. 
Therefore these differences in patient characteristics (age, socio-
economic status, type of admission and diagnosis) can be explained and 
their impact outcomes studied. However, variation of the quality 




Confidence limits on the case-mix adjusted funnel plots provide the best 
available method for identification of performance outliers. London was 
clearly an outlier when the proportion of predicted hospital deaths; 
emergency admissions and lengths of stay were compared to other SHA’s 
and were found beyond the 3 s.d’s limits. It accounted for higher than 
expected hospital deaths, lower than expected emergency admissions, 
lower than expected procedures and higher than expected emergency 
lengths of stay. Similar results from another more recent study confirmed 
a higher proportion of hospital deaths for London, but did not postulate 
the reasons for the same other than ‘metropolitan issues’ that require 
further exploration (130). The results of this analysis can be explained 
possibly by the premise that gynaecological cancer patients in London at 
the end of life may avoid an unplanned stay in hospital, but once admitted 
in to hospital have a prolonged stay in hospital often dying in hospital. 
There may be a number of potential reasons that contribute to London 
being an outlier that have not been explored by this work, but must be 





accessibility and utilisation of end of life care and specialist palliative 
care services (200). London has a higher concentration of teaching 
hospitals and centres of excellence for gynaecological cancer patients in 
the country, which may encourage the patient or relatives to contact the 
treating physician. Those living in the city may belong to a higher socio-
socioeconomic group and thus be more able to access certain services 
than those resident in more rural areas(203). Lack of immediate 
availability of hospice or ‘funded’ care home beds in the City of London 
may make it difficult for patients to be transferred to their preferred place 
of death. Similar differences were observed amongst urban and more 
rural based colorectal cancer patients in Nova Scotia (204). A systematic 
review of 58 studies also suggested that healthcare support e.g. number of 
hospital beds, formal carer support at home, impacted on place of death 
(144). A Danish study of 55,772 deaths found that while younger and 
more educated patients died at home, those who lived in more urbanised 
areas were more likely to die in hospital Cohen, 2006 #7177}. In addition 
recent work performed by PH England suggests that older people living 
alone, in areas with fewer care home beds per head of population, such as 
London, were possibly more likely to die in hospital rather than at home 
(http://journals.sagepub.com/toc/pmja/32/1_suppl.; 
https://fingertips.phe.org.uk). In order to understand these reasons further 
research is required to ensure equitable access to services, including 
hospital, hospice, home or care home based care. These may be specific 
to local communities and regions and dependant on available resources. 
 
 
The South East of England on the other hand had the lowest ratio of 





expected emergency admissions and emergency procedures with lower 
than expected emergency lengths of stay. This suggests that patients in 
the last month of life in the South East of England come into hospital as 
an emergency, have their needed intervention for symptom control, and 
are relatively swiftly discharged into the community.. We found that 
patients in the South East of England had the highest ratio of 
observed/predicted interventions along with patients in the East 
Midlands. Other factors such as patient and family preference, ethnicity, 
education, marital status, those with informal/formal carer support and 
with access to home care palliative services or specialised input from the 
GP may be more likely to die at home and therefore less likely to access 
emergency services (179). Accessibility to palliative care services may 
also play an important role. In the UK approximately 6% of the 
population lives more than 30 minutes by road from an inpatient hospice 
service (205). Thus it appears that these variations are clinically 
important and would warrant further investigation. Understanding the 
significance of the size of the variations with respect to decisions on 
policy related issues might not be so straightforward until these reasons 
are explored in detail. 
 
 
None of the above models of regional care echo ideal end of life care 
however; these results open the doors to a range of quality developments. 
The impact of national initiatives, adopted at differential levels of 
healthcare, such as ‘Electronic Palliative Care Co-ordination Systems’ 
(EPaCCS), use of ‘Marie Curie Nursing Service’ (MCNS), ‘Advance care 
planning model’, ‘AMBER care bundle’, ‘Rapid Discharge Home to Die 





aforementioned care initiatives may have partially impacted on the 
quality of end of life care in certain regions, and thus regional variations 
of such care may have been exaggerated somewhat in their context. 
 
 
The main strength of this analytical work is the magnitude of the 
population studied. The use of the linked-database provides new 
prospects for future in depth analysis of specific outcomes and 
benchmarking performance. Appropriate risk case-mix adjustment allows 
comparison of outcomes and populations thus allowing appropriate 
allocation of resources and service planning. However, data analysis is 
not without its limitations. Although the variability in hospital deaths 
discriminates between patients in various regions and appears to be the 
most accurate quality indicator of regional variations in end of life care 
there may be other factors not considered in this study that contribute to 
regional variations in care. For example, the density of community 
palliative care services, communication between tertiary care teams and 
community palliative care, physician expertise and engagement in 
managing end of life care. Patient preferences may also vary. These 







The routine linked database allows for assessment of the variation in the 





Statistically significant and clinically important variations exist amongst 
SHA’s with respect to the proportion of patients who die in hospital, 
emergency hospitalisations, electively or emergency interventions and 
emergency length of stay in the last month of life. Further investigation 
into the reasons for these variations needs to occur in order to provide 

























7 Chapter 7: Annual trends and impact of hospital-based 
interventions on place of death in the last month of life for 




The last days and weeks of existence are precious to both patients and 
their families. Many patients will suffer unpleasant symptoms as a result 
of advanced disseminated disease that may require symptom control. This 
may be due to their pelvic location and pattern of spread. As a result, 
most patients with advanced, recurrent gynaecological cancer will often 
have several palliative options offered to them, including chemotherapy, 
radiotherapy and surgery for treatment of their symptoms (19). However, 
best supportive care, hospital or hospice based palliative care must be 
considered as a suitable option when at the end of life (6). In order to 
share decision-making about treatment options with the patient, the 
clinician needs to review the extent of disease, treatments already 
received, assess interval from last treatment, current performance status 
and patient preferences with frank conversations regarding ‘futility’ of 
further treatment, included, if necessary. An intended treatment may 
prove futile when it is unlikely to improve survival, such as 
chemotherapy. (6). It is recognised that patients will often choose 
aggressive therapies over comfort-inducing interventions due to an 
overestimation of response and prognosis (206). The most advantageous 
setting for discussions is likely to be with involvement of multi-
disciplinary teams including physicians and palliative care teams. At this 
stage it is also important to elucidate patients’ views about where they 





treatment options mean in terms of preferred place of care and place of 
death. In addition, if the timing of conversations around end of life care 
occur too late then patients more likely to be exposed to aggressive and 
futile therapies (207).  
 
 
Currently, there is a dearth of literature on the comprehensive analysis of 
specific interventions undergone by cancer patients prior to death (156). 
Fauci et al reviewed the interventions received by 268 gynaecology 
oncology patients in the six months prior to death and concluded that 
57% had received treatment in the form of chemotherapy or radiotherapy, 
and many had been referred to a hospice less than a month before death 
(156). Second and third line palliative chemotherapy has been known to 
result in low response rates (207). Thus, establishing the quality of care 
received by each individual at the end of life remains a nebulous concept, 
especially in a background of multiple treatments being offered to 
patients, associated with prolonged stays in hospital. Inappropriate 
interventions may negate any benefits with an overall deleterious effect 
on the quality of life at the end of life and therefore prospective studies 
are required to asses the impact of various interventions and qualitative 
studies to assess the psyche of the treating physician and patient, to allow 




Multiple interventions in the last month of life resulting in prolonged 
hospital stays have been regarded as ‘negative indicators’ of the quality 





last month of life, is one such recognised intervention where a survival 
benefit was not achieved (9). In addition the above studies showed that 
patients who presented as an emergency to achieve symptom control, 
often died in hospital. Therefore better integration of heath and social 
care and improved communication between primary and secondary care 






This chapter focuses on the interventions received by gynaecological 
cancer patients in the last month of life from the first of January 2000 to 
the first of July 2012. It describes the trends over the past decade, 
describes the numbers of interventions in the last month of life and 
hospital stays associated with these interventions and attempts to uncover 
the intention behind these interventions. Most importantly, it questions 
whether some of these interventions increase the risk of death in hospital. 
An overview of the procedures that gynaecological cancer patients have 
undergone in England in the last year of life is provided and the trends of 
these interventions over the twelve and half year study period described.  
A study of annual trends of hospital-based interventions, over more than 
a decade, allows identification of those interventions that are most 
received by gynaecological cancer patients in the last year and last month 
of life. It also examines how this care was delivered, either as elective or 
emergency. This informs on those hospital-based interventions that will 
require future resource allocation and raises the argument for 







Particular emphasis is given to the study of the interventions in the last 
month of life, when it might be assumed that the dying phase has been 
recognised and all interventions performed are directed to ease death. 
This work looks more closely at those hospital-based interventions that 
have steadily increased in frequency over the study period with the aim to 
identify whether they significantly influenced death in hospital. The 




Interventions also have implications with respect to changing pattern of 
use of hospital resources. This is of significance, as it has been estimated 




 This chapter also provides insight into the quality of life of these patients 
by identification of the common types of interventions (diagnostic, 
therapeutic i.e. providing symptom relief) and therefore, infers the intent 
of all minor and major, invasive and non-invasive procedures offered to 
patients following an elective or an emergency admission.  Some 
interventions are essential to provide important symptom control such as 
drainage of ascites and pleural effusion or insertion of  bowel stents, and 
of these some can only be provided as inpatient in hospital. Whereas, 
there are other interventions, promoting symptom control, which could be 





hospital or hospice. An example of such a procedure is paracentesis for 
malignant ascites. There are other interventions, which are unlikely to 
prolong life or its quality and may be classified as ‘futile’ such as the 
administration of chemotherapy.  
 
7.2 Materials and Methods 
 
 
7.2.1 Study population 
 
The linked database contained all the extracted results of all women who 
died of gynaecological cancer from 1st January 2000 to 1st of July 2012 
who were resident in England. Information on age, postcode, and number 
of hospital visits, type of admission, length of stay in hospital in the last 
month of life, place of death and interventions received in the last year of 
life were extracted (as described in chapter 3, page 112). 
 
 
The impact of interventions in the last month of life on place of death 
(multivariable analysis) was restricted to all deaths beyond 2007 in the 
last month of life, as the recording of all procedures as per the OPCS 4.5 
codes, especially with respect to imaging procedures was found to be 
relatively more accurate and complete. This included a subset of 17,723 
patients with gynaecological cancer over a five and a half year period i.e. 
till July 2012.  
 






The first step of the extraction was to review all the clinical interventions 
undergone by gynaecological cancer patients in the last year of life by 
familiarisation with the OPCS 4.5codes. 
 
The OPCS-4 stands for the Office of Population and Surveys 
Classification of Surgical Operations and Procedures (4th revision). This 
is in essence the recording of all procedures performed following 
admitted patient care (either as inpatient or day case) in the NHS. These 
codes can be used in combination to describe a whole operation or as 
single representative code. 
Due to introduction of novel procedures and therapies, the coding is 
regularly and continuously updated to ensure that accurate accounts of all 
types of procedures is maintained and is recoded as such in the HES 
database so that hospital trusts can be reimbursed.  
 
 
 All procedures that related to the management of gynaecological 
oncology patients in the last year of life were extracted. Each procedure is 
recorded in the HES database as four character code. Several codes may 
relate to the same procedure. For example, drainage of ascites may have 
several codes relating to the words ‘paracentesis’, ‘drainage of ascites’ 
‘other specified drainage of peritoneal cavity’ or ‘other unspecified 
drainage of peritoneal cavity’. The choice of code used is probably 
dependant on the coders who performed the clinical coding at the time in 
various trusts. 138 different codes were extracted for the number of 
primary procedures recorded for a Finished Consultant Episode (FCE). 
These codes were then grouped manually so that all chemotherapy 









The frequency of all procedures was ranked after grouping and with the 
application of clinical insight, the first 22 procedures were found to be 
relevant to gynaecological cancer patients in the last year of life. A 
number of unrelated procedures were recorded during an admission spell 
in very minor single numbers or numbers less than 10, such as a ‘skin 
biopsy’ or a ‘disarticulation of tarsal bone’ or ‘surgical removal of a 
retained tooth’ and such procedures were excluded from the analysis. 
These other procedures that were excluded for further analysis were 
based on the fact that they were too small a number (less than 10) for a 
study of trends. They were also excluded if considered not to contribute 
to quality of care or impact on place of death, or where the intent was not 
directly relevant to the end of life care of an individual and where 
decision-making would need to be explored on an individual basis (for 
example bloods for haematology or biochemistry). The first twenty-two 
grouped OPCS codes accounted for (205,386/ 259,982) 79% of all the 
procedures performed in the last year of life. The numbers of these 
twenty-two relevant procedures were then extracted for last six months, 
last three months and last month of life.  
 
 
Data on these top 22 procedures performed on gynaecological cancer 
patients in the last month of life were extracted including type of 
admission and length of stay for the study period. We distinguished 





cycle of chemotherapy at that interval prior to death and those that 
continued with chemotherapy. Similar clarity was defined for the last 6 
months, 3 months and last month of life. Data for all the other procedures 
were similarly extracted (exclusive) over the study period for the last 3 
months (included only month 2 & 3), 6 months (included months 4, 5 and 
6) and last year of life (included months 7-12). The reasons for this 
method of extraction was to provide the reader a clear insight of the 
trends of the interventions over the last year of life by presenting the data 
in an exclusive manner where thought pertinent. This gives the reader a 
clear snap shot of routes of presentation in the last year of life and 
indicates how this varies as death approaches  (highlighted in Figure 7.1).  
This division of the last year of life into time frames based on the patterns 
of admission shown in Figure 7.1 allows one to speculate that all 
emergency admissions in the last month of life were more likely to be 
secondary to advance disease presentation with little contribution from 
symptoms from other co-existing co-morbidities. We calculated the 
number of procedures per elective or emergency admission whilst day 
















Descriptive statistics were used to detail the data on admissions and 
interventions performed. To assess the trends of the procedures 
performed in the last month of life over the study period, univariate 
analysis was performed. Multivariable analysis was performed to identify 
those interventions that significantly predicted death in hospital when 
performed in the last month of life, having adjusted for age, year of death, 







In this study a novel use of the linked database is described. Aspects of 
quality of care at the end of life are investigated by examination of 
aggregated episodes of care in hospital to assess how they may impact on 
the quality of end of care of gynaecological cancer patients in the last 
year and month of life. This section of the results describes the most 
commonly performed procedures in the last year and month of life, 
examines the trends of these interventions and links these procedures to 
the mode of presentation as either emergency or elective. In addition this 
aspect of the work focuses on those interventions with significantly 
increasing trends in the last month of life and describes those 
interventions that predict death in hospital when socio-demographic 
factors are adjusted for. These results provide a snapshot of the disease 
trajectory in the last year of life and address the quality of life of 





via emergency pathways and the associated length of stay in hospital in 
the last month of life. 
 
7.3.1 Emergency admissions  
 
This section reports on the variation in the ratio of emergency to elective 
admissions for the specific sections of time (as described in the methods 
section of this chapter) over the last year of life. Examination of the ‘type 
of admission’ and their trends in the last year of life is reflective of the 
behavior of advanced disease. It may also reflect levels of community-
based provision and anticipatory care packages. 
 
 
In the last year of life over a twelve and a half period, there were 429,466 
admissions for gynaecological cancer patients. Of these 154,741 were 
emergency admissions and 274,725 were elective admissions. The overall 
ratio in the last year of life was 0.6 emergency admissions to elective. 
Table 7.2 describes how this ratio changed over the year. In the first 6 
months of the last year of life (months 7-12 before death) the ratio was 
0.3, which changed to 1.0 in months 2 and 3 prior to death. The reader is 
reminded that the numbers of admissions are exclusive to each time 
interval. Figure 7.1 shows how this ratio reverses at approximately 6 
months prior to death with a steep upward incline in the number of 
emergency admissions seen to begin about 9 months prior to death. 
 
 
Table 7.2: Shows the absolute number of admissions (elective and emergency) of 





month 4, 5 and 6 and then months 7-12 before death to reflect the proportion of 




Figure 7.1 shows the absolute number of elective and emergency admissions in 
the last year of life prior to death and plots their trends. The numbers of 
emergency admissions start rising 9 months prior to death with the highest 






Over the last month of life, the ratio of emergency admissions is 2.5 times 
elective admissions. The emergency admission route appears to be the 





than twice the number of emergency admissions compared to elective 
admissions in the last year of life. The ratio of emergency to elective 






This section describes the interventions received by gynaecological 
cancer patients over the last year of life for the twelve and a half year 
study period. 
 
In the last year of life, 93% (66,241/71,269) of gynaecological cancer 
patients had at least one procedure clearly related to the management of 
their symptoms, diagnosis or recurrence. A total of 205,386 procedures 
were performed during 429,466 admissions. On average a gynaecological 
cancer patient had 3 procedures in the last year of life and every other 
admission involved at least one intervention. 
 
 
During months 7-12 prior to death, 66,241 patients underwent 70,805 
procedures following either an elective or emergency admission. On 
average each patient had one procedure (1.1) and was admitted twice to 
hospital. A total of 134,201 elective admissions and 37,225 emergency 
admissions occurred over this time frame. Following an emergency 
admission the odds of an intervention was 0.5 (19,330/ 37,225) whereas 
following an elective admission into hospital the odds of an intervention 







During months 4, 5 and 6 prior to death, 51,258 patients had 44,835 
procedures during 32,554 emergency and 77,093 elective admissions. On 
average a patient had two admissions into hospital (109, 647/ 51,258). 
Following an emergency admission the odds of an intervention remained 
unchanged as during months 7-12 prior to death i.e 0.5 (17,547/ 32,554) 




During months 2 and 3 prior to death, 55,544 patients underwent 58,588 
procedures. On average each patient was exposed to at least one 
intervention. There were a total of 93,615 admissions to hospital with on 
average a patient attending hospital 1.7 times. Following an emergency 
admission the odds of an emergency procedure were 0.7 (29,840/45,909) 
and 0.6 (28,748/47,706) following an elective admission. 
 
 
In the last month of life 30,847 patients underwent 31, 158 procedures. 
On average each patient had 1 procedure.  There were 54,778 admissions 
to hospital in the last month of life, with 1.8 admissions per average per 
patient (54,778/ 30,847). Following an emergency admission the odds of 
an intervention were 0.7 and following an elective admission the odds 
were 0.5. 
 
Chemotherapy, imaging and drainage of ascites were identified as 





Chemotherapy was the most common and continued to be performed 
procedure in the last year of life with a majority (87%) of patients 
continuing to accept chemotherapy (Table 7.3).  In addition one in five 
patients commenced a new cycle of chemotherapy with under a year to 
live. Six months prior to death, 62% continued with chemotherapy. At 
three months prior to the end of life, about 1 in 3 patients still continued 
with chemotherapy and another 6% commenced their first cycle, with 
11% of patients continuing with chemotherapy in the last month of life. 
Chemotherapy was at least five times more likely to be administered 
electively in the last three months of life and was four times as likely, in 
the last month of life (table 7.3 and 7.4). 
 
 
In the last year of life, 1 in 10 patients continued with, and a similar 
number had a new central venous catheter (CVC line) line inserted for 
administration of chemotherapeutic agents. The CVC line insertion was 
1.4 times more likely to be inserted as an emergency rather than 
following an elective admission during the last three months of life, 
whereas in months preceding this time frame the proportion of elective 
procedures were higher (Tables 7.5 and & 7.6). 
 
 
Blood transfusions continued in the last year of life with 41% of 
gynaecological cancer patients requiring the same presumably as a result 
of chemotherapy, bleeding or symptoms of anaemia. 30% of patients 
received a blood transfusion in the last six months of life were at least 
four times more likely to present as an emergency (Table 7.5), 





with chemotherapy. 11% of patients had blood transfused in the last 
month of life. 
 
 
Table 7.3 shows the cumulative proportion of patients who had a specific 




Notes: LMOL: last month of life; L3MOL: last 3 months of life; L6MOL: 
last 6months of life; LYOL: last year of life 
 
Diagnostic or investigative tests continued to be performed in large 





modality of imaging i.e. either an ultrasound, X-ray, CT Scan or MRI. In 
the last six months of life imaging was the second most frequent 
intervention (55%) to administration of chemotherapy. In the last three 
months of life imaging was the most frequently performed intervention 
(43%). One in four patients (24%) underwent assessment of their disease 
status via an imaging modality in the last month of life and it remained 
the most common intervention. Throughout the last year of life imaging 
was more likely to be performed following an emergency admission 
rather than an elective admission. Imaging was 4-5 times more likely to 
be performed as an emergency than electively in the last three months of 
life (Table 7.3 and 7.4). It is likely that image guided procedures 
performed on day assessment units were not rigorously recorded for all 
hospitals over the study period and therefore one can speculate that these 
figures are likely to be an underestimate.  
 
 
Imaging will have identified patients with ascites or pleural effusion. 
Ascites drainage was the most common procedure performed for 
symptom control. 56% of patients had their ascites drained in the last year 
of life and 48% in the last six months of life. 1 in 3 patients attended 
hospital over the last three months of life for relief of their symptoms 
secondary to ascites. These patients were twice more likely to present as 
an emergency for relief of their symptoms in the last three months of life 
and three times as often in the last month of life (Table 7.3). Drainage of 
pleural effusions continued to be undertaken in the last year of life with 1 
out of 7 patients requiring drainage in the last year of life and about 1 in 
20 patients in the last month of life. The emergency route throughout the 





fact the highest ratio of attendance as an emergency when compared to an 
elective admission was for drainage of pleural effusion. This was 
recorded as 8.9 during the time frame for 4-6 months prior to death 
(Table 7.3, 7.4 and 7.5). This study found that patients who required 
drainage of ascites or pleural effusion were more likely to present as an 
emergency. From clinical experience it is not often that patients can not 
be admitted under various other teams in the hospital, for example care of 
the elderly, acute respiratory medicine, cardiac care or accident and 
emergency, possibly without an accurately recorded diagnosis. Some 
patients will be well known to radiology and will have multiple drainages 
under their care whereas, some patients will be managed as outpatient 
when the recording of such procedures following a brief visit on the ward 
is probably variable and under recorded. 
 
 
It is likely that ureteric obstruction will have been confirmed or identified 
with imaging. 18% of patients, in the last year of life, had relief of urinary 
obstruction by insertion of a ureteric stent for presumed planned 
chemotherapy or to prolong life by alleviating renal failure. 1 in 10 
patients underwent a urological intervention during the last three months 
of life. The Absolute numbers of procedures and the proportion of 
patients undergoing an intervention are shown in tables 7.3, 7.4, 7.5 and 
7.6 exclusive to each specified period at the end of life. 
 
 
A small number of patients were exposed to surgical interventions in the 
last year of life. Salpingo-ophorectomy was performed in about 1 in 8 





6% an omental biopsy in the last year of life, for either treatment of 
symptoms such as heavy bleeding secondary to endometrial cancer or 
with diagnostic intent. Most procedures were performed electively apart 
from the last month of life when the majority of major surgery i.e 
hysterectomy and laparotomy was performed as an emergency. 
Defunctioning of large and small bowel was undertaken in 1 of every 10 
patients in the last year of life, and was noted more likely to be a response 
to an emergency presentation of acute bowel obstruction. In the last year 
of life 5% of patients were noted to have had a cervical biopsy, an almost 
equal proportion an examination under anesthetic (EUA) and 3% a 
vaginal biopsy evidently for either a new disease diagnosis or diagnosis 
of relapsed disease. 8% of patients had a sigmoidoscopy in the last year 
of life for presumed PR bleeding (Table 7.7). 
Pelvic exenteration or pelvic clearance is a major surgical procedure with 
a high morbidity and mortality rate and usually only undertaken and 
offered to a very few patients, when it is thought to provide a survival 
benefit of at least a year. 0.5% of patients underwent this procedure in the 
last year of life. 
 
 
Procedures such as orthopaedic, neurological, unspecified taking of blood 
samples for biochemistry and or haematology accounted for 15% of the 
additional different types of procedures. 6% of missing data (no specific 
or incorrect OPCs codes recorded) were excluded from analysis. A 
variety of procedures relating to ‘intent’ can be identified by the reader as 
either diagnostic, aimed at treatment or for the purpose of palliation of 





procedures for gynaecological cancer patients and the proportion of all 
procedures performed for the study period in the last month of life. 
 
 
Table 7.3 shows the absolute number of procedures in the last month of life as an 











Table 7.4 shows the absolute number of procedures in months 2 & 3 prior to 



















Table 7.5 shows the absolute number procedures in months 4 to 6 prior to death 

















Table 7.6 shows the absolute number of procedures in months 7 to 12 prior to 















7.3.3 Trends of the Interventions and admissions 
 
 
This results section describes the trends of the proportion of procedures 
undergone by gynaecological cancer patients in the last month of life over 
the 12 and a half year study period. Identification of key trends related to 
the most commonly performed procedures in hospital in last month of life 
were undertaken. This will help inform providers, commissioners and 
policy makers about changes in patterns of the quality of life of 
gynaecological cancer patients in the last month of life. The trends of 
these procedures performed also inform on the need for future service 
provision and allows for reflection of any key national policies that may 
have been implemented over the study period. Trends are described for 
both elective and emergency interventions in Table 7.8 - 7.16.  
 
 
The significance of key trends was further confirmed by performing a 













Table 7.8 Annual Trends of the proportion of emergency procedures performed 
in the last month of life following admitted care in the last month of life from 1st 





















Table 7.9 Annual Trends of the proportion of emergency procedures performed 










Table 7.10 Annual Trends of the proportion of emergency procedures performed 
in the last month of life following admitted care from 2000 to July 1st 2012 
 
 
Table 7.11 Annual Trends of the proportion of emergency procedures performed 








Table 7.12 Annual Trends of the proportion of elective procedures performed in 
























Table 7.13: Annual Trends of the proportion of elective procedures performed in 








Table 7.14: Annual Trends of the proportion of elective procedures performed in 
the last month of life following admitted care from 2000 to July 1st 2012 
 
 
Table 7.15: Annual Trends of the proportion of elective procedures performed in 







 Over the study period of twelve and a half years it was noted that the 
administration of elective chemotherapy in the last month of life had 
shown to have significantly increased (Tables 7.12 and 7.17). In the last 
month of life 6.2% of patients received chemotherapy in the year 2000 
and this increased to 8.8% in 2008. The End of Life Care Strategy was 
launched in 2008. The proportion of patients who received elective 
chemotherapy dropped to 7.6% in 2009, but gradually increased to 8.6% 
in the first half of 2012 (OR = 1.04; CI 1.02-1.05; p < 0.0001).  
 
 
A parallel increase was seen for those who began their first treatment 
with chemotherapy in their last month of life. In 2008, 0.8% had their 
first cycle of chemotherapy in the last month of life, which gradually rose 
to 2.5% in 2012 (Table 7.12). Whilst this increase was found not to be of 
statistical significance, a shift in clinical practice appears to have taken 
place in clinical oncology and careful future monitoring and audit of 
these numbers should occur with the aim of administration clearly stated. 
The ‘first cycle of chemotherapy’ (X72.3) does not appear to have been 
coded for the years prior to 2008.  On further devolving into the online 
archives of OPCS codes it was found that, no codes existed for 
administration of the first cycle of chemotherapy in OPCS 4.2, adopted 
for coding till March 2006. X72.3 was assigned to this intervention in 
2006 (April 1st); however, this code does appear to have been used till 
OPCS 4.4 was introduced in March 2008. Related to the administration of 
chemotherapy, of note was the six-fold increase in central venous line 
(CVC) insertions from 0.1% in 2000 to 0.6% in 2012 (Table 7.12) 
presumably to continue with future chemotherapy administration (OR = 





The administration of emergency chemotherapy has significantly reduced 
from 2.1% in the year 2000 to 0.9% in the first half of 2012 (Table 7.8). 
This is a significant decrease over the study time period (OR = 0.97; CI 
0.94-0.99; p < 0.01).  
 
Table 7.16: Trends of interventions performed in the last month of life with 
significant (p<0.05) increase in numbers over study period 
 
 
The practice of imaging in the last month of life has significantly 
increased (table 7.11 and 7.15). In 2000, 0.8% of patients were coded as 
electively being imaged in the last month of life compared to 5.1% in the 
beginning of 2012. Imaging was more likely to be performed as an 
emergency intervention with 1.4% imaged in the year 2000, followed by 
a steep incline to 37.4% imaged in 2012 (Table 7.8). Beyond 2007, when 
the coding was deemed to be more accurate, it was found on univariate 
analysis that, each year an additional 16% of patients had emergency 
imaging in the last month of life and another 7% as an elective. This was 
a significant increase (elective; p = 0.001 and emergency imaging; p < 
0.0001, Table 6.17). It appears that imaging has been increasingly used 
not only to assess symptoms of metastatic disease, but also for the 





The need for drainage of ascites (7.8 and 7.12) has also significantly 
increased in the last month of life and patients presented following either 
an elective (elective drainage: OR = 1.03, CI 1.02-1.05, p < 0.001) or an 
emergency admission (OR = 1.04, CI 1.03-1.05; p < 0.0001). 10% 
presented for planned drainage of ascites and another 4% for emergency 
drainage respectively in 2000. In 2011, 14% presented for planned and 
another 5% for emergency drainage of their ascites. Significant trends 
were also noted for patients who needed emergency drainage of their 
pleural effusion from 3% in 2000 to 5% in 2011 (OR = 1.05, CI 1.04-
1.07; p < 0.0001). Emergency urological procedures have increased 
significantly in the last month of life. Some of these patients may belong 
to the group of patients yet without a diagnosis presenting with advanced 
disease in the last month of life. 
 
 
The number of patients admitted for blood transfusion both as an elective 
and as an emergency in the last month of life has significantly reduced 
over the study period (Table 7.17; Emergency blood transfusion OR = 
0.83, CI 0.81-0.84; p < 0.0001 and elective blood transfusion OR = 0.97, 
CI 0.95-0.99; p < 0.0001). Trends of major surgical interventions such as 
elective or emergency laparotomy and elective hysterectomy have 
significantly reduced over the study period and as have some minor 
surgical procedures such as examination under anesthetic, vaginal 
biopsies and peritoneal biopsies Table 7.16. 
 
 
Table 7.19 shows those interventions where significant trends are not 





of cases that are performed for patients in the last month of life. Most of 
these procedures were invasive procedures such as emergency 
hysterectomy, pelvic clearance, elective omental biopsy, elective 
urological procedures, cervical biopsy, CVC catheter maintenance and 
peritoneal biopsy to describe a few. 
 
 
Table 7.17: Trends of the interventions performed in the last month of life that 
























This section describes the proportion of the total emergency and elective 
admissions for each specific procedure performed in hospital, over the 
last year of life and for each exclusive time frame (tables 7.19a and b). 
These tables provide an over view of the pattern of bed usage in the last 
year of life.  For months 7-12 prior to death, 41.8% of all admissions 





accounted for 52% of all elective admissions. During Months 4, 5 and 6, 
(prior to death) chemotherapy accounted for 36% of all admissions, and 
49% of these were elective admissions. Months 2 and 3 accounted for 
21% of all admissions and 37.5% of which were elective. During the last 
month of life 8.3% of all admissions recorded administration of 
chemotherapeutic drugs. During the last month of life, 24% of all elective 
admissions were for continuing chemotherapy and another 5% of elective 
admissions were for a first cycle of chemotherapy. In addition 9% of 
admissions during months 7 - 12, 8% during months 4 -6, 7% during 
months 2 and 3, and 5% of elective admissions during the last month of 
life accounted for a new cycle start of chemotherapy. 
 
 
70% of radiological investigations executed in the last year of life 
followed an emergency admission and imaging accounted for 40% of the 
total number of admissions in the last year of life. During the last month 
of life the highest number of admissions included imaging. 17% of 
admissions were emergency and 7.6% elective, together accounting for 
14.3% of admissions in the last month of life. The proportion of patients 
requiring drainage of ascites as an impatient increases as one approaches 
the last month of life from 4.4% to 12.5% of all admissions. During the 
last month of life, 1 out of 8 admissions were for patients requiring 
drainage of ascites. 13% of all emergency admissions and 11% of all 
elective admissions accounted for patients needing drainage of their 
ascites in the last month of life.  Over the last year of life for, 15% of 
emergency admissions and 10% of elective admissions were for 
management of urinary tract obstruction. About 8 % of emergency 





required for surgical relief of bowel obstruction i.e. defunctioning 
ileostomy or colostomy.  
 
 
7.3.5 Trends of admissions 
 
One method of planning future hospital service provision is by analysis of 
the trends of admissions and the interventions undergone by patients. 
This analysis aims to predict future usage of hospital services. 
 
 
In the last month of life it was observed that 19% of elective admissions 
in the year 2000 were for the administration of chemotherapy and this 
gradually increased to 32.6% for the first half of 2012. The reverse was 
observed for emergency admissions where chemotherapy was 
administered with 2.4% of admissions noted for the year 2000 and 
dropped to 0.9% in the first half of 2012. A significant rise in the number 
of elective admissions were noted for the first cycle of chemotherapy in 
the last month of life, from the year 2006 onwards with 2% of admissions 
had increased to 11% in 2011.  
 
 
2.1% of elective admissions in the last month of life in the year 2000 had 
some form of imaging. This increased to 15.5% of admissions in the last 
month of life for the year 2011 when the patient underwent a modality of 
imaging. Imaging was more often performed following an emergency 





associated with the use of an imaging procedure in the year 2000 
increasing to 37.4% by 2012.  
 
 
Ascites once symptomatic requires drainage. In the year 2000, about one 
in four elective admissions in the last month of life were for ascites 
drainage. This was found to have increased to more than one in three 
being admitted for the same in 2012. Gradual increases in the number of 
emergency admissions were also noted for patients who required 




Admissions for emergency urological interventions were noted to have 
increased from 3.6% in 2000 to 4.2% in 2012. Emergency admissions for 
drainage of pleural effusion were also found to have increased in the last 
year of life from 3.6% in the year 2000 to 4.7% in 2011. Emergency 
admissions for blood transfusion had significantly dropped from 9.1% in 
the year 2000 to 1.3% in 2012. 
 
 
Emergency admissions for major surgical interventions were found to 
have declined over the study period in the last month of life, such as 
emergency laparotomy from 1.3 to 0.3 % and hysterectomy from 0.5 to 
0.3%. In addition, elective admissions were noted to have declined with 
2.3% of elective admissions recording a hysterectomy in the year 2000 
and admission rates for an elective laparotomy fell from 1.2% to 0.4%. 





from 0.7% to 1.3% over the study period in the last month of life whereas 


































Tables 7.19 a: Shows the proportion of admissions (elective / emergency and of 
the total) for each exclusive period of the last year of life utilised for an 

















Table 7.19b Shows the proportion of admissions (elective / emergency and of the 
total) for each exclusive period of the last year of life utilised for an intervention 















Multivariable logistic regression analysis was performed (as originally 
explained in chapter 3 and 5) to assess whether the place of death of 
gynaecological oncology patients undergoing a disease related 
interventions in the last month of life, in hospital, was significantly 
impacted on by such an event. Those interventions that had significantly 
increased in number over the study period in the last month of life were 
included in the analyses. The dependent variable was death in hospital. 
To assess this outcome the model was adjusted for age, socio-economic 
status, year of death, type of gynecological cancer, number of elective 
and emergency admissions and length of stay following an admission. It 
was found that elective administration of chemotherapy in the last month 
of life, significantly increased the risk of dying in hospital by a factor of 
1.8  (CI 1.55-2.09; p < 0.001) and that emergency CVC line insertion 
increased the odds of dying in hospital by 3.6 times (CI 2.58-4.88; p < 
0.001).  Also, the odds of dying in hospital were impacted by a factor of 
1.38 (CI 1.16 - 1.63; p < 0.001) when elective imaging was performed 
and by a factor of 1.32 (CI 1.11 – 1.58; p < 0.001) when followed by 
emergency urological procedures. In contrast, emergency drainage of 
ascites significantly decreased the risk of death in hospital (OR = 0.82; CI 
0.74 - 0.9; p < 0.001). It was found that emergency admissions were 
significantly associated with an increased risk of death in hospital 
including their increase in frequency and length of stay (frequency OR 
1.59, CI 1.49 – 1.7; p < 0.001 and length of emergency stay OR  1.24, CI 





dying in hospital (OR = 1.21, CI 1.16-1.63) escalated, however the 
number of elective admissions did not escalate the risk of death in 
hospital but actually decreased it significantly (OR 0.88, CI 0.82 – 0.95; p 
< 0.001). As identified in the model on place of death when adjusted for 
socio-demographic variations (Chapter 5) increasing age significantly 
increased the risk of death in hospital, as did increasing socio-economic 
deprivation and significant geographical variations in hospital deaths 
were noted based on the postcode at the time of death. When compared to 
ovarian cancer, patients with cervical cancer (OR = 1.19, CI 1.07-1.32; p 
< 0.001), endometrial cancer (OR = 1.11, CI 1.03 – 1.2; p = 0.01) and 
placental site trophoblastic disease (OR = 1.91, CI 0.29- 12.6; p = 0.05) 
when admitted for an intervention in the last month of life were more 
likely to die in hospital. Patients with vaginal cancer were significantly 
less likely to die in hospital (OR 0.7, CI 0.51- 0.95) and although patients 





















Table 7.20 Adjusted odds ratios following multivariable logistic regression 
analysis to assess the impact of socio-demographic factors and interventions on 












The results from this study confirm that the linked HES-ONS database 
can be used to identify hospital-based interventions in the last year and 
last months of life undertaken by gynaecological cancer patients. This 
information provides insight into the type of care patients receive and 
need at the end of life, factors that influence death in hospital and 
examines interventions, which may impinge on quality of life at the end 
of life. The study of the trends of the interventions performed and the 
pathways via which patients attend hospital to access these services, 
primarily to obtain symptom relief, has provided insight into those 
interventions that have impacted on death in hospital in the context of 
existing socio-demographic factors. This use of person-linked health data 
permits public health researchers and policy makers to assess the effects 
of the individual patient, the disease and the health system on various 
aspects of the disease trajectory to inform on current health care 
outcomes, allowing thought for future service and resource provision. 
The linked data should also not only allow for generalisation of some of 
the results but should also encourage the study of other specific cancer 
sites to detect differences in disease behavior at the end of life (165). 
 This study found that chemotherapy, imaging and drainage of ascites 
were the three most common interventions performed at the end of life 
for gynaecological cancer patients in England. The interventions received 
by patients were either aimed at treatment, diagnosis and or prognosis 
and palliation of symptoms. The emergency admission route remains the 
most common referral route by which patients access these interventions 





increasing the possibility of death occurring in hospital. Elective 
admissions per se significantly decreased the risk of dying in hospital. It 
therefore follows that the elective route should be the preferred route in to 
hospital, if such an inpatient stay would benefit the individual, reducing 
the likelihood of prolonged stays and unplanned interventions. In chapter 
5 we hypothesized that if 50% of emergency admissions could be avoided 
then 16% less patients would die in hospital. One could suggest further 
from the above results that the conversion of emergency admissions to 
elective admissions by improving communication between primary and 
secondary care, patient and carer education with regards to achieving 
symptom control or assessment of disease in a planned manner, direct 
access to oncology wards via help lines or CNS input and services such 
as hospice at home and home palliative care may all impact on eventual 
place of death. (https://www.nao.org.uk/wp-
content/uploads/2008/11/07081043.pdf) A future analysis would be 
required to assess the impact of each intervention. 
 
 
Gynaecological cancer patients in the last month of life are 2.5 times 
more likely to present as an unplanned admission. The high proportion of 
emergency admissions is seen to rise in the last 6 months prior to death 
and is probably secondary to the need for symptom control as a result of 
disease progression. So, discussions on the aims of the future 
management of the individual should be performed with multi-
disciplinary input at each step of the cancer trajectory and with renewed 
interest at the end of life i.e. an integrated care approach (208). This is 
particularly important following an emergency admission. It is essential 





prescription; especially if the oncologist is confident that the survival 
advantage will be insignificant and may be associated with the risk of life 
threatening side effects (e.g. neutropenia) then the treatment is unlikely to 
improve the quality of life (6). These discussions prevent inappropriate 
interventions and prolonged lengths of stay. However, prognostication is 
simpler in retrospect and gynaecological cancers comprise a group of 
heterogeneous tumors where often the distinction from cure to palliation 
is unclear.  
 
 
From the work on ‘Routes to Diagnosis’ it has been shown that 
approximately one quarter of patients present via the emergency route 
with a new delayed diagnosis of cancer. This subset has especially been 
found to have poor outcomes and is probably at the end of life (209). It is 
known that approximately 25% of ovarian cancer patients present as an 
emergency (209). Emergency presentation is associated with poor 
survival outcomes with 27% expected to survive less than a month and 
48% less than six months. Thus some gynaecological cancer patients will 
not have a year of relative survival. For such patients involving palliative 
care physicians early in their management is important and should be a 
future focus of discussion. It must also be remembered that the later half 
of the disease trajectory in patients with ovarian cancer does not differ 
from those who have a shorter aggressive disease course following 
diagnosis when compared to those who have had a longer journey with 







There have been recent attempts in various regions of the country to set 
up 24-hour emergency oncology helplines providing telephonic advice 
and direct access into oncology wards (210). By providing this this 
service the authors found that the proportion of emergency department 
visits reduced and 30% of patients were less inclined to die in hospital 
when this service was accessed over a 6-month period by 3594 patients at 
the end of life.  
 
 
Byock, Twohig, Merriman et al reported on a certain acceptability of de-
institutionalization of care at the end of life with the placement of 
advanced care planning, on a background of individual and 
environmental factors, which may determine where patients wished to be 
cared for or, to die (211). Where excellent care in the community is 
evidenced, multiple admissions with short hospital stays may still occur, 
especially if symptom control measures are set up better in a specialist 
environment, converse to the original aim of initiating, supporting and 
maintaining end of life care in the community. The level of palliative care 
available in the community, the density of affordable care homes or NHS 
hospice care remains unmeasured in England at present and therefore, 




The top three interventions identified as being performed in the last year 
of life and responsible for admission into hospital are chemotherapy, 
imaging and drainage of ascites. Chemotherapy is regarded as a marker 





refer to a new cycle of chemotherapy administration in that last month of 
life or chemotherapy continued to the last 2 weeks of life and 
inappropriate admissions, either to the emergency department or intensive 
care (9).  
 
 
In our study, which spanned over 12 years, 62% of women continued 
with chemotherapy in the last 6 months of life accounting for 54% of 
admissions into hospital, compared to an American study of 268 patients 
where 57.8% of women with ovarian cancer had chemotherapy in the last 
six months of life (156). In another study, including 2040 gynaecological 
cancer patients, 4% had chemotherapy in the last two weeks of life (155). 
In this analysis, 11% of patients had chemotherapy in the last month of 
life and 2% commenced their first cycle of chemotherapy in the last 
month of life accounting for 5% of elective admissions. The trend of 
chemotherapy administration has increased significantly with the 
possibility of 4% of additional patients each year being prescribed a cycle 
of chemotherapy in the last month of life. This may have resulted from 
the more recent availability of a vast number of chemotherapeutic agents, 
including possible participation in research trials, as described in chapter 
2, individual patient reports of success from chemotherapy, request for 
treatment from the patient and family members and the reluctance of the 
oncologist to discuss the end of life (20). This may suggest that clear 
decisions regarding prognosis have not been made and communicated 
clearly to the patient or family and that possibly the pros and cons of 







It has been shown that aggressiveness of cancer care in the last months of 
life does not translate into a survival benefit, as most chemotherapies 
cause toxic side effects and thus the quality of life following 
chemotherapy may be deeply compromised (7). In addition the increased 
use of CVC lines, to support chemotherapy or parenteral nutrition at the 
end of life can be associated with its own complications (212). Infact, a 
randomised of trial of metastatic lung cancer patients showed an 
improved quality of life at the end of life in those patients whom had 
been introduced to palliative care input early in their disease trajectory 
compared to those who had standard oncological care. In addition this 
group was less likely to be exposed to aggressive interventions and had a 
longer survival than those who received chemotherapy (213).  
 
 
In our study, imaging was the commonest intervention practiced in the 
last year of life in hospital, with significant rise in trends noted beyond 
the year 2007. Every year, from 2007 to 2012, an additional 16% of 
patients with gynaecological cancer underwent an imaging modality i.e. 
ultrasound, CT or MRI scan. It is not possible however to confirm the 
individual aim for each investigation and it is possible that some scan 
performed on the ward were not included in the coding. However, The 
results suggest that imaging is increasingly used to support decision 
making by establishing stage and extent of disease including involvement 
of organs. The imaging outcome appears to influence a clinician’s 
decision on operability and feasibility of symptom control. For example 
whether it is appropriate to consider a defunctioning stoma for relief of 
malignant bowel obstruction, insertion of a stent or consideration of a 





radiology, particularly CT scans play a role in the recognition of patients 
palliative needs and possibly prevents futile interventions. This is 
evidenced by our results, which confirm decreasing cases of operative 
intervention, reducing significantly between 2007 and 2012.  
 
 
These results highlight important implications for NHS resource use and 
have significant financial implications. Patients and physicians appear to 
have a requirement of visual evidence of worsening disease prior to 
withdrawing active treatment. A study of 268 patients in the last 6 months 
of life showed that of the 189 referred to a hospice only 3.2% had a 
procedure or chemotherapy compared to 58.6% of patients who were 
admitted to hospital (156).  In another study, the end of life care cost of 
84 ovarian cancer patients was calculated depending on whether they 
were cared for i.e. in a hospice or hospital for the last 60 days of life (19). 
Patients dying in hospital had significantly higher costs of end of life care 
contributed by inpatient stay, chemotherapy and radiology with no 
survival advantage.   
 
 
Paracentesis for symptomatic relief of ascites was the commonest 
intervention performed for patients with cancer of the ovary at the end of 
life (5). Our study confirmed this finding. Patients had reduced odds of 
dying in hospital when elective drainage of their ascites was undertaken 
having adjusted for socio-demographic variables. It can therefore be 
inferred from our study results that clearly defined accessible pathways 
into hospital, followed by an efficient and organised method of symptom 





availability of a portable scan machine) may prevent a subsequent 
unwanted impact on the preferred place of death. 
 
  
It was recognised that certain procedures are being decreasingly 
performed in hospital on patients in the last month of life. These are 
blood transfusions, emergency palliative chemotherapy and major 
surgical procedures such as a laparotomy or hysterectomy. This provides 
reassurance to some extent that ‘heroic’ surgical or invasive procedures 
are being avoided in preference to preservation of the quality of end of 
life care.  
 
 
When socio-demographic factors, year of death, age and cancer type and 
admission characteristics were controlled for, it was found that 
emergency imaging, emergency urological procedures, elective 
chemotherapy and emergency CVC insertion significantly increased the 
risk of dying in hospital. This suggests that a noteworthy number of 
patients with advanced disease continue to be investigated and treated in 
the last month of life. Anecdotes of such cases are all part of ones’ 
clinical experience but now statistical proof is available. Thus careful 
individual clinical case review with involvement of a multi-disciplinary 
team is essential to avoid unnecessary interventions and stays in hospital 
if a hospital death is to be avoided (10). Patients and their relatives must 
be included in all clinical decisions to ensure patient centered care is 










The ONS-HES linked database is a robust source of person-linked data 
that allows analysis of hospital-based interventions at the end of life. This 
assessment enhances our understanding of the patterns of end of life for 
patients with gynaecological cancer and allows exploration of those 
interventions that increase the risk of death in hospital. The need for 
interventions at the end of life impact on how care is accessed, services 
are structured, informs on the future need for service provision in NHS 
hospitals in England and finally, on where patients die. Better 
understanding and recognition of the end of life care stage is required to 
prevent inappropriate interventions, with special attention to those 
patients who present with advanced disease as an emergency. Integrated 
multi-disciplinary input should occur to ensure shared decision-making 
and advance care planning is forwarded into the community. 
Chemotherapy administration continues to occur late in the cancer 
journey and thus medical oncologists should work closely with palliative 
care physicians with honest discussions on prognosis with the patient and 
the family. Imaging appears to play a significant role in decision making 
with regards to the diagnosis and management of complications of 
advanced relapsed disease. Paracentesis appears to be an intervention that 
increasingly brings patients into hospital both as planned and 
occasionally following an unplanned admission, however this does not 
impact on death in hospital. With a perceived increase in future demand, 
day case service provision in NHS hospitals or specialised palliative care 
services need to be directly accessible to patients in the community via 





of end of life care are required both in hospital and in the community. 































8 Chapter 8: Ascites Drainage in patients with ovarian cancer and 





Patients report ascites as a distressing symptom of recurrent ovarian 
cancer at the end of life (215). Most patients will require drainage of their 
ascites in order to obtain relief from the resultant abdominal pain, 
discomfort and shortness of breath (5). We reported in chapter 6, 
following analyses of the linked database, significant increases in the 
number of ovarian cancer patients seeking drainage of their ascites in 
hospital over the study period, in England, via either the elective or an 
emergency route. This chapter explores whether variation in socio-
demographic characteristics explain these increases. Pathways for 
patients with ascites must be efficient in providing symptom control with 
improved patient experiences at the end of life. This chapter aims to 
provide an overview of malignant ascites, its impact on patients and 
hospitals, in particular ovarian cancer patients at the end of life and 






Malignant ascites is defined as ‘the pathological accumulation of fluid 
containing cancer cells in the abdomen’ (216). Ovarian cancer is the most 





previous chapters, the incidence of cancer of the ovary has increased with 
an aging population (http://www.cancerresearchuk.org/health-
professional/cancer-statistics/statistics-by-cancer-type/ovarian-
cancer/incidence#heading-One). In the absence of an appropriate 
screening method the detection of this cancer is often at a late stage no 
(218). Many patients present for the first time with frank abdominal 
distension secondary to massive ascites (219, 220). The pathogenesis is 
often multifactorial and related to peritoneal infiltration; lymphangitic 
carcinomatosis and lymphatic obstruction that is further enhanced by 
stimulation of VEGF and interleukin 6 and 8 (220, 221). Ascites is also a 
recurring symptom of the disease at the end of life (215). At this time of 
life, ascites secondary to cancer can be accompanied with an expected 
survival range from 1-4 months (222). About 28% of patients with cancer 
of the ovary, at the end of life, have refractory ascites, defined as ascites 
that quickly re-accumulates and requires repeated drainage, remaining a 
distressing symptom of end stage disease (5).  
 
 
The symptoms of ascites primarily relate to the degree of distension of 
the abdomen such feelings of early fullness, nausea, shortness of breath,  
swelling of the legs and reduced mobility (122, 223). Current treatment 
strategies include repeated paracentesis, placement of indwelling 
peritoneal catheters, intraperitoneal chemotherapy and most recently 
consideration of targeted therapies (224). These approaches have a 
varying but substantial impact on quality of life, hospital resources, and 
issues around accessibility and cost (225). Most patients will repeatedly 
attend hospital for symptom relief either as a planned or an emergency 





in hospital and impact on place of death, possibly affected by route of 
presentation (209). Some NHS hospitals and hospices have specialist 
services encouraging patients to make contact, so that elective day care 
drainage can be organised (227).  
 
 
How services in the community vary with geography and hospices or 
specialised palliative care units (SPCU’s) provide assessment and 
drainage of ascites thus preventing trips into hospital, especially in the 
last few months of life when valuable time each day with loved ones may 
be compromised. The Sue Ryder Hospice at Leckhampton Court, 
Gloucestershire, is one such hospice providing specialised end of life care. 
 
 
Sue Ryder Hospice is a charity that provides services, which cater to 
various aspects of health and social care across the UK. Its main aim is to 
provide palliative care to individuals in their preferred environment, be it 
in the community or at home this, along with hospices and care centers.  
This organisation provides holistic end of life care across communities to 
include patients and their families (http://www.sueryder.org/care-
centres/hospices/leckhampton-court-hospice). In general, over 900 
million pounds is spent by hospices looking after terminally ill patients 
and their families. Funding for most hospices is received from NHS 
England, Local commissioning groups and Local Authorities 
(http://www.togetherforshortlives.org.uk/assets/0001/1502/Hospice_com
missioning_and_funding_survey_results_2015.pdf). Following a recent 
survey in 2015, over 66% of hospices in the UK have found their 










At present there is limited information on the use of hospital resources 
with respect to ascites drainage in the last few months of life for England. 
The recent aim of the NHS has been to shift inpatient work to outpatient 
or day care if possible. This initiative has resulted in hospitals being 
awarded financial incentives to maintain outpatient services. Hospices 
based in the community provide end of life care services, either for 
inpatients or as day care or home care services. Some also provide 
specialist services such as drainage of ascites as day care attendances. 
However, recording of this change in practice is scant for hospitals and 
this information is not collated for all hospices either. 
 
 
This chapter looks at two separate analyses:   
 
 
The first analysis involves the study of ovarian cancer patients with 
ascites in the last month of life, the largest sub-group of gynaecological 
cancer patients studied through out this thesis, to assess the impact of 
socio-demographic factors of this population on death in hospital. The 
data is derived from the linked database and this analysis will aim to 
show its ‘usefulness’ in assessing a ‘single cancer site’ with respect to 





The second analysis compares a general cancer population (all cancers) at 
the end of life, derived from the National HES-ONS linked database 
attending hospital for ascites drainage with a similar, but much smaller, 
cancer population attending a local hospice for symptom relief of their 
ascites over a two year period. This analysis investigates whether the time 
to death following drainage in hospital differs from those seeking relief in 
a hospice.  
 
 
Therefore, this chapter looks at three separate populations of ascites 
patients at the end of life, describing two separate analyses to provide an 
overview of the potential impact of this symptom of advanced 
malignancy on end of life care. 
 
 
The aims of this chapter are: 
1. To study ovarian cancer patients who have their ascites drained in 
hospital. The aim is to explore the socio-demographic features of 
this population to assess whether age, socio-economic status, place 
of death, place of residence (SHA) and whether elective or 
emergency drainage of ascites impacts on death in hospital. This 
information would be useful to oncology centres and community 
services to inform on future planning of resource allocation to 
improve patient experience. This would also allow an assessment 
of the linked database for assessing hospital resource utilisation. 
 
2. To explore the impact of ascites in a general cancer population at 





management of their ascites, and whether the place of drainage of 






This chapter describes two separate exploratory analyses involving three 
study populations. The first analysis focuses on the ovarian cancer 
population. This study population is derived from the HES-ONS linked 
dataset described in Chapter 3. The ovarian cancer patients are described 
in detail in Chapter 4. This derivative population includes ovarian cancer 
patients in the last one-month of life, who underwent drainage of ascites 
following either an elective or an emergency admission. The aim of this 
analysis is to understand the socio-demographic factors of the ovarian 
cancer patients who attended hospital in the last month of life for 
drainage of their ascites. It also allows investigation of the HES-ONS 
database as a useful tool for assessing hospital resource utilisation. 
 
 
The second analysis is a comparative audit of the time to death from the 
first drainage of ascites for a general cancer population managed 
individually for their ascites, at the end of life, in hospital compared to 
the same occurring in a hospice. The national linked HES-ONS database 
was used to identify patients with an underlying diagnosis of cancer from 
the 1st November 2010 to 31st October 2012, who had ascites drained in 
hospital. A similar audit of the patients who had their ascites drained in a 





aimed to identify any differences in the time to death following drainage 
of ascites when hospital was compared to hospice. 





8.2.1 Ovarian cancer patients requiring ascites drainage in hospital 
the last month of life 
 
 
The derivation of the HES-ONS linked end of life care database is 
described in detail in Chapter 2. Briefly, this study used person-linked 
routine inpatient, day case and mortality data. The HES database 
provided information on number and type (emergency or elective) of 
admissions in the last year of life and the interventions undertaken in this 




Data was extracted from the linked database for all women who died of 
ovarian cancer (ICD-10 code C56 and C57.0-57.4) from 1st of January 
2000 to the 1st of July 2012. This included 41,227 women. A subset of 
23,830 (58%) ovarian cancer patients had one or more than one 
intervention in the last month of life. Data was extracted in such a manner 
to compare elective versus emergency admissions for ascites drainage in 
the last month of life and the socio-demographic characteristics of each 





number of patients, who had drainage in the last month of life as an 
elective and as an emergency, was perceived to be negligible and unlikely 
to affect analysis and results. Data on these hospital admissions either as 
inpatient or day case were extracted for all those patients who had at least 
one or more paracentesis in the last month of life including baseline data 
on age, place of death, and year of death, socio-economic quintile and 
geographical region at time of death. 
 
 
8.2.2 Statistical analysis 
 
 
 Descriptive statistics were used to describe data on admissions; 
univariate analysis was performed to study trends in the number of 
paracentesis procedures performed in the last month of life over the study 
period. Multivariable analysis was performed to identify those factors 
that significantly predicted death in hospital following elective or 
emergency paracentesis in hospital having adjusted for age, year of death, 
socio-economic status and postcode at time of death. 
 
 
8.3 Results 1 
 
Exploratory Analysis 1: 
 
8.3.1 Drainage of ascites in patients with ovarian cancer in hospital 







This section of the thesis describes the socio-demographic characteristics 
of the ovarian cancer patients who had their ascites drained in hospital. 
An attempt to differentiate and identify those socio-demographic 
characteristics that may predispose some patients to an admission into 
hospital is made. Having controlled for the differences in socio-economic 
demographics, the trends of the proportion of ovarian cancer patients who 
were admitted either as an elective or an emergency admission into 
hospital for drainage of their ascites have been reported. This description 
provides an overview of the dominant route of hospital use by this subset 
of patients and provides some insight into how this proportion may have 
changed over more than a decade of the study period.  
 
 
In the last month of life 23,830, patients with ovarian cancer 
(23,830/41,227 or 58% of the total number of ovarian cancer patient 
deaths) had one or more intervention in hospital during their last month 
of life. The study period covered twelve and a half years to include the 
1st of January 2000 to the 1st of July 2012. Of 23,830 ovarian cancer 
patients, 5943 (23%) patients had at least either an elective or emergency 
attendance for drainage of ascites in hospital, in the last month of life. Of 
them, 4,103 patients had at least an emergency drainage in the last month 
of life and 1,390 had at least an elective procedure. An emergency 
attendance was found the dominant route into hospital, the frequency of 
an emergency attendance being three times more likely than an elective 







8.3.2 Characteristics of patients who had their ascites drained 
following an emergency admission: 
 
This section of the study describes the socio-demographic characteristics 
of the ovarian cancer patients who had their ascites drained in hospital 
with respect to their age group, socio-economic quintile, year of death, 
postcode at death and type of admission. Subsequently, this section 
investigates whether these variables impacted on death in hospital for 
patients who attended following an emergency admission for drainage of 
ascites. Table 8.3 highlights all the variables studied. With respect to age, 
on average, 17% of patients required drainage of their ascites in the last 
month of life for each age group. Table 8.1 shows the proportion of 
patients from each age group who underwent emergency drainage of their 
ascites. No trends were identified with respect to the proportion of 
patients attending hospital and their age ranges. Despite controlling for 
socio-demographic factors, following multivariable analysis, there was no 
correlation between increasing age and an emergency presentation for 
drainage of ascites (OR 1.01; p = 0.3) (Table 8.3). 
 
Table 8.1: The proportion of patients by age group whose ascites was drained in 









Table 8.2 describes the overall trends of emergency ascites drainage 
(paracentesis) in hospital, using HES data, for the study period i.e. from 
1st January 2000 to 31st of July 2012. This table shows that the increase in 
the proportion of ovarian cancer patients who had at least one 
paracentesis performed in the last one month of life as an emergency, 
from 14% in the year 2000 to 18% in 2014 (Table 8.2), with those 
requiring multiple emergency drainages in the last one month of life also 
doubling from 1% in the year 2000 to 2% in 2010. Following 
multivariable analysis, which allowed controlling for socio-demographic 
variables, the odds (OR 1.04; p< 0.001) of requiring an emergency 
paracentesis performed in hospital, increased by 4% for each year since 
the year 2000 (Table 8.3). 
 
 
Table 8.2: The trends of the proportion and frequency of emergency 









Table 8.3: Adjusted and unadjusted odds ratio following multivariate analysis to 





The impact of socio-economic deprivation status on patients whose 
ascites was drained as an emergency in hospital in the last month of life is 
demonstrated in Tables 8.3 and 8.4. Table 8.4 shows that with each 
quintile increase in socio-economic deprivation, the proportion of patients 
whose ascites was drained following an emergency admission into 
hospital increased from 14.8% to 17.5%. Those in the most deprived 
quintile group were also more likely to have had multiple drainages in 
hospital (Table 8.4). This trend was confirmed on univariate analysis and 
when other socio-demographic variables were controlled for, it was found 
that a lower socio-economic deprivation status significantly predicted an 







Table 8.4: The percentage (number) and frequency of emergency paracentesis 





Over the study duration, of patients who had their ascites drained at least 
once in hospital as an emergency (4103), 14% died in a care home, 16% 
in a hospice, 19% died elsewhere and 18% died either in hospital or at 
home (Table 8.5). This table also showed that of those patients who died 




Table 8.5: The proportion of patients and frequency of paracentesis in the last 
one month of life (not at all, once, multiple) in hospital following an emergency 










On univariable analysis (Table 8.3) there was a statistically significant 
decrease in the trend of the number of hospice deaths over the study 
period, for those patients who had their ascites drained in the last month 
of life in hospital following an emergency admission (OR = 0.91; P = 
0.03) indicating that these admissions possibly impacted on place of 
death. Once differences in socio-demographic characteristics were 
adjusted for (Table 8.3) it was found that 17% (4103/23,830) of patients, 
who had drainage of their ascites in hospital following an emergency 
admission, had an increased risk of death in hospital of 11% (OR=1.11, P 
= 0.005). One explanation that may be offered is that the end of life care 
stage had probably been recognised in those drained electively, and 
therefore these patients symptoms were relieved in a planned and swift 
manner, followed by discharge to their usual place of residence be it 
home or a care home. 
 
 
Table 8.6 shows the variations in the numbers of paracentesis performed 
following an emergency admission by geography (SHA’s). The 
proportion of patients undergoing emergency paracentesis varied between 
15% and 19% by SHA. When age group, socio-economic status, year of 
death and hospital death were adjusted for, the North West (OR = 1.22; P 
= 0.006), East Midlands (OR = 1.30; P = 0.001), East of England (OR = 
1.25; P = 0.003) and South East (OR = 1.34; P < 0.0001) had 
significantly higher trends of emergency admissions for paracentesis 
when compared to London (Table 8.3). This may reflect on how services 
are accessed, awareness of availability of the services and the differences 







Table 8.6: The percentage (number) of patients and frequency of paracentesis in 






Therefore, following multivariable analysis the statistically significant 
determinants for death occurring in hospital for patients with ovarian 
cancer, presenting with ascites in the last month of life to hospital as an 
emergency were, belonging to a lower socio-economic quintile, a more 
recent year of death, resident of the North West, East Midlands, East of 
England or the South East (Table 8.3). 
 
 
8.3.3 Characteristics of patients who had their ascites drained 
following an elective admission: 
 
This section of the study describes the socio-demographic characteristics 
of the ovarian cancer patients admitted electively for drainage of their 
ascites with respect to age, socio-economic quintile, year of death, 





possible impact of these variables is assessed with respect to death in 
hospital, for patients who attended following an elective admission for 
drainage of ascites, the predictor variables for which are shown in table 
8.8. Over the study duration, 1390/23,830 (6%) patients had their ascites 
drained at least once in hospital following an elective admission. With 
respect to age, on average, 7% of patients attended hospital electively for 
drainage of their ascites in the last month of life, for the three age groups 
between 45 and 75 years. Table 8.7 shows the proportion of patients from 
each age group who underwent elective drainage of their ascites. Beyond 
the age of 75 years the attendance into hospital for elective paracentesis 
dropped from 6.5% for the 65-75 year age group to 1.6% for the 95-104 
years age group (Table 8.7). Younger patients were therefore more likely 
to attend for ascites drainage following a planned admission (OR 0.84; p 
<0.001). Age proved to be a significant predictor as suggested by the 
concordance of univariable and multi-variable analysis, with the odds of 
dying in hospital reduced following elective paracentesis in hospital in 
younger age groups (Table 8.8). 
 
 
Table 8.7: The proportion of patients by age group whose ascites was drained in 







Table 8.8: Adjusted and unadjusted odds ratio following multivariate analysis to 





Table 8.9 describes the overall trends of elective ascites drainage 
(paracentesis) in hospital, using HES data, for the study period i.e. from 
1st January 2000 to 31st of July 2012. This table shows that the increase in 
the proportion of ovarian cancer patients who had at least one elective 
paracentesis performed in the last one month of life, from 5% in the year 
2000 to 8% in 2012 (Table 8.9) where as the proportion of ovarian cancer 
patients undergoing more than a single elective drainage remained 
constant over the study period. Therefore, a more recent year of death 
was associated with a significant increase in the number of elective 
admissions for drainage of ascites, a trend confirmed on univariate 
analysis (Table 8.8). Following multivariable analysis, which allowed 
controlling for socio-demographic variables, the odds (OR 1.03; p< 
0.001) of an elective paracentesis performed in hospital, increased by 3% 






Table 8.9: The trends of the proportion of all ovarian cancer patients in the last 
month of life and frequency of elective paracentesis performed in hospital in the 





Over the study period, 6.2% died in a hospice, 8.3% at home, 3.6% in a 
care home and 5.2% of deaths occurred in hospital (Table 8.10). Patients 
who died in a care home were least likely to attend hospital for drainage 
of ascites or have multiple drainages. On univariate analysis the numbers 
of ovarian cancer deaths occurring in a hospice had increased over the 
study period for those who had had their ascites drained electively in 




Table 8.10: The percentage (number) of patients and frequency of paracentesis 
in the last one month of life in hospital following an elective admission by place 









With increase in socio-economic deprivation (by quintile), opposing 
trends for emergency presentations were reflected, as the number of 
elective admissions for drainage of ascites decreased from 5.9% to 4.7% 
for a single drainage and decreased from 0.6% to 0.4% for a subsequent 
drainage (Table 8.11). The significant impact of socio-economic status on 
the number of elective drainages of ascites was confirmed not only on 
univariate, but also on multivariable analysis when other demographic 
variables were controlled for (Table 8.8). 
 
 
Table 8.11: The percentage (number) and frequency of elective paracentesis 





Table 8.12 shows the percentage variation in the number of paracentesis 
performed following an elective admission by geographical regions in 





and the South West of England the highest (3% vs. 7%). These variations 
were confirmed on univariable and multivariable analysis and found to be 
of statistical significance when compared to London as the reference 
standard (Table 8.8). 
 
 
Table 8.12: The percentage (number) of patients and frequency of paracentesis 








Following multivariable analysis, the variables that significantly 
predicted a less likely to death in hospital, if an elective drainage of 
ascites had been undergone were, those of a younger age group, had died 
more recently, belonged to a higher socio-economic group and lived 
anywhere, other than London (Table 8.8). 
 
 
Table 8.13 correlates the place of death with the proportion of ascites 





admission. It shows that overall; patients being cared for and dying in 
care homes were least likely to be transferred into hospital for drainage of 
ascites. On the other hand, patients dying at home were most likely to 
attend hospital for drainage of their ascites to achieve symptom relief 
prior to death. This suggests that patients and their families, at home, 
require additional support from the community palliative care teams and 




Table 8.13: Shows the proportion of ovarian cancer patients who had at least one 
emergency or elective drainage of ascites in hospital in the last month of life, 







Analysis 2: Hospice and HES Data for all cancer types with ascites, at 
the end of life 
 
 
This section of the thesis looks at two general cancer populations who 
had ascites drained either in hospital or in a hospice in the last year of life 
over a two-year period. The aim of this analysis was two-fold. The 





management of ascites, as a symptom of advanced malignancy and, to 
assess whether hospice involvement significantly impacted on place of 
death irrespective of type of cancer when compared to a hospital 
population. The second aim was to investigate whether any differences in 
life expectancy existed if the ascites was drained in hospital rather than in 
a hospice. The hospice population is acknowledged as a much smaller 
population and the results reflect outcomes of an audit of the experience 
of 28 cancer patients with respect to their ascites drainage over a similar 





Data was collected about the paracentesis procedure to assess outcomes 
for all patients who had their ascites drained from the November 1, 2010 
to 31st of October 2012 at a local hospice. In 2010 Sue Ryder, 
Leckhampton Court purchased an ultrasound scanner with charitable 
money (LOGIQ e BT09 TSP ultrasound machine with a 4C-RS Convex 
Curved Array Probe). It gave the ability to scan patients, perform 
paracentesis and discharge them the same day. This was in contrast to the 
local Oncology centre at the time where patients would often wait for 
admission, wait for an ultrasound scan and then wait for a junior doctor to 
perform the procedure. At the hospice an ultrasound scan was performed 
prior to paracentesis for every patient. A suitable pool of fluid (a depth of 
5cm or more) was identified and a drain inserted. When a patient died the 







The above group was compared to a group of patients who had had their 
ascites drained in hospital, as a result of advanced cancer, at the end of 
life and is described in the following paragraphs. A subset of patients, 
and their data were extracted from the linked HES-ONS database and 
retrospective analysis of this linked HES-ONS data was performed for all 
cancer deaths from the 1st of November 2010 to 31st of October 2012: 
National data was extracted from the joint ONS (Office of National 
Statistics)-HES (Hospital Episode Statistics) database held at the Public 
Health England Knowledge and Intelligence Team (South West). This 
database holds detailed death information linked to hospital 
inpatient/day-case care for all residents of England. All people with an 
underlying cause of death of cancer, from 1st November 2010 to 31st 
October 2012 were selected to cover the same study period as the hospice 
population. 12, 542 people from this population had a recorded treatment 
code for drainage of ascites (Office of Population Censuses and Surveys 
codes: T315, T348, T349, T461, T462, T468, T469, T483, T484, T488, 
T489) within a year of their death. For these patients the date of first 






A t-test on the percentage of deaths occurring at home or in hospital was 
used to test whether there were significant differences in place of death 
following drainage of ascites at the hospice or in hospital. We performed 
a Kaplan-Meier survival analysis to calculate the median life expectancy 





repeated the same test for the hospital group (as this was a larger cohort) 
to assess if differences in survival existed by cancer diagnosis after the 
first tap. This was performed for the three common cancer diagnoses of 
lung, breast or colorectal cancer and compared with ovarian cancer, 
which was the most common diagnosis in both groups of hospice and 
hospital patients who had paracentesis at the end of life.  
 
8.4 Results 2 
 
 
From the 1st November 2010 to 31st October 2012, 28 patients had at 
least a single paracentesis at the hospice. There were 39 ascites drainages 
performed in total with a range of 1 – 5 per patient. When patients 
required a repeat paracentesis, referral to the hospital for placement of a 
semi-permanent drain was discussed. Patients would have repeated 
paracentesis in the hospice if they did not wish to have a semi-permanent 
drain or their prognosis was too poor for placement. 
 
 
Baseline data for comparison with the extracted national data for patients 
with cancer who were in the last year of life and who had paracentesis 
performed in hospital, over the same period is shown for both groups in 
table 8.14. This included information on age, gender, diagnosis and place 
of death. There appeared to be no significant differences in the gender of 
patients attending for drainage either in a hospital or hospice. The mean 
age of the patients attending for ascites drainage in hospital was on 
average 6 years younger than the population attending for drainage in a 





diagnosis for both groups. Just under a third of ovarian cancer patients 
attended the hospice in the last year of life for drainage of their ascites 
whereas just less than one-fifth attended hospital at the end of life for 
symptom control. Patients with an unknown primary were more likely to 
continue with drainage in hospital possibly as a result of the poor 
prognosis. Of significance was the difference in the number of home 
deaths for both populations, with 53.8% (14/26) of the hospice patients 




Median life expectancy after paracentesis for those who died at the 
hospice was 42 days from their first hospice paracentesis (range 4 – 803 
days post-procedure). 2 patients were still alive when data was censored 
on 1st October 2013. For the hospital cancer study population, median 
survival was 39 days post first paracentesis (Figure 8.1). We also 
compared the median time to death for patients who had their first ascites 
tap in hospital by cancer diagnosis. We found that patients with ovarian 
cancer had a longer median survival of 93 days compared to breast cancer 
(32 days), lung (30 days) and colorectal cancer (38 days) (Figure 8.2). 
The location of the drain for patients is in Table 8.15 with the left frank 
being more commonly approached rather than the right flank. If a patient 
required a repeat procedure this was performed in the same anatomical 
area. There were no complications from patients undergoing this 






Table 8.14: Baseline demographic data on all hospice and hospital patients with 













Figure 8.1: Kaplan Meier curves for hospital and hospice patients with the 








Figure 8.2: Kaplan Meier Survival curves depicting median time to death from 








This chapter explores the impact of ascites on three separate cancer 
populations at the end of life in two separate analysis; a specific 
gynaecological cancer type i.e. ovarian cancer patients dying in hospital, 
and all cancer types by place of death i.e. in a hospice or hospital.  
The results suggest that the linked database is a useful source of data for 
assessing hospital resource use at the end of life. Comparisons between 





intervention provided, and thus can inform on future resource allocation 
and planning of services. The linked database gives insight to understand 
the impact of socio-demographic characteristics on the type of admission 
i.e. elective or emergency and to question whether these variables impact 
on place of death. The results conclude that patients with cancer of the 
ovary presenting with ascites in the last month of life to hospital as an 
emergency, were significantly more likely to die in hospital if they 
belonged to a lower socio-economic quintile, had died more recently and 
lived in the North West, East Midlands, East of England or the South East. 
Of the same group, patients were significantly less likely to die in 
hospital, if they had had an elective drainage of ascites, were of a younger 
age group, had died more recently, belonged to a higher socio-economic 
group and lived anywhere, other than London. 
 
 
Ascites affects a substantial proportion of cancer patients at the end of 
life. This distressing symptom has resulted in a noteworthy increase in 
the incidence of elective and emergency admissions for drainage of 
ascites of ovarian cancer patients in hospital over the past decade. In fact 
NICE recommends that cancer patients should have access to devices to 
treat fluid retention at home 
(http://www.bmj.com.bris.idm.oclc.org/content/344/bmj.e2272/related). 
The advantages as described by NICE of the use of such devices are 
better control of symptoms, reduced risk of infection by avoiding 
repeated drainages and resource saving by avoiding inpatient stays and 
hospital appointments. Our study shows that since the year 2000, the odds 
of ovarian cancer patients presenting to hospital each year for drainage of 





for symptom control for refractory ascites at the end of life may relate to 
the increase in overall incidence of ovarian cancer, late diagnosis of those 
patients not amenable to treatment, improved survival; the increased 
availability of image guided interventions and inaccessibility to specialist 
palliative care in the community. It is unlikely that a large number of 
patients in the past, prior to the study, were drained outside hospital. 
These results inform on the need for future service provision and have 
implications on resource utilisation for NHS hospitals in England. The 
data shows that the number of patients attending for multiple drainages 
have reduced more recently, suggesting that it is possible that outpatient 
acute oncology services, hospices and community palliative care teams 
have further assisted patients in avoiding multiple hospital admissions. 
An attempt to quantify these contributions, and the timing of when they 
took place in the patient journey, has not been made in this study and 
would be a suggested future area of focus. 
 
 
A clear gradient was recognised with respect to the socio-economic 
deprivation group of the patient and specifically the ovarian cancer 
population. The proportion of emergency drainages increased with 
increasing socio-economic deprivation and the contrary was observed for 
planned paracentesis in hospital. Emergency admissions for drainage of 
ascites increased the risk of death in hospital by 11%. Several analyses 
show that cancer patients from higher socio-economic groups and of a 
higher education status had a higher probability of a home death and 
ability to access care at home (10, 135, 179). It can thus be hypothesized 
that patients from lower socio-economic strata are more likely to attend 





focus on this group to enhance the quality of their end of life experiences 
and ultimately ensure that personal situation does not impact on the 
preferred place of death or inequitable end of life care resources.  
 
 
The Pilgrims Hospice Group based in Kent, South East of England 
assessed the impact of a hospice rapid response service (RRS) on 
preferred place of death. They found that users of the service (247/688) 
were more likely to achieve their preferred place of death (69%; 171) 
which was death at home. The non-users (441/688) were more likely to 
live alone or in a care home. The non-users were also more likely to 
access hospital services and other hospice services. This study also 
showed that those who lived in care homes were more likely to achieve 
their preferred place of death. This study provided some insight into the 
utilisation of end of life care services in the south-east of England, based 
on preferred place of death, the presence or absence of a carer at home 
and the use of the RRS and it’s impact on actual place of death (228). Our 
study results show that patients who died in care homes were least likely 
to attend for ascites drainage to hospital either as a planned or unplanned 
admission (82% of care home patients did not seek drainage in hospital 
vs. 74% of patients who died at home). It is likely that patients in 
residential care homes have access to skilled medical services in house, 
thus avoiding transfer for acute hospital services. In a study of 661,773 
Belgium decedents, the change in trends in the place of death was found 
to be related to the increasing availability of nursing home beds in care 







Specialist palliative care teams are in place at many, but not all, acute 
hospitals in England. A systematic review by the team lead by Professor 
Higginson at King's College and Hospital found that specialist palliative 
care teams had a beneficial effect for patients but there is anecdotal 
evidence that transfer of care did not always occur at an appropriate time 
(10). Previous interviews with cancer nurse specialists highlighted a 
fixation with continued treatment, negative perceptions of palliative care, 
and uncertainty of the best course of action. The same study noted that 
clinical decision-making in advanced disease is subjective and that 
critical junctures to review the care plan are not always recognised. This 
is one factor that may have contributed to variations in regional care 
further impacting on regional variations in the place of death for cancer 
patients (135). These variations and have been actively explored for 
gynaecological cancer patients in chapter 7. Regional variations in the 
number of elective and emergency paracentesis performed are observed 
in this study, the causes for which are likely to be multi-factorial, and the 
socio-demographic differences highlighted above may just be one 
contributing reason. Currently, we are also not aware of the measure of 
hospices offering ascites drainage in the community.  
 
Variations in socio-economic deprivation are likely to impact on regional 
variations in presentation i.e. the younger, more well informed patient is 




This is the first study to document the trends of ovarian cancer patients 





The use of such data is representative of England. Accurate trends can be 
studied from Cancer registry data that is subject to a vigorous process of 
quality assurance. There are limitations to the routine data. There was a 
high volume of missing co-morbidity data in HES, and presence of other 
limiting conditions, or poor prognosis cancers such as cancers of 
unknown primary, may have affected the suitability of a patient to receive 




When comparing the hospice data with a hospital cohort we chose a 
population who died within a year of the procedure. This was not a 
matched cohort but a sample of patients with a poor prognosis – the 
median life expectancy after a hospital paracentesis was 39 days, which 
was very similar to the hospice cohort’s prognosis of 42 days.  
 
 
The hospice data showed that paracentesis is a procedure that can be 
successfully carried out in a hospice setting as outpatient or day case 
attendance in hospital. The longer median survival of ovarian cancer 
patients suggests that this subset of patients may benefit from early 
referral to the local hospice for symptom control following re-
accumulation of ascites or for earlier consideration of a semi-permanent 
drain, which may help maintain a better quality of life. A recent study 
published local to a New Zealand population reported on the advantages 
of portable ultrasound machines available to specialists in the community 
with respect to the provision of specialist palliative care at home. Of the 





was identified in 19 and 17 drainages were performed. Half of these 
procedures were performed at home (229).  
 
 
The potential influence of place of management of ascites on place of 
death is interesting. When compared with a population of patients who 
had paracentesis performed in the hospital during the last year of their life, 
patients who had their ascites managed in the hospice were much more 
likely to die at home and much less likely to die in hospital. There are 
possible reasons for this. Perhaps patients who were willing to come to 
the hospice were the kind of patients who wished to continue with their 
support and their plan for the future was to die at home in any case. 
However, it might be that engagement with the hospice service and then 
onward referral to community specialist palliative care, if appropriate, 
could change the disease journey for patients. This data will not answer 
this clinical question. Likewise, the hospice data is too small a sample to 
draw any conclusions about ascites recurrence. 
 
 
The ideal method of assessing the best setting for management of ascites 
patients with end of life care needs is a randomised trial where 
paracentesis is performed either in hospital or hospice via a multi-armed 
study. To obtain further clarity the advantages of expanded outpatient 
oncology services in hospital vs. randomization with inpatient care and 
comparison with hospice at home and daycare hospice services must be 
balanced with the ethics of performing such a study and underlying 
individual patient preferences.. This trial may be also be able to explain 





the ease of accessibility to care e.g. distance between home and hospice 
or hospital, carer availability, and the impact of permanent drain systems 
on future utilisation of resources (230). This would be challenging 
methodologically but is needed to answer this question. Any trial should 
simultaneously appraise the cost of the use of healthcare resources along 






This retrospective population based study has shown that the incidence of 
both elective and emergency drainage of ascites in the last one month of 
life has increased. This has significant resource implications and these 
results can inform on future resource allocation. The presentation of the 
patient as an emergency significantly impacted on the place of death. 
Patients of a lower socio-economic stratum are more likely to present as 
an emergency. The distribution of specialist palliative care services with 
the required available expertise in the community remains unmeasured 
and this may influence the place and mode of presentation. 
 
 
Drainage of ascites in a hospice setting may alter the patient journey and 
ultimately the preferred and actual place of death.  Patients with 
refractory ascites may benefit from early consideration of a semi-
permanent drain thus avoiding the need for multiple emergency 
attendances into hospital. This necessitates further research with a larger 












‘All member countries of the United Nations are obliged to ensure that 
patients have equitable access to end of life care to alleviate avoidable 
pain and distress, allowing them to die with dignity’ (1, 2). In the UK, 
public health and health promotion is dedicated to reducing health 
inequalities and enabling people to take control over their lives including 
at the end of life (Marmot 2010). According to the results of a survey of 
end of life care services of 80 nations in 2016, the UK end of life care 
practice has been praised as the best in the world 
(http://www.bbc.co.uk/news/health-34415362). However, this study also 
recommended some space for improvement with respect to symptom 
control and communication. Most recently, in 2015, the government 
released a document ‘Ambitions for Palliative and end of life care: A 
national framework for local action 2015-2020’ 
(http://endoflifecareambitions.org.uk/wp-
content/uploads/2015/09/Ambitions-for-Palliative-and-End-of-Life-
Care.pdf.). This framework builds on the End of Life Care Strategy, 
2008, the NICE guidance on end of life care and the results of the most 
recent VOICES questionnaires in response to reports for the need for 
more effective and responsive end of life care at a local level. The 
document sets out six ambitions or visions of care which includes ‘each 





maximising comfort and wellbeing, care is coordinated, All staff are 
prepared to care and each community is prepared to help’. Policy 
documents with respect to end of life care in the United Kingdom have 
historically been influenced predominately by public opinion. Of note, 
the failure of the ‘Liverpool Care Pathway’, which was designed around 
the principles of good communication with the patient and family about 
death and dying with the aim of providing holistic care around the time of 
death. The criticism of the LCP resulted in the publishing of  ‘One chance 
to get it Right’ following the identification of national deficiencies in the 
end of life care, after the Baroness Neuberger report 
(https://www.gov.uk/government/publications/review-of-liverpool-care-
pathway-for-dying-patients). The introduction and revision of new 
documents and policies as a result of feedback from the public have 
highlighted the gaps in the provision of end of life care. The Ambitions 
2016 document aims to provide a number of building blocks on which 
future services and care can be based. 
 
 
The hypothesis of this study was to use person-linked, routinely collected 
hospital activity data, and mortality data in order to explore the various 
aspects of the equity and quality of end of life care for patients with 
gynaecological cancer in England. This study is the largest study of 
gynaecological cancer patients in the world. This study, therefore, is of 
national and international significance  
 






• To establish the ‘usefulness’ of routine data sources (HES and 
ONS) to assess whether end of life care for gynaecological cancer 
patients in England is equitable and that ‘quality indicators’ of end 
of life care can be evaluated 
• To report where patients with gynaecological cancer die in 
England 
• To report trends of the place of death for these patients  
• To assess the influence of socio-demographic variables and 
hospital admissions on the place of death 
• To assess interventions received by gynaecological cancer patients 
in hospital in the last year of life.  
• To evaluate the impact of these interventions in last month of life 
on death in hospital  
• To assess regional variations in EOLC for gynaecological cancer 
patients in England to include variations in hospital deaths, 
emergency admissions and emergency interventions in the last 
month of life. 
• To report on the trends of ovarian cancer patients who require 
paracentesis in the last month of life in NHS hospitals and also to 
reflect on resource usage by comparing drainage in a hospital and 
hospice setting 
 
The results are derived following analysis of 71,269 gynaecological 
cancer patients and include women at the end of life of their cancer 
trajectory, studied over a 13 year period.  
 
Gynaecological cancers are a complex group of tumours specific to 





Studies have shown that cancer patients differ from non-cancer patients 
(179) when the quality of end of life care is assessed and may vary by 
cancer type (149). There are only a handful of retrospective published 
studies of small cohorts of patients. Establishing quality of care and 
‘appropriateness’ of end of life care is a complex issue, however this 
comprehensive exploratory analysis of end of life care of gynaecological 
cancer patients allows conclusions to be drawn and recommendations to 
be made based on comparisons drawn from available national data.  
 
 
‘Place of death’ is regarded as a quality marker of end of life care (9) and 
‘death in the usual place of residence’ is regarded as a Key Performance 
Indicator (KPI) or ‘proxy marker’ for end of life care in the United 
Kingdom. Many Surveys have reported that a majority of patients wish to 
die at home (138). This study confirmed that the number of deaths that 
had occurred at home, in hospices and in care homes over the study 
period (January 2000 to July 2012) had increased with a proportionate 
decrease in the number of deaths occurring in hospital. These results 
endorse the ‘usefulness’ of the linked database in allowing the derivation 
of such results upon analyses. However, the literature continues to 
suggest that, less than half the population at the end of life, achieve death 
in their preferred location in England (149). Long-term projections 
suggest that although the trends towards deaths occurring at home have 
increased, the number of hospital deaths will continue to rise by 20% by 
2030 (193). This is expected to occur in response to the more likely 
achievement of better symptom control in hospital and until such a time 
that reliable and specialised palliative care services can be universally 






2014.html). Thus, careful plans must be put in place to cope with this 
expected rise in hospital resource utilisation at the end of life. Although 
no conclusions can be drawn, the ‘place of death’ may no longer remain a 
‘proxy’ quality marker of end of life care and may be replaced by other 
quality markers that better describe a ‘good death’. This proposal follows 
Sue Ryder’s published results from a questionnaire called ‘A time and 
place’. The survey recommends that the ‘where’ patients die be separated 
from the ‘how’ patients die and thus interpretation of outcomes of quality 
of life at the end of life be decoupled from place of death. The results 
suggest that patients value more a control of their symptoms such as pain 
above their place of death and therefore as their symptoms change their 
preference with respect to place of death is also likely to change and this 
may steer death at home towards death in hospital or a hospice. The 
report also suggests that focussing on location as a ‘proxy’ quality 
indicator diverts the progress of facilitating high quality end of life care 
in all settings. Thus it is recommended that indicators such as ‘the 
proportion of people who express their wishes for end of life’ and ‘the 
proportion of people who have met their wishes for end of life’ be 
recorded through their advanced care plans and be analysed. 
 
 
 This study found that the socio-demographic background of 
gynaecological cancer patients greatly impacted on where they die and 
how they present to hospital in the last month of life. Age, significantly 
impacted on place of death of women beyond the age of 65 years, with 
more women likely to die in hospital compared to in homes and hospices 





found that advancing age was more likely to be associated with death in a 
place other than at the patients own home or hospice, and that the gap 
between the young and old was getting smaller (149). Future care may be 
influenced by previous experiences and success with symptom control 
such as pain relief or prompt drainage of ascites, following an inpatient 




The incidence of deaths occurring in care homes has significantly 
increased beyond the age of 85 years, and as found in this study, for 
women with ovarian cancer that lived outside London. The extent of use 
of care homes by gynaecological cancer patients, the socio-demographic 
makeup of this subset and the impact of locally provided palliative care to 
this group, warrants further study.  It was found that in a study of 133,055 
people in England aged above the age of 75years, there was an overlap 
between social care usage and NHS hospital care usage. People living in 
care homes were less likely to present to hospital as an emergency or 
attend hospital outpatients for consultation compared to people receiving 
high intensity home care (174). When terminal care was compared in 
hospices with conventional care, the National Hospice Study found that 
symptom control was better in inpatient settings, however the quality of 
life was similar for both sets of patients with hospice patients more likely 
to achieve a home death and their family members were more likely to be 
satisfied with the outcome (231). 
 
‘The more care, less pathway’ the report published following an 





foremost calls for independent assessments of the quality of end of life 
care available to individuals at the end of life in England. 
 
 
The place of death was further impacted on by the socio-economic 
deprivation status, with women with increasing socio-economic 
deprivation more likely to die in hospital. The results of this study agree 
with the results of Gao et al; who have shown that gender differences 
impact on place of death and women who are single, widowed or 
divorced should have concentrated end of life care support to reduce 
gender and social inequalities to the quality of care at the end of life 
(149). Socio-demographic differences also impacted on the patients’ 
ability to access services for symptom relief. Thus our results also agreed 
with the conclusions of Grande et al who systematically reviewed 
published studies on the relationship between patient characteristics and 
home deaths (179) to include cancer and non–cancer populations and 
found that less deprived patients were more likely to access home care 
and hospice care if symptomatic (231). This study also found that with 
increasing socio-economic deprivation, patients were more likely to 
attend as an emergency for symptom control, as also highlighted in the 
chapter on drainage of ascites. The impact of socio-economic deprivation 
status was also found to be true for other study populations as described 
by a study on the analyses of hospital admission data for 84, 423 patients 
admitted to adult critical care units in England which confirmed that as 
deprivation increased, the risk of mortality in hospital also increased over 







Emergency admissions are regarded as a negative indicator of the quality 
of end of life care as described by Earle et al (20). Controlling the rate of 
emergency admissions in to hospital is a ‘proxy’ marker also of success 
of primary and preventive care 
(http://www.nuffieldtrust.org.uk/sites/files/nuffield/publication/Trends_in
_emergency_admissions_BRIEFING.pdf). Patients present as an 
emergency in the last year of life on average twice as much as a planned 
admission and this is thought to impact on whether they die in hospital 
(9). Our study confirmed that not only had the number of emergency 
admissions increased over the study period of almost 13 years for 
gynaecological cancer patients in England, but also that this presentation 
significantly impacted on place of death. Some patients or their family 
members request admission to a hospital for symptom control, however 
alternative specialist palliative care units and improved domiciliary care 
may prevent an unscheduled admission and reduce the risk of an 
unplanned hospital admission and therefore exposure to unnecessary 
interventions. This requires future improvement in clinical practice 
including better prognostication and, the need for communication and 
discussions upfront with the patient and her family with regards to future 
care (232). A recently published Canadian study looked at stepping up 
community specialist palliative care, subsequently reducing hospital 
admissions and deaths in hospital (233). I hypothesized, prior to this 
published study, that if the number of emergency admissions could be 
halved assuming that 50% would be essential, it might be possible to 
reduce the number of deaths occurring in hospital. The result of this 
postulation was a prediction model.  The model was based on assuming a 
50% reduction of the number of emergency admissions by taking steps to 





improving clinical pathways for accessing symptom control, such that 
16% of deaths in hospital could be avoided. The question therefore 
remains as to whether the continued rise of emergency admissions is 
inevitable and necessary and if so what steps need to be taken to absorb 
this increased capacity in the future.  
 
One of the constraints to dying at home in the UK is thought to be poor 
co-ordination of care between tertiary and primary care with poor 
provision of resources over the weekend in the community and out of 
hours (182). We found that the percentage of patients whose length of 
stay in the last month of life in hospital ranged from 7-14 days had 
steadily increased over the past decade from 13% to 17%. These results 
resonate with care and decision making which is especially poor when 
reviewed in the ‘out of hours’ and ‘weekend’ setting as described in 
various national enquiries including the review of the LCP pathway. The 
‘24 hour rapid discharge to home’ for patients dying in hospital may have 
helped some patients achieve a home death following its recent 
implementation in the process of discharging patients from hospital and 
organising care which had previously taken almost two weeks from 
recognition of end of life to execution of care at home. 
 
 
The ONS-HES database allowed a comprehensive analysis of procedures 
and interventions undertaken by patients at the end of life and allowed the 
reader to determine the patterns of care provided to patients at the end of 
life.  Chemotherapy, imaging and drainage of ascites were identified as 
the three most commonly performed procedures in hospital in the last 





interventions are more likely to take place, conversely the need for an 
intervention to achieve symptom control may mandate an emergency 
admission. Chemotherapy continues to be prescribed to patients to the 
end days. This study showed that 11% of patients had had chemotherapy 
in the last month of life. In comparison Barbera et al reported that after 
analysis of 2040 Canadian gynaecological cancer patients, 4% received 
chemotherapy in the last two weeks of life (155). Often, decision-making 
is based on imaging and the patient spends several days in hospital 
waiting for imaging to take place. In this thesis I have shown that there 
has been a significant increase in the proportion of patients undergoing 
imaging over the study period with on average a quarter of patients being 
scanned in the last month of life, each year. Moreover, this increase in 
imaging has been accompanied by a parallel decrease in major surgery 
such as hysterectomy and bilateral salpingo-oophorectomy. This may 
indicate that imaging is being used to reassess and restage patients and 
therefore better clinical decisions are being made to avoid futile surgery 
and perhaps plan end of life care. Some patients are admitted for 
symptom control such as drainage of ascites and this can be performed as 
a day case if planned, or may in some cases take several days in hospital, 
in the absence of a dedicated unit where ultrasound guided paracentesis is 
performed. Whilst some of these interventions are necessary such as 23% 
of ovarian cancer patients requiring ascites drainage in the last month of 
life, if accessed electively and managed efficiently, the risk of death in 
hospital can be reduced, as was demonstrated following analyses of 
planned attendances for drainage of ascites in chapter 8. Patients with 
ovarian cancer often require several drainages and the median time to 
survival can be considerably longer than patients with lung, breast or 





prolong stay and can alter the final weeks and days of individuals. 
Therefore in patients with refractory ascites at the end of life more semi-
permanent drains should be considered to improve their quality of life 
and reduce hospital attendances (227).  
 
 
The existence of regional variations in the accessibility of end of life care 
in England has already been acknowledged in national policy documents 
such as the ‘End of Life Care Strategy’ (DH 2009), however these 
variations are yet to be formally quantified and more specifically for 
gynaecological cancer patients in England. Community palliative care 
services and hospice bed availability varies by region in England and the 
commissioning of community care is provided by a number of local 
providers. The toolkit for the commissioning of person centred end of life 
care has recently been updated in April 2016, to promote equality in 
accessing generic and specialist end of life care in localities 
(https://www.england.nhs.uk/wp-content/uploads/2016/04/nhsiq-comms-
eolc-tlkit-.pdf).  It was postulated at the time of the analyses that the 
variation in community care was likely to impact on the pathway of 
obtaining equitable high quality end of life care. Significant geographical 
variations in the number of hospital deaths, emergency admissions and 
interventions in the last month of life were depicted in this thesis using 
funnel plots (Chapter 6). London differed significantly in the number of 
hospital deaths, emergency admissions and emergency procedures 
performed on patients with a higher than expected number of hospital 
deaths, lower than expected emergency admissions and lower than 
expected emergency procedures. Regional variations in end of life care 





study of 2,040 cases, by comparing whether there were differences in 
resource use. The study found that there were differences in the number 
of hospital deaths, emergency department visits and physician house calls 
made to patients in three provinces of Canada (155). 
 
 
With an aging population and improved survivorship, a rising percentage 
of emergency admissions may be inevitable (234). It could be put forth 
that with well-organised healthcare, a facilitated and efficient in patient 
stay following an emergency admission i.e. “a quick in and out” may be a 
compassionate way of dealing with symptoms. In addition, imaging and 
assessment in the community followed by a day case attendance for a 
minor procedure, if necessary, or to the local hospice, may be more cost 
effective and have a much less significant impact on the quality of end of 
life care. It would allow patients to spend more time in their preferred 
place of care and with their family. 
 
 
Some questions on how best to deliver care at the end of life remain. 
There are further questions that include which are the most appropriate 
‘markers’ to be used to assess standards or ‘proxy markers’ of the quality 
of end of life care  that are based on ‘individual choice’ for the British 
society. Clearly progress has been made as highlighted by the results of 
this thesis with more patients achieving a home death or death in their 
usual place of residence. The linked database had not been used in the 
past for such detailed analysis of an individual cancer population. 
Geographical variations in end of life care were also identified by 





emergency admissions, strengthening our hypothesis. The quality of care 
at the end of life of all people including that of gynaecological cancer 
patients in England in the wake of evolving national strategy, public 
healthcare policies and national initiatives encourages further research 
and review. The recently updated Cochrane Review on the use of end of 
life care pathways has cautioned the use of pathways in view of the recent 
controversy on the use of the Liverpool care pathway. ‘Clinical pathways 
are structured multi-disciplinary care plans used by health services to 
detail essential steps in the care of patients with a specific clinical 
problem’ as defined by Rotter et al. They were founded on evidence-
based practice and were adopted to improve clinical outcomes and 
enhance clinical efficiency. End of life care pathways, however focus on 
specific aspects of care in hospices and hospitals, supporting a ‘good 
death’ including support to relatives, has wider medical, social, economic 
and political implications with respect to dying 
(https://www.gov.uk/government/uploads/system/uploads/attachment_dat
a/file/136431/End_of_life_strategy.pdf). The initiation of an end of life 
care pathway is dependent on correct prognostication of the terminal 
phase, which should be based on reaching a multi-disciplinary 
professional consensus. Complex decision-making is often also 
associated with dealing with uncertainty. Further exploration into 
developing a better understanding of the prognostication of the dying 
phase is required to be combined with ‘personalised end of life care 
plans’ to support the dying patient and the relatives. 
 
 
Recently in the USA, the drive has been to integrate the concept of 





the beginning of the cancer trajectory. The most recent steps taken by the 
government to improve end of life care have been to introduce the 
AMBER Care Bundle (Guy’s and St Thomas’s NHS Trust, 2013) and the 
Gold Standard Framework (2013) and most recently the transforming end 
of life care in acute hospitals (2016) (https://www.england.nhs.uk/wp-
content/uploads/2016/01/transforming-end-of-life-care-acute-
hospitals.pdf). The Electronic Palliative Care Co-ordination Systems and 
Records, Rapid Discharge Models and Advance Care Planning have been 
introduced to ensure that patients’ needs and preferences are recorded and 
communicated effectively to all levels of health care, so that the preferred 
place of death and other wishes of the patients are respected and 
achieved. These steps have been rolled out in a few parts of the country 







9.2 Strengths and Weaknesses 
 
 
The results of the study are strengthened by the fact that a very large 
dataset of person level linked data with standardised data items was used. 
This allowed an assessment the equity and quality of end of life care for 
gynaecological cancer patients on a national level. This dataset was large 
enough to also allow subset analysis of interest, including specific 





paracentesis in detail to be examined. In addition the case mix analysis 




The study was limited by the fact that with such a large database, 
conclusions on individual ‘patient centred’ care could not be made. 
Hence, the opportunity to explore individual patient outcomes to report 
on was not available. An attempt at a prospective interpretation of a 
‘qualitative analysis’ was not an aim of this study, however this would be 
a future proposed area of study. It was accepted that minor 
misclassifications with respect to coding of procedures might have 
occurred, however, I was satisfied that this did not affect the analyses. 
Coding has significantly improved since 2007, and it is from this point in 
time that the multivariable analysis of the possible impact of procedures 
on place of death is based. It was likely that very uncommon procedures 
were probably not coded for at all, or coded incorrectly as coders lack 
clinical insight. This study only used inpatient HES data which includes 
day case admissions and procedures. However, it is possible that some 
outpatient procedures, such as ultrasound scans for patients attending the 
ward for drainage of ascites performed by on call registrars or consultants 
would not have been captured and may have resulted in under 
representation of numbers.  
 
Ethnicity is an important factor and has been shown to impact on end of 
life care (235). It was not included as a variable in this analysis as this 










This thesis has demonstrated that routine administrative data can be used 
to examine aspects of the quality and equity of end of life care. This 
research study has been able to comprehensively describe the socio-
demographic factors that impact on place of death for gynaecological 
cancer patients in particular, including derivation of a prediction model 
for reduction of hospital deaths based on reduction of emergency 
admissions, the interventions that gynaecological cancer patients 
experience at the end of life including identification of significant trends, 
proven the possibility of geographical variations in end of life care in 
England, and informed on the need for future service provision by 
specifically looking at the increasing incidence of elective and emergency 
paracentesis. 
 
This thesis has shown that there is still opportunity to improve patient 
choice at the end of life. Discussions need to occur engaging the patient 
and the family early on in the cancer patients’ journey, with regards to 
their preferred place of care and place of death and other things that are 
important to them so that their wishes can be respected. This raises the 
search for new ‘proxy’ markers of patient choice at the end of life. 
 
Integrated multi-disciplinary care at the end of life must be the standard 
of care, to ensure appropriate clinical decision-making. This should 
include enhanced communication between primary and secondary and 






In order to initiate discussions with the patient and end of life care 
planning there needs to be recognition that a patient is terminal and of the 
dying phase. There is a need for more research into prognostic scoring to 
aid diagnosis. 
 
This thesis demonstrates that there will need to be a greater focus in 
policy development on enhanced social care for the elderly and socio-
economically deprived to ensure that the quality of end of life care of 
disadvantaged individuals is not compromised. 
 
The results presented in this thesis have shown that there are still 
inequities in End of Life care for gynaecological patients. End of life care 
should be ‘equitable’ and based on patient need rather than their 
sociodemographic characteristics or where they live. Further research into 
quantifying the current regional differences in resource provision for end 
of life care in the community and steps to improve the quality of services 
available in certain areas is needed. 
 
Development of ways of assessing and comparing the outcomes of care 
across different care providers needs to occur so that emerging models of 
care can be recognised and better management pathways can be 
developed between hospitals and out-of-hospital care. Thus high quality 
care is ensured. 
 
The work from this thesis suggests that improved communication with 





life care needs to occur more often. Personalised support at the end of life 
should be the main target. 
 
 
9.4 Proposals for future research 
 
 
This exploratory analysis identifies specific areas for future study that 
currently remain under-researched. Further work is required in accessing 
the preferences of gynaecological cancer patients at the end of life. 
‘Home’ although thought to be the preferred place of death may be 
influenced by various factors and may no longer remain a quality marker 
for end of life care with the emergence of more scientific measures of 
quality of care. The use of qualitative methods will allow this question to 
be answered and along with an assessment of the interaction of socio-
demographic factors to such responses. 
 
 
Most studies focus on patients dying in hospital, however about one in 
ten patients dying from gynaecological cancers now die in care homes 
and the incidence of care home deaths is steadily rising in those beyond 
the age of 85years. The reasons for a care home death need to be explored 
in detail. Is this the new emerging model of place of care and place of 
death and, are patients medical problems related to their end stage 
gynaecological cancers being adequately managed. One question which 
this raises is whether care homes will become increasing important in 
providing alternative care to hospices and acute hospitals. The underlying 







The cost of hospital end of life care and non-hospital end of life care in 
England is difficult to quantify due to fragmented providers of care. 
Chemotherapy is funded separately and significantly contributes to costs 
of inpatient care at the end of life. The care home admissions for some 
patients are funded by NHS budgets and some hospices are attached to 
NHS hospitals. Thus assessing geographical variations in end of life care 
is complex and not completely explained. 
 
 
Pelvic cancers include uro-genital and colorectal cancers. Often these 
patients share similar complications at the end of life. The specialities of 
gynaecological oncology, colo-proctology and urology have experience 
in working together for the management of complex surgery especially in 
cancer when there may be management of more than one organ.  This 
thesis has several implications for joint working across these specialities. 
Firstly it has demonstrated that large national data sets can be used to 
gain insight into issues for gynaecological cancer patients at the end of 
life, similar studies could be conducted for colorectal, urological cancer 
patients to look for the similarities and differences faced by the patients 
and their clinicians. Secondly, it highlights opportunities for 
improvements in practice in the care of terminally ill gynaecological 
cancer patients some of which could be similar for colorectal and 
urological cancer patients. Following discussion with clinicians managing 
all three types of pelvic malignancies it has been suggested that 
integrating specialist palliative and end of life care for all pelvic 





best quality care to these patients at their end days. Further research to 
compare and contrast the differences and similarities in the end of life 
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